Toxicology Research Laboratory

UIC The University of Illinois at Chicago

Department of Pharmacology (M/C 868) 1940 W. Taylor St. Chicago, Illinois 60612-7353

20100915151

Task Order No.: UIC-7A UIC/TRL Study No.: 105

Study Report for Task Order No. UIC-7A ACUTE ORAL AND INTRAPERITONEAL TOXICITY

STUDY OF WR242511 AND WR269410 IN MICE

Sponsor: U.S. Army Medical Materiel

and Development Activity

Contract No.: DAMD17-92-C-2001

Task Order No.: UIC-7A

Test Articles: WR242511 Tartrate

WR269410

Study Director

Barry S. Levine, D.Sc., D.A.B.T.

In-Life Phase Completed On

June 30, 1993

Performing Laboratory

Toxicology Research Laboratory (TRL)
University of Illinois at Chicago (UIC)
Department of Pharmacology
1940 W. Taylor St.
Chicago, IL 60612-7353

The views, opinions, and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.

				TION		

REPORT D	OCUMENTATIO	N PAGE	Form Approved OMB No. 0704-0188			
1a. REPORT SECURITY CLASSIFICATION		16. RESTRICTIVE MARKINGS				
2a. SECURITY CLASSIFICATION AUTHORITY Unclassified		3. DISTRIBUTION/AVAILABILITY OF REPORT				
2b. DECLASSIFICATION/DOWNGRADING SCHEDU	E	Unlimited				
4. PERFORMING ORGANIZATION REPORT NUMBE	R(S)	5. MONITORING ORGANIZATION REPORT NUMBER(S)				
UIC-7A (UIC/TRL Study No. 105)						
Toxicology Research Laboratory University of Illinois at Chicago	6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MO			ition Activity	
Department of Pharmacology (M/C 868) 1940 W. Taylor Street Chicago, IL 60612-7353	7b. ADDRESS (Cit ATIN: SCRD Fort Detri Frederick,	ck	Code)			
ORGANIZATION U.S. Army Medical Material Development Activity	8b. OFFICE SYMBOL (If applicable) SGRD-UMP	9. PROCUREMENT DAMD17-92-C-		ENTIFICATI	ON NUMBER	
Sc. ADDRESS (City, State, and ZIP Code)	OUR OF THE	10. SOURCE OF F	UNDING NUMBER	RS		
Fort Detrick Frederick, MD 21702-5009	PROGRAM ELEMENT NO. 63807A	PROJECT NO. 30463807	TASK NO. QC	WORK UNIT ACCESSION NO. 073		
Acute Oral and Intraperitoneal Toxic 2. PERSONAL AUTHOR(S) Levine, Barry S. 3a. TYPE OF REPORT Final FROM 5/24 6. SUPPLEMENTARY NOTATION	14. DATE OF REPORT		<i>Day)</i> 15.	PAGE COUNT 279		
7. COSATI CODES FIELD GROUP SUB-GROUP	18. SUBJECT TERMS (WR242511 Tarts WR269410 Acute Toxicity	ate	e if necessary and	identify b	y block number)	
ABSTRACT (Continue on reverse if necessary and identify by block number) This study examined the acute oral and intraperitoneal toxicity of WR242511 tartrate and WR269410 in mice. The dose levels were selected on the basis of range-finding tests. After dosing, the animals were weighed weekly, observed daily for 14 days, and the survivors were necropsied on Day 14. Nonsurvivors were also necropsied. The acute oral LD50s of WR242511 tartrate, administered in 1% methylcellulose/0.4% Tween 80 by gavage, were not significantly different between sexes (males; 23.0 mg base/kg and females; 22.45 mg base/kg). The LD50 values obtained when WR242511 tartrate was administered intraperitoneally in the same vehicle were identical for both sexes (21.82 mg base/kg). Thus, the LD50 of WR242511 tartrate was unaffected by sex or route of administration. Due to dosage formulation problems, WR269410 was administered as a solution in polyethylene glycol 200 (PEG 200). An oral LD50 could not be calculated because of apparent vehicle lethality at the dosing volumes necessary to administer lethal doses of WR269410. The oral LD50 of WR269410 is however estimated to exceed 1000 mg/kg, based on the additive contribution of the vehicle to the mortality observed. In the intraperitoneal acute toxicity test, WR269410 was administered in PEG 200 resulting in a LD50 value of 117.43 mg/kg in males and 190.04 mg/kg in females. Thus, WR269410 is several-fold less acutely toxic than WR242511 tartrate administered by either route. This latter drug also demonstrated a significantly steeper dose-mortality curve.						
UNCLASSIFIED/UNLIMITED SAME AS RE 2a. NAME OF RESPONSIBLE INDIVIDUAL	T. DTIC USERS	Unclassified	nclude Area Code			
Barry S. Levine D Form 1473, JUN 86	Previous editions are o	(312) 996-5		CLASSIFICA	TION OF THIS PAGE	

Task Order No.: UIC-7A UIC/TRL Study No.: 105

STATEMENT OF COMPLIANCE

To the best of my knowledge, (Study No. 105 - ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE) was conducted in compliance with the Good Laboratory Practices regulations as published in 21 CFR 58, 40 CFR 160 and 40 CFR 792 in all material aspects with the following reservations:

The stability of the test or control articles under the test conditions has not been determined by the testing facility (Sections 105 and 185). This requirement is not applicable since only a single dose was administered in this study. Test article stability will be reported following completion of the repeat dose toxicity studies.

The protocol for this study was approved by the UIC Animal Care Committee.

Signature

Study Director

Barry S. Levine, D.Sc., D.A.B.T.

Date

QUALITY ASSURANCE STATEMENT

STUDY TITLE: ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR264910 IN MICE

STUDY NUMBER: 105

STUDY DIRECTOR: BARRY S. LEVINE

INITIATION DATE: 12/3/92

This study has been divided into a series of phases. Using a random sampling approach, Quality Assurance monitors each of these phases over a series of studies. Procedures, equipment, documentation, etc., are examined in order to assure that the study is performed in accordance with the Good Laboratory Practice regulations of the Food and Drug Administration and the Environmental Protection Agency to assure that the study is conducted according to the protocol.

The following are the inspection dates, phases inspected, and report dates of QA inspections of the study.

INSPECT ON 12/7/92, TO STUDY DIR 12/7/92, TO MGMT 12/7/92 PHASES: PROTOCOL REVIEW

INSPECT ON 4/19/93, TO STUDY DIR 4/20/93, TO MGMT 4/22/93 PHASES: ANIMAL RECEIPT AND ROOM ENVIRONMENT

INSPECT ON 4/28/93, TO STUDY DIR 4/29/93, TO MGMT 5/4/93 PHASES: TEST ARTICLE PREPARATION AND ANALYTICAL LABORATORY ANALYSIS

INSPECT ON 4/29/93, TO STUDY DIR 4/29/93, TO MGMT 5/4/93 PHASES: BODY WEIGHT, DOSING (ORAL AND INTRAPERITONEAL) AND CLINICAL SIGNS

INSPECT ON 6/28/93, TO STUDY DIR 6/29/93, TO MGMT 6/29/93 PHASES: RAW DATA AND REPORT FROM ANALYTICAL LABORATORY

INSPECT ON 8/2-3/93, TO STUDY DIR 8/4/93, TO MGMT 8/6/93 PHASES: RAW DATA

INSPECT ON 8/3-4/93, TO STUDY DIR 8/4/93, TO MGMT 8/6/93 PHASES: DRAFT FINAL REPORT

INSPECT ON 9/10/93, TO STUDY DIR 9/10/93, TO MGMT 9/14/93 PHASES: FINAL REPORT

QUALITY ASSURANCE

DATE

Task Order No.: UIC-7A UIC/TRL Study No.: 105

ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE

TRL Chemical Nos.: 1620614 & 1720614

Sponsor: U.S. Army Medical Materiel

and Development Activity Frederick, MD 21702-5009

Test Articles: WR242511 Tartrate

WR269410

Sponsor

Representative: George J. Schieferstein, Ph.D.

Testing Facility: Toxicology Research Laboratory (TRL)

University of Illinois at Chicago (UIC)

Department of Pharmacology

1940 W. Taylor St.

Chicago, Illinois 60612-7353

Dosing Initiation: April 29, 1993

In-Life Completion: June 30, 1993

Task Order No.: UIC-7A UIC/TRL Study No.: 105

TABLE OF CONTENTS

											Pa	ige
TITLE	PAGE					 	 		 	 	 	1
STATE	EMENT	OF CO	MPLIA?	NCE		 	 	• • •	 	 	 	2
QUAL	ITY AS	SURAN	CE STA	ATEMENT		 	 		 	 	 	3
SIGNA	TURE	PAGE				 	 		 	 	 	4
TABLE	E OF CO	ONTEN	rs			 	 		 	 	 	5
1.	SUMM	ARY .				 	 		 	 	 	9
2.	INTRO	DUCTI	ON .			 	 		 	 	 	9
3.	MATE	RIALS	AND M	ETHODS		 	 		 	 	 	9
	3.1 3.2 3.3 3.4	Dosage Test Sy	Formul stem	ations		 	 		 	 	 	10 10
		3.4A	WR242	511 Tartrate		 	 		 	 ٠.	 	12
			3.4A.1	Range-Finding 3.4A.1.1 3.4B.1.2	Test . Gavage Intraper	 	 		 	 	 	12
			3.4A.2	Acute Toxicity 3.4A.2.1 3.4A.2.2	Test . Gavage Intraper	 	 		 	 	 	13
		3.4B	WR269	410		 	 		 	 	 	13
			3.4B.1	Range-Finding 3.4B.1.1 3.4B.1.2	Test . Gavage Intraper	 	 		 	 	 	13
			3.4B.2	Acute Toxicity 3.4B.2.1 3.4B.2.2	Test . Gavage	 	 		 	 	 	14

Task Order No.: UIC-7A UIC/TRL Study No.: 105

TABLE OF CONTENTS (contd.)

4.	RESU	LTS .				5
	4.1	Range-	-Finding	Test		5
		4.1A V	WR2425	11 Tartrate		5
			4.1A.1	Gavage		5
				4.1A.1.1 4.1A.1.2	Clinical Signs	
			4.1A.2	Intraperitoneal		5
				4.1A.2.1 4.1A.2.2	Clinical Signs	
		4.1B	WR269	9410		7
			4.1B.1	Gavage		7
				4.1B.1.1 4.1B.1.2	Clinical Signs	
			4.1B.2	Intraperitoneal		7
				4.1B.2.1 4.1B.2.2	Clinical Signs	
	4.2	Acute	Toxicity	Test		3
		4.2A	WR242	2511 Tartrate .		3
			4.2A.1	Gavage		3
				4.2A.1.1 4.2A.1.2 4.2A.1.3 4.2A.1.4 4.2A.1.5	Dosage Formulation Analysis18Clinical Signs18Body Weight18Necropsy18Mortality19	8
			4.2B.2	Intraperitoneal)
				4.2A.2.1 4.2A.2.2 4.2A.2.3 4.2A.2.4	Dosage Formulation Analysis 19 Clinical Signs 19 Body Weight 19 Necropsy 19	9
				4.2A.2.5	Mortality	1

Task Order No.: UIC-7A UIC/TRL Study No.: 105

TABLE OF CONTENTS (contd.)

		4.2B	WR269	9410		20
			4.2B.1	Gavage (Set 1)		20
				4.2B.1.1 4.2B.1.2 4.2B.1.3 4.2B.1.4 4.2B.1.5	Clinical Signs Body Weight Necropsy	20 20 20 20 20
			4.2B.1	Gavage (Set 2)		20
				4.2B.1.1 4.2B.1.2 4.2B.1.3 4.2B.1.4 4.2B.1.5	Dosage Formulation Analysis Clinical Signs Body Weight Necropsy Mortality	21 21 21
			4.2B.2	Intraperitoneal		22
				4.2B.2.1 4.2B.2.2 4.2B.2.3 4.2B.2.4 4.2B.2.5	Dosage Formulation Analysis Clinical Signs Body Weight Necropsy Mortality	22 22 22
5.	DISCU	SSION/0	CONCL	USION		22
5.	PERSC	NNEL				24
7.	ARCH	IVES .				24
8.	REFER	RENCE				24
					TABLES	
	1	LD50 V	alues			25
	2	Dosage	Formul	lation Analysis		26
	3	Male S	ummary	of Clinical Sig	ns	28

Task Order No.: UIC-7A UIC/TRL Study No.: 105

TABLE OF CONTENTS (contd.)

4	Female Summary of Clinical Signs
5	Male Summary of Body Weights
6	Female Summary of Body Weights
7	Male Summary of Body Weight Gains
8	Female Summary of Body Weight Gains
9	Necropsy Observations
10	Dose-Mortality Data
	APPENDICES
1	Analytical Chemistry Methodology and Dosage Formulation Analysis 1-
2	Analytical Chemistry Report from Dr. Flanagan (Univ. of Iowa) 2-
3	Individual Observations
4	Individual Body Weights and Body Weight Gains 4-
5	LD50 Data
6	Protocol and Amendments
7	Study Deviations

Task Order No.: UIC-7A UIC/TRL Study No.: 105

SUMMARY

This study examined the acute oral and intraperitoneal toxicity of WR242511 tartrate and WR269410 in mice. The dose levels were selected on the basis of range-finding tests. After dosing, the animals were weighed weekly, observed daily for 14 days, and the survivors were necropsied on Day 14. Nonsurvivors were also necropsied.

As shown in Table 1, the acute oral LD50s of WR242511 tartrate, administered in 1% methylcellulose/0.4% Tween 80 by gavage, were not significantly different between sexes (males; 23.0 mg base/kg and females; 22.45 mg base/kg). The LD50 values obtained when WR242511 tartrate was administered intraperitoneally in the same vehicle were identical for both sexes (21.82 mg base/kg). Thus, the LD50 of WR242511 tartrate was unaffected by sex or route of administration.

Due to dosage formulation problems, WR269410 was administered as a solution in polyethylene glycol 200 (PEG 200). An oral LD50 could not be calculated because of apparent vehicle lethality at the dosing volumes necessary to administer lethal doses of WR269410. The oral LD50 of WR269410 is however estimated to exceed 1000 mg/kg, based on the additive contribution of the vehicle to the mortality observed. In the intraperitoneal acute toxicity test, WR269410 was administered in PEG 200 resulting in a LD50 value of 117.43 mg/kg in males and 190.04 mg/kg in females (Table 1). Thus, WR269410 is several-fold less acutely toxic than WR242511 tartrate administered by either route. This latter drug also demonstrated a significantly steeper dose-mortality curve.

2. INTRODUCTION

The purpose of this study was to assess the toxicity of the test article in CD^o mice following a single oral or intraperitoneal dose. The experimental design was based on the Sponsor's requirements. The protocol for this study was approved by the UIC Animal Care Committee. The mouse is a standard and accepted species for toxicology studies, and was specified by the Sponsor. The routes were also specified by the Sponsor. No unforseen circumstances affected the integrity of the study. Dosing was initiated on April 29, 1993 and the in-life portion was terminated on June 30, 1993.

3. MATERIALS AND METHODS

3.1 Test Articles

The test article (WR242511 Tartrate, Bottle No. BM05816, Lot No. DJD-08-235), a yellow, crystalline powder, was received on December 15, 1992 from Herner & Co. and was assigned an in-house chemical number (1720614). It was stored in the original container at -20 to -15°C and at the ambient relative humidity of the freezer. The Analytical Chemistry Report is contained in Appendix 1. The test article was initially identified by GC-MS and the purity was determined by HPLC (99.51 \pm 0.02%).

The second test article [WR269410 in Polyethylene Glycol 200 (PEG 200); concentration 100 mg/ml] was received on April 27, 1993 from Dr. Douglas R. Flanagan, University of Iowa, College of Pharmacy. The test article was assigned an in-house chemical number (1620614). It was stored in the original container at 0 - 4°C and at the ambient relative humidity of the refrigerator. The Analytical Chemistry Report is contained in Appendix 1. The test article

Task Order No.: UIC-7A UIC/TRL Study No.: 105

was initially identified by GC-MS and the purity was determined by HPLC (100%). The concentration of two batches of the received test article in PEG 200 was determined to be 99.95 and 99.5 mg/ml by Dr. Flanagan, and is documented in Appendix 2.

3.2 Dosage Formulations

WR242511 tartrate was administered as a suspension using 1% methylcellulose/0.4% Tween 80 as the vehicle. The dose levels and formulation concentrations of WR242511 tartrate in this report refer to quantities of base, not tartrate salt. Because a suspension of WR269410 in 1% methylcellulose/0.4% Tween 80 could not be passed through needles necessary to dose mice, following discussions with the Sponsor, the drug was administered as a solution in PEG 200. Stock solutions of WR269410 (concentration 100 mg/ml) were received from Dr. Douglas R. Flanagan as described above. Samples of all WR242511 tartrate dosage formulations were analyzed for test article concentration prior to their use. Samples of all WR269410 dosage formulations were sent to Dr. Flanagan for analysis, but the analysis report of test article concentration shown in Appendix 2 was received subsequent to test article use. Therefore, because report analysis was not released prior to dosing, one dosage formulation of WR269410 was used in the acute toxicity study by intraperitoneal administration that was not within 10% of its intended concentration (11.8% of target). The results of these analyses are summarized in Table 2.

3.3 Test System

Virus Antibody Free male and female CD® mice, approximately 6 weeks of age (Date of Birth: March 15, 1993), were obtained from Charles River Breeding Laboratories, Portage, Michigan on April 19, 1993. A second set of Virus Antibody Free male and female CD® mice, approximately 6 weeks of age (Date of Birth: April 27, 1993), were obtained from Charles River Breeding Laboratories, Portage, Michigan on June 09, 1993. Upon arrival, the animals were sexed and examined to determine their health, and were assigned a study-unique quarantine/pretest number. They were individually housed in polycarbonate cages, with Anderson Bed-o-cob® bedding (Heinold Co., Kankakee, IL), which conformed to the upper weight range recommended in the Guide for the Care and Use of Laboratory Animals, DHHS (NIH) No. 86.23. Animal room temperature and relative humidity were generally maintained at 65 - 78 °F and 30 - 70%, respectively. The room was on a 14 hour light/10 hour dark cycle. The animals were transferred to clean cages once weekly.

The mice were provided ad libitum access to drinking water via an automatic watering system in which the room distribution lines were flushed daily, and to Purina Certified Rodent Chow No. 5002 (Ralston Purina Company, St. Louis MO) except for a 3 - 6 hour fast prior to oral dosing and until ≈ 2 hours after dosing. The water was untreated with additional chlorine or HCl. The animals were quarantined for approximately one week prior to test article administration, except for the range-finding test which was conducted during the quarantine period. They were examined by the Clinical Veterinarian near the end of the quarantine period, and were released for placement on test at that time.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

3.4 Experimental Design

The study was conducted in phases. The particular phases of the study are designated in the summary and the individual data as follows: (1) the study number, "105" in the first three digits; (2) the route, either "PO" (oral) or "IP" (intraperitoneal) in the next two digits; and (3) the test article, either "24" (WR242511 tartrate) or "26" (WR269410) in the last two digits. One exception exists for this designation of study phase; data obtained from the second group of animals administered WR269410 by gavage. In this case, test article WR269410 is designated by the number "6" and the indication that this is a second set is designated by the letter "A".

In range-finding tests, the selected animals were identified by their pretest number. A cage card appeared on the front of each cage and contained the following information: study number, animal number, test article identification, treatment group number and dose level. Oral dosing (gavage) was accomplished by the use of a rigid oral feeding needle. In intraperitoneal tests, dosing was accomplished by the use of a 25 gauge x 5/8 inch needle.

Body weights were obtained on Day 0 for dosing calculations. The animals were observed for clinical signs and mortality for at least 5 days. Survivors were euthanized and discarded. No post-mortem observations were conducted on these animals.

In acute toxicity tests, at the end of the quarantine/pretest period, 5 animals/sex/group were chosen for the study using a computer generated-randomization program. The selected animals were uniquely identified by an ear tag. A cage card appeared on the front of each cage and contained the following information: study number, animal number, test article identification, treatment group number and dose level.

The test animals were given either a single oral dose or a single intraperitoneal dose of the appropriate concentration of the test article. Following an approximate 3 hour fast, the oral dosing was accomplished by the use of a rigid oral feeding needle. The intraperitoneal dosing was accomplished by the use of a 25 gauge x 5/8 inch needle.

All animals were observed at least three times on Day 0 following test article administration (designated in the data as either "1, 2, or 3", or as "#1, #2 or #3" following the clinical sign of toxicity seen) and daily thereafter. Body weights were obtained in Week -1, and on Days 0, 7 and 14. All test animals which died were grossly necropsied as soon as possible. At fourteen days post-treatment (Day 14), all surviving animals were sacrificed by carbon dioxide and a gross necropsy was performed. The necropsy procedure was a thorough and systematic examination and dissection of the animal viscera and carcass. A veterinary pathologist was available to verify gross lesions. All tissues and organs were discarded following termination of the gross necropsy procedure.

The incidence of all pharmacologic and/or toxicological effects were calculated for each dose levels by sex. For body weights, means and standard deviations were calculated for each dose level by sex and time point. For the toxicity tests, probit analysis of dose-mortality data was

Task Order No.: UIC-7A UIC/TRL Study No.: 105

used to calculate the LD50 and its 95% confidence interval and the slope of the dose-mortality curve. The method of Miller and Tainter (1944) was used to calculate an LD50 values because it is able to perform linear regression with one only data point between 0% and 100% mortality, which occurred with WR242511 tartrate due to a very steep dose-mortality curve.

3.4A WR242511 Tartrate

3.4A.1 Range-Finding Test

3.4A.1.1 Gavage

Dose levels listed below were tested in the range-finding test.

Dose Level (mg base/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
15	1.5	10	2	2
20	2.0	10	2	2
25	2.5	10	2	2
35	3.5	10	2	0
50	5.0	10	2	2

3.4A.1.2 Intraperitoneal

Dose levels listed below were tested in the range-finding test.

Dose Level (mg/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
5	1.0	5	0	2
10	2.0	5	0	2
15	3.0	5	2	2
20	4.0	5	2	2
25	5.0	5	2	2
35	7.0	5	2	0
50	10.0	5	2	2

Task Order No.: UIC-7A UIC/TRL Study No.: 105

3.4A.2 Acute Toxicity Test

3.4A.2.1 Gavage

Based on the range-finding test, the following were administered.

Treatment <u>Group</u>	Dose Level (mg base/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
1	10	1.0	10	5	5
2	13	1.3	10	5	5
3	17	1.7	10	5	5
4	23	2.3	10	5	5
5	30	3.0	10	5	5

3.4A.2.2 Intraperitoneal

Based on the range-finding test, the following were administered.

Treatment <u>Group</u>	Dose Level (mg base/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
1	10	2.0	5	5	5
2	13	2.6	5	5	5
3	17	3.4	5	5	5
4	23	4.6	5	5	5
5	30	6.0	5	5	5

3.4B WR269410

3.4B.1 Range-Finding Test

3.4B.1.1 Gavage

The following dose levels were tested in the range-finding test.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

Dose Level (mg/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
0	0	10	2	2
100	10	10	2	2
400	40	10	2	2
650	65	10	2	2
1000	100	10	2	2
1500	100	15	2	2

3.4B.1.2 Intraperitoneal

The following dose levels were tested in the range-finding test.

Dose Level (mg/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
0	0	5	2	2
100	20	5	2	2
150	30	5	2	2
200	40	5	2	2
400	80	5	2	2

3.4B.2 Acute Toxicity Test

3.4B.2.1 Gavage

Based on the range-finding test, the following were administered. The dosing volume was increased from 10 ml/kg in the range-finding test to 20 ml/kg in order to administer the necessary doses.

Dose Level (mg/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
800	40	20	5	5
1100	55	20	5	5
1300	65	20	5	5
1500	75	20	5	5
1750	87.5	20	5	5
2000	100	20	5	5

A second set of animals was subsequently added to determine if the increase in dosing volume (10 ml/kg in the range-finding tests to 20 ml/kg in the toxicity tests) had contributed to a higher incidence of mortality of WR269410 than expected (see Section 4.2B).

Task Order No.: UIC-7A UIC/TRL Study No.: 105

Dose Level (mg/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
0	0	10	5	5
0	0	20	5	5
800	80	10	5	5
1000	100	10	5	5

3.4B.2.2 Intraperitoneal

Based on the range-finding test, the following doses were administered.

Treatment <u>Group</u>	Dose Level (mg/kg)	Dosage Formulation (mg/ml)	Dosing Volume (ml/kg)	No. of Males	No. of Females
1	100	20	5	5	5
2	120	24	5	5	5
3	140	28	5	5	5
4	170	34	5	5	5
5	200	40	5	5	5

4. RESULTS

- 4.1 Range-Finding Test
- 4.1A WR242511 Tartrate
 - 4.1A.1 Gavage

4.1A.1.1 Clinical signs

- 15 mg base/kg: no abnormal signs observed
- 20 mg base/kg: rough coat, hunched posture, ataxia, found dead
- 25 mg base/kg: rough coat, hunched posture, found dead
- 35 mg base/kg: rough coat, hunched posture, found dead (only ♂ dosed)
- 50 mg base/kg: convulsions, found dead

Task Order No.: UIC-7A UIC/TRL Study No.: 105

4.1A.1.2 Mortality

	Mortality ^a	
Dose Level (mg base/kg)	Males	<u>Females</u>
15	0/2	0/2
20	2/2	2/2
25	1/2	2/2
35	2/2	-
50	2/2	2/2

*number of deaths/number of animals in group.

4.1A.2 Intraperitoneal

4.1A.2.1 Clinical Signs

5 mg base/kg: no abnormal signs observed ($^{\circ}$ only dosed) 10 mg base/kg: no abnormal signs observed ($^{\circ}$ only dosed)

15 mg base/kg: rough coat, hunched posture
20 mg base/kg: rough coat, hunched posture, found dead (\$\delta\$ only)
25 mg base/kg: rough coat, hunched posture, lethargic, found dead (\$\Pi\$ only)
35 mg base/kg: no abnormal signs observed (\$\delta\$ only dosed)

50 mg base/kg: rough coat, lethargic, found dead

4.1A.2.2 Mortality

	Mortality ^a	
Dose Level (mg base/kg)	Males	<u>Females</u>
5	•	0/2
10	-	0/2
15	0/2	0/2
20	1/2	0/2
25	0/2	2/2
35	0/2	•
50	2/2	2/2

*number of deaths/number of animals in group.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

4.1B WR269410

4.1B.1 Gavage

4.1B.1.1 Clinical Signs

0 mg/kg: no abnormal signs observed

100 mg/kg: rough coat, decreased activity (slight)

400 mg/kg: rough coat, decreased activity (slight)

650 mg/kg: rough coat, lethargic

1000 mg/kg: rough coat, decreased activity (slight), lethargic

1500 mg/kg: rough coat, decreased activity (slight), lethargic, comatose, found dead

4.1B.1.2 Mortality

	Mortality ^a	
Dose Level (mg base/kg)	Males	<u>Females</u>
0	0/2	0/2
100	0/2	0/2
400	0/2	0/2
650	0/2	0/2
1000	0/2	0/2
1500	0/2	1/2

*number of deaths/number of animals in group.

4.1B.2 Intraperitoneal

4.1B.2.1 Clinical Signs

0 mg/kg: decreased activity (slight)

100 mg/kg: rough coat, decreased activity (slight), lethargic

150 mg/kg: rough coat, hunched posture, decreased activity (slight), lethargic, comatose,

found dead

200 mg/kg: rough coat, decreased activity (slight), lethargic, bloated, ataxia, comatose,

found dead

400 mg/kg: found dead

Task Order No.: UIC-7A UIC/TRL Study No.: 105

4.1B.2.2 Mortality

	Mortality ^a	
Dose Level (mg base/kg)	Males	Females
0	0/2	0/2
100	0/2	0/2
150	0/2	2/2
200	2/2	2/2
400	2/2	2/2

^{*}number of deaths/number of animals in group.

4.2 Acute Toxicity Test

4.2A WR242511 Tartrate

4.2A.1 Gavage

4.2A.1.1 Dosage Formulation Analysis

Dosage formulation analysis is shown in Table 2 and is described with the analytical chemistry methodology in Appendix 1. All test article dosage formulations were within 10% of their intended concentration.

4.2A.1.2 Clinical Signs

Clinical signs of toxicity (hunched posture, decreased activity, lethargy, ataxia) were primarily limited to the two highest treatment groups (23 and 30 mg base/kg) in both sexes. Rough coat was observed in many of the lower dose animals. However, hunched posture was only seen in a few lower dose animals (Tables 3 and 4, and Appendix 3).

4.2A.1.3 Body Weight

Body weights and body weight gains were generally unaffected by test article treatment for those animals which survived the fourteen day observation period (Tables 5, 6, 7 and 8, and Appendix 4).

4.2A.1.4 Necropsy

Necropsy observations are shown in Table 9. Gross lesions were not observed.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

4.2A.1.5 Mortality

Dose-mortality data are shown in Table 10 and the LD50 data are shown in Appendix 5. The oral LD50 (and its 95% confidence interval) of WR242511 tartrate for males are 23.0 (15.47 to 34.19) mg base/kg and the dose-mortality curve slope (probit/log dose) is 15.8. For females, the corresponding data are 22.45 (15.14 to 33.29) mg base/kg and the dose-mortality curve slope is 15.9. The LD50 and corresponding values were calculated by the method of Miller and Tainter (1944).

4.2A.2 Intraperitoneal

4.2A.2.1 Dosage Formulation Analysis

Dosage formulation analysis is shown in Table 2 and is described with the analytical chemistry methodology in Appendix 1. All test article dosage formulations were within 10% of their intended concentration.

4.2A.2.2 Clinical Signs

Significant clinical signs of toxicity (hunched posture, decreased activity, ataxia, comatose state) were seen only in the two highest treatment groups (23 and 30 mg base/kg) in both sexes (Tables 3 and 4, and Appendix 3). Rough coat was seen in all treatment groups.

4.2A.2.3 Body Weight

Body weights and body weight gains were generally unaffected by test article treatment for those animals which survived the fourteen day observation period (Tables 5, 6, 7 and 8, and Appendix 4).

4.2A.2.4 Necropsy

Necropsy observations are shown in Table 9. No gross lesions were observed.

4.2A.2.5 Mortality

Dose-mortality data are shown in Table 10 and the LD50 data is shown in Appendix 5. The intraperitoneal LD50 of WR242511 tartrate for both males and females is 21.82 mg base/kg with a 95% confidence interval of 14.75 to 32.29 mg base/kg. The dose-mortality curve slope (probit/ log dose) is 15.99. The LD50 and corresponding values were calculated by the method of Miller and Tainter (1944).

Task Order No.: UIC-7A UIC/TRL Study No.: 105

4.2B WR269410

4.2B.1 Gavage (Set 1)

4.2B.1.1 Dosage Formulation Analysis

Dosage formulation analysis is shown in Table 2 and Appendix 2. All test article dosage formulations were within 10% of their intended concentration.

4.2B.1.2 Clinical Signs

Due to the high incidence of mortality, signs of toxicity were observed in all treatment groups in both sexes (Tables 3 and 4, and Appendix 3). Animals which survived generally recovered from treatment-related clinical signs.

4.2B.1.3 Body Weight

Body weights are shown in Tables 5 and 6. All surviving animals gained weight (Tables 7 and 8, and Appendix 4), but because of the high incidence of mortality, differences between treatment groups could not be discerned.

4.2B.1.4 Necropsy

Necropsy observations are shown in Table 9. Gross lesions were not observed.

4.2B.1.5 Mortality

Dose-Mortality data are shown in Table 10. LD50 values could not be calculated due to the excessive mortality seen at all dose levels. See below for further discussion.

4.2B.1 Gavage (Set 2)

A second set of animals were subsequently added to determine if the increase in dosing volume (10 ml/kg in the range-finding tests to 20 ml/kg in the toxicity tests) had contributed to a higher incidence of mortality of WR269410 than expected. This set included two vehicle control groups at different dosing volumes (10 ml/kg and 20 ml/kg), and two test article treatment groups at a dosing volume of 10 ml/kg. The 800 mg/kg dose level was included to allow a comparison to the previous data of 800 mg/kg at a dosing volume of 20 ml/kg.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

4.2B.1.1 Dosage Formulation Analysis

Dosage formulation analysis is shown in Table 2 and Appendix 2. The test article dosage formulations were within 10% of their intended concentration.

4.2B.1.2 Clinical Signs

Signs of toxicity (rough coat, hunched posture) were observed in all treatment groups in males, including both vehicle-treated groups (Table 3). Decreased activity was seen in vehicle-treated (dosing volume of 10 ml/kg) and WR269410-treated (1000 mg/kg) males. In vehicle-treated females administered 10 ml/kg, only rough coats were observed. All other female treatment groups, including vehicle-treated at a dosing volume of 20 ml/kg, demonstrated rough coat, hunched posture, decreased activity, and lethargy following treatment. Blue feet were seen in WR269410-treated females at a dose of 1000 mg/kg.

4.2B.1.3 Body Weight

Body weights and weight gains are shown in Tables 5, 6, 7 and 8, and Appendix 4. A significant decrease in weight gain was observed in test article-treated males as compared to vehicle-treated males. In female mice, 1000 mg/kg treated females lost body weight. All other treatment groups of both sexes gained a minimal amount of weight in the 14-day observation period.

4.2B.1.4 Necropsy

Necropsy observations are shown in Table 9. A subcutaneous cyst was seen in one 0 mg/kg (10 ml/kg) male and one 800 mg/kg WR269410-treated male. An enlarged mesenteric lymph node was seen in a vehicle-treated male (10 ml/kg). Also, a 1000 mg/kg WR269410-treated female had an irregular shaped lesion on the left kidney (~ 0.6 cm band around the midzone).

4.2B.1.5 Mortality

Dose-mortality data is shown in Table 10 and LD50 data is shown in Appendix 5. PEG 200 toxicity is evident in both vehicle treated groups, except for females receiving a dosing volume of 10 ml/kg. Accordingly, an oral LD50 could not be calculated from the dose-mortality data obtained in both sets. However, cursory inspection of all data including vehicle mortality suggests that the oral LD50 of WR269410 is greater than 1000 mg/kg.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

4.2B.2 Intraperitoneal

4.2B.2.1 Dosage Formulation Analysis

Dosage formulation analysis is shown in Table 2 and Appendix 2. All test article dosage formulations were within 10% of their intended concentration, except for the mid dose treatment group. The dosage formulation of 28 mg/ml, the 140 mg/kg treated animals, was administered in 11.8 % excess of its intended concentration because report analysis was not released prior to dosing.

4.2B.2.2 Clinical Signs

Signs of toxicity (rough coat, hunched posture, decreased activity, lethargy) were observed in all treatment groups; characterized by an increase of incidence with ascending dose levels (Tables 3 and 4, Appendix 3).

4.2B.2.3 Body Weight

Body weights and body weight gains were generally unaffected by test article treatment for those animals which survived the fourteen day observation period (Tables 5, 6, 7 and 8, and Appendix 4).

4.2B.2.4 Necropsy

Necropsy observations are shown in Table 9. One female treated with 140 mg/kg WR269410 had a fusion of the lobes of liver with the diaphragm. One male treated with 170 mg/kg of WR269410 had apparent fusion of the lobes of the liver.

4.2B.2.5 Mortality

The dose-mortality data is shown in Table 10 and the LD50 data is shown in Appendix 5. The intraperitoneal LD50 of WR269410 for male mice is 117.43 mg/kg with a 95% confidence interval of 89.56 to 153.97 mg/kg and the dose-mortality curve slope is 7.47. For female mice, the calculated intraperitoneal LD50 is 190.04 mg/kg with a 95% confidence interval of 134.87 to 267.78 mg/kg. The dose-mortality curve slope is 7.80. The method of Miller and Tainter (1944) was used to calculate LD50 values.

5.0 DISCUSSION/CONCLUSION

In the oral acute toxicity test of WR242511 tartrate, the test article was administered in 1% methylcellulose/0.4% Tween 80 by gavage to five groups of mice (5 animals/sex) at single oral doses of 10, 13, 17, 23 and 30 mg base/kg. LD50s of WR242511 tartrate were calculated using the method of Miller and Tainter (1944), and are shown in Table 1. The oral LD50 of WR242511 tartrate for male

Task Order No.: UIC-7A UIC/TRL Study No.: 105

mice is 23.0 mg base/kg with a 95% confidence interval of 15.47 to 34.19 mg base/kg and the dose-mortality curve slope (probit/log dose) is 15.8. The calculated LD50 for female mice is 22.45 mg base/kg with a 95% confidence interval of 15.14 to 33.29 mg base/kg and the dose-mortality curve slope is 15.9. In the intraperitoneal acute toxicity test of WR242511 tartrate, the test article was administered in 1% methylcellulose/0.4% Tween 80 to five groups of mice (5 animals/sex) at single doses of 10, 13, 17, 23 and 30 mg base/kg. From the results of the toxicity test, the calculated intraperitoneal LD50 of WR242511 tartrate for both male and female mice is 21.82 mg base/kg with a 95% confidence interval of 14.75 to 32.29 mg base/kg. The dose-mortality curve slope (probit/ log dose) is 15.99. Because of the similarity of the LD50 values, 95% confidence intervals, and dose-mortality curve slopes, these data demonstrate that the LD50 value of WR242511 tartrate is unaffected by either sex or route of administration. This is an unexpected finding: one would expect the oral route to yield a lower LD50 value because the drug must first undergo reduction to yield the physiologically active compound responsible for the formation of methemoglobin.

Due to dosage formulation problems, WR269410 was administered as a solution in polyethylene glycol 200 (PEG 200) received from Dr. Douglas R. Flanagan of the University of Iowa. An oral LD50 for WR269410 could not be calculated because of excessive mortality at all dose levels tested and the apparent lack of a dose-response relationship. A second set of animals was added to determine if this was caused by the increase in the dosing volume from 10 ml/kg (most of the range-finding tests) to 20 ml/kg in the acute toxicity tests. This increase was necessary to administer sufficiently high and therefore lethal doses. The second set of data demonstrated that the vehicle alone contributed to the mortality and clinical signs of toxicity observed in mice. Therefore, this vehicle was inappropriate for oral administration in mice. Although, an oral LD50 of the test article could not be calculated from these data, it can be estimated assuming that PEG, 200 contributed additively to the lethality observed. If the data from both sexes are combined at each dose level, it is estimated that the oral LD50 exceeds 1000 mg/kg for acute administration of the test article.

In the intraperitoneal acute toxicity test, WR269410 was administered in PEG 200 to five groups of mice (5 animals/sex) at single doses of 100, 120, 140 170 and 200 mg/kg. LD50s of WR269410 were calculated using the method of Miller and Tainter (1944). The calculated intraperitoneal LD50 of WR269410 for male mice is 117.43 mg/kg with a 95% confidence interval of 89.56 to 153.97 mg/kg and the dose-mortality curve slope is 7.47 (Table 1). For female mice, the calculated intraperitoneal LD50 is 190.04 mg/kg with a 95% confidence interval of 134.87 to 267.78 mg/kg. The dose-mortality curve slope is 7.80. Thus, female mice are slightly less susceptible to WR269410-induced toxicity than male mice. Also, based on the estimated oral and the calculated intraperitoneal LD50 values of WR269410, this drug is several-fold less acutely toxic than WR242511 tartrate administered by either route in both sexes. WR242511 tartrate also demonstrated a significantly steeper dose-mortality curve.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

6.0 PERSONNEL:

Study Director

Barry S. Levine, D.Sc., D.A.B.T. **Toxicologist** E. Marianna Furedi-Machacek, D.V.M.

Michael J. Tomlinson, D.V.M., Ph.D., D.A.C.V.P. Pathologist

Pathology Support Ralph Bunte, D.V.M., D.A.C.V.P.

Adam Negrusz, Ph.D. Analytical Chemist

James Artwohl, D.V.M., M.S., D.A.C.L.A.M. Clinical Veterinarian

Craig Wardrip, D.V.M. Veterinarian Support Soudabeh Soura, B.S. Tox. Lab Supervisor Lead Technician Nancy Dinger, B.S. Thomas Tolhurst, B.S. Chemistry Specialist

Ronald C. Schoenbeck Quality Assurance

Report preparation was assisted by Clyde W. Wheeler, Ph.D. and Nancy Dinger, B.S..

7.0 ARCHIVES

The raw data, test article reserve sample and final report are archived at the Toxicology Research Laboratory (TRL), University of Illinois at Chicago (UIC), Department of Pharmacology, 1940 W. Taylor St., Chicago, IL 60612-7353.

8.0 REFERENCE

Miller and Tainter (1944). Estimation of the LD50 and its error by means of logarithmic-probit graph paper. Proc. Soc. Exp. Bio Med. 57, 261-264.

Table 1

ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE

Calculated LD50 Values

WR242511 Tartrate

Route	Sex	LD50 (mg base/kg)	95% Confidence Interval (mg base/kg)	Dose-Mortality Curve Slope (probit/log dose)
01	Male	23.00	15.47 - 34.19	15.80
Oral	Female	22.45	15.14 - 33.29	15.90
*	Male	21.82	14.75 - 32.29	15.99
Intraperitoneal	Female	21.82	14.75 - 32.29	15.99

WR269410

Route	Sex	LD50 (mg/kg)	95% Confidence Interval (mg/kg)	Dose-Mortality Curve Slope (probit/log dose)
International	Male	117.43	89.56 - 153.97	7.47
Intraperitoneal	Female	190.04	134.87 - 267.78	7.80

Table 2

ACUTE ORAL AND INTRAPERITONEAL TOXICITY
STUDY OF WR242511 AND WR269410 IN MICE

Dosage Formulation Analysis*

WR242511 Tartrate (Gavage)

Target Concentration (mg/ml)	Day 0 ^b	% Target
1.0	0.99 ± 0.0133	98.9
1.3	1.31 ± 0.0070	100.5
1.7	1.69 ± 0.0297	99.6
2.3	2.32 ± 0.0437	101.0
3.0	2.97 ± 0.0061	99.1

WR242511 Tartrate (Intraperitoneal)

Target Concentration (mg/ml)	Day 0 ^b	% Target
2.0 2.6	$2.17 \pm 0.0096 \\ 2.55 \pm 0.0203$	108.7 98.0
3.4	3.39 ± 0.0411	99.8
4.6	4.58 ± 0.0336	99.7
6.0	5.81 ± 0.0037	96.9

^{*}Mean + standard deviation for triplicate runs.

^bThe samples were assayed within 24 hours prior to use.

Table 2 (contd.)

ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE

Dosage Formulation Analysis*

WR269410 (Gavage) Set 1

Target Concentration (mg/ml)	Day 0 ^b	% Target
40	40.3	100.8
55	50.3	91.5
65	66.8	102.8
75	77.6	103.5
87.5	84.2	96.3
100	100.0	100.0

WR269410 (Gavage) Set 2

Target Concentration (mg/ml)	Day 0 ^b	% Target
80	73.2	91.5
100	100.0	100.0

WR269410 (Intraperitoneal)

Target Concentration (mg/ml)	Day 0 ^b	% Target
20	18.2	91.0
24	26.4	110.0
28	31.3	111.8
34	31.7	93.2
40	40.3	100.8

^{*}Mean + standard deviation for triplicate runs.

^bThe samples were assayed within 24 hours prior to use.

Table 3.1

ACUTE ORAL TOXICITY STUDY OF WR242511 IN MICE

	SUMMARY	OF CLIN	ICAL S	IGNS			
STUDY: 105P024	, , , , , , , , , , , , , , , , , , , ,	S	EX: MA	LE			
	DOSE:(mg/kg) GROUP:	10 1-M	13 2-M	17 3-M	23 4-M	30 5-M	
Scheduled Saci Animal Found I Activity Decre Ataxia Comatose Hunched Postu Lethargic Rough Coat	Dead Pased	5 0 0 0 0 0 0	5 0 0 0 0 0 0	5 0 0 0 0 0 0	3 2 2 1 0 1 1	0 5 0 0 1 0 1 3	
Total Number of	Animals	5	5	5	5	5	

Table 3.2

ACUTE INTRAPERITONEAL TOXICITY STUDY
OF WR242511 IN MICE

		SUMMAR	Y OF CLIN	ICAL S	IGNS			
 STUDY:	105IP24		S	EX: MA	LE			
		DOSE:(mg/kg) GROUP:	10 1-M	13 2-M	17 3-M	23 4-M	30 5-M	
	Scheduled Sac Animal Found I Activity Decre Ataxia Hunched Postu Rough Coat	Dead eased	5 0 0 0 0 5	5 0 0 0 0 5	5 0 0 0 0 0 5	1 4 1 0 2 5	0 5 4 2 1 4	
	Total Number of	Animale	5	5	5	5	5	

Table 3.3

ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

STUDY: 105P026 SEX: MALE DOSE:(mg/kg)								
DOSE:(mg/kg)		SUMMARY OF	CLINIC	AL SIGN	S			
Scheduled Sacrifice 3 2 1 0 1 1	STUDY: 105P026		SEX	: MALE				
Animal Found Dead Activity Decreased O O O O O O O O O O O O O O O O O O O								
	Animal Found Dead Activity Decreased Comatose Hunched Posture Lethargic Rough Coat Lethargic #1 Lethargic #2 Lethargic #2 Lethargic #2 Activity Decreased #1 Activity Decreased #2 Activity Decreased #3 Comatose #1 Comatose #2 Comatose #3 Rough Coat #1	3 2 0 0 0 0 3 1 0 0 4 4 4 0 1 1	2 3 1 0 1 0 2 2 1 1 3 2 2 0 1 1 1 3	1 4 0 0 1 1 1 2 2 3 1 2 1 2 1	0 5 0 0 0 0 1 2 3 3 2 1 1 1 1 0 0	1 4 1 1 1 2 1 2 1 1 2 2 2 2 2 1	1 4 1 0 0 1 2 3 3 2 2 2 2 3 0 0	
		5	3 5	1 5	·	2 5	3	

Table 3.4

ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

8'	UMMARY OF	CLINICAL	SIGNS		
STUDY: 105P06A		SEX: N	IALE		
DOSE GROU	E:(mg/kg) JP:	0 1-M	0 2-M	800 3-M	1000 4-M
Scheduled Sacrifice Animal Found Dead Decreased Activity Hunched Posture Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Hunched Posture 1 Hunched Posture 2 Hunched Posture 3 Decreased Activity Decreased Activity	1 2	4 1 1 5 1 1 0 0 0 0	4 1 0 2 4 4 4 4 4 1 0 0 0 0	2 3 0 1 2 3 4 4 0 0 0 2 3 2	4 1 1 4 4 4 4 4 4 4 3 2 2 1
Total Number of Anima	ls	5	5	5	5

Table 3.5

ACUTE INTRAPERITONEAL TOXICITY STUDY OF WR269410 IN MICE

	SUMMARY	OF CLI	VICAL S	IGNS					
105IP26	SEX: MALE								
	DOSE:(mg/kg) GROUP:	100 1-M	120 2-M	140 3-M	170 4-M	200 5-M			
Animal Found (Activity Decre Ataxia Comatose Hunched Postur Rough Coat Rough Coat #1 Comatose #1 Activity Decre Rough Coat #2 Comatose #2 Activity Decre Comatose #3 Rough Coat #3 Lethargic #1 Lethargic #1 Lethargic #3 Activity Decre	pead eased #2 eased #3 eased #1	4 1 0 0 0 0 0 5 4 0 5 5 0 0 0 4 0 0 0 4	1440124033104042210	2320001504111113300	1 4 3 2 0 3 4 0 5 0 0 3 1 1 1 0 2 3 0	0520012050050300020			
Total Number of	Animals	5	5	5	5	5			
	Scheduled Saci Animal Found I Activity Decre Ataxia Comatose Hunched Postur Rough Coat #1 Comatose #1 Activity Decre Rough Coat #2 Comatose #2 Activity Decre Comatose #3 Rough Coat #3 Lethargic #1 Lethargic #2 Lethargic #3 Activity Decre	DOSE:(mg/kg) GROUP: Scheduled Sacrifice Animal Found Dead Activity Decreased Ataxia Comatose Hunched Posture Rough Coat Rough Coat #1 Comatose #1 Activity Decreased #2 Rough Coat #2 Comatose #2 Activity Decreased #3 Comatose #3 Rough Coat #3 Lethargic #1 Lethargic #1	DOSE:(mg/kg) 100 GROUP: 1-M Scheduled Sacrifice 4 Animal Found Dead 1 Activity Decreased 0 Ataxia 0 Comatose 10 Rough Coat 5 Rough Coat #1 Comatose #1 0 Activity Decreased #2 Rough Coat #2 Comatose #2 Activity Decreased #3 Comatose #	DOSE:(mg/kg) 100 120 GROUP: 1-M 2-M Scheduled Sacrifice 4 1 Animal Found Dead 1 4 Activity Decreased 0 4 Ataxia 0 0 Comatose 0 1 Hunched Posture 0 2 Rough Coat #1 4 0 Comatose #1 4 0 Comatose #1 4 0 Comatose #2 5 3 Rough Coat #2 5 1 Comatose #2 Activity Decreased #3 Comatose #3 4 4 Comatose #3 0 0 Activity Decreased #3 Comatose #3 0 0 Rough Coat #3 4 4 Lethargic #1 1 2 Lethargic #2 Lethargic #3 0 1 Activity Decreased #1 4 0	DOSE:(mg/kg) 100 120 140 GROUP: 1-M 2-M 3-M	DOSE:(mg/kg)	Dose: make Dos		

Table 4.1

ACUTE ORAL TOXICITY STUDY OF WR242511 IN MICE

		•••••••	SUMMARY	OF CLINI	CAL S	IGNS			
•••••	STUDY:	105PO24		SEX:	FEMA	LE			
			DOSE:(mg/kg) GROUP:	10 1-F	13 2-F	17 3-F	23 4-F	30 5-F	
		Scheduled Sacr Animal Found D Ataxia Dehydrated Hunched Postur Lethangic Rough Coat	ead	5 0 0 0 0 0	5 0 0 0 0 0	5 0 0 1 1 0 2	2 3 1 0 1 0 2	0 5 2 0 0 2	
		Total Number of	Animals	5	5	5	5	5	

Table 4.2

ACUTE INTRAPERITONEAL TOXICITY STUDY OF WR242511 IN MICE

***************************************	SUMMARY	OF CLINI	CAL S	IGNS			
STUDY: 105IP24		SEX:	FEMA	LE	,		
	DOSE:(mg/kg) GROUP:	10 1-F	13 2-F	17 3-F	23 4-F	30 5-F	
Scheduled Sac Animal Found Activity Dec Ataxia Comatose Hunched Postu Rough Coat	Dead reased	5 0 0 0 0	5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	5 0 0 0 0	1 4 3 1 0	0 5 2 1 1	
Total Number of	Animals	5	5	5	5	5	

Table 4.3

ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

	SUMMARY OF	CLINIC	CAL SIGN	S			
STUDY: 105P026		SEX:	FEMALE				
DOSE:(mg/kg) GROUP:	1100 1-F	1300 2-F	1500 3-F	1750 4-F	2000 5-F	800 6-F	
Scheduled Sacrifice Animal Found Dead Activity Decreased Comatose Hunched Posture Lethargic Rough Coat Lethargic #1 Lethargic #2 Lethargic #3 Activity Decreased #1 Activity Decreased #2 Activity Decreased #3 Comatose #1 Comatose #1 Rough Coat #2	1 .40 0 1 1 2 2 1 1 1 2 1 1 2 1	1 4 0 0 1 0 1 2 1 1 3 3 2 0 1 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	1 4 1 0 1 1 2 3 1 1 1 3 2 1 1 1 0 3 2 1 1 0 3 2 1 1 1 0 3 2 1 1 1 0 3 2 1 1 1 0 3 2 1 1 1 1 0 3 2 1 1 1 1 1 0 3 2 1 1 1 1 1 1 1 1 1 2 3 3 3 3 3 3 3 3	0 5 0 0 0 1 1 0 1 2 2 1 1 3 3 2 1	0 5 0 0 0 0 1 3 0 1 2 1 2 0 4 1 0	0 5 0 1 0 0 2 4 3 2 1 2 3 0 0 0 1 2	
Rough Coat #3 Hunched Posture #3	0	2	0	0	0	0	
Total Number of Animals	5	5	5	5	5	5	

Table 4.4

ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~					
SUMMARY	OF CLINICA	L SIGNS	3		
STUDY: 105P06A	SEX: F	EMALE			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
DOSE:(mg/kg) GROUP:	0 1-F	0 2-F	800 3-F	1000 4-F	******************
Scheduled Sacrifice Animal Found Dead Hunched Posture Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Hunched Posture 1 Hunched Posture 2 Hunched Posture 3 Blue Feet 1 Blue Feet 2 Decreased Activity 1 Decreased Activity 2 Decreased Activity 3 Lethargic 1 Lethargic 2 Lethargic 3 Labored Breathing 2 Labored Breathing 3	500300000000000000000000000000000000000	32025554220042100100	323345501100322111111	32334443443132200000	
Total Number of Animals	5	5	5	5	

Table 4.5

ACUTE INTRAPERITONEAL TOXICITY STUDY
OF WR269410 IN MICE

		SUMMARY	OF CLIN	ICAL S	IGNS			
STUDY: 1	.05IP26		SEX	: FEMA	LE			
		DOSE:(mg/kg) GROUP:	100 1-F	120 2-F	140 3-F	170 4-F	200 5-F	
	Scheduled Sacr	ifice	5	5	3	4	2	
	Animal Found D Activity Decre Hunched Postur	0	0	1 0	0	0		
	0	5	5	5	0 3			
	Rough Coat #1 Comatose #1 Activity Decre	ased #2	0	2	4	5	5	
	Rough Coat #2 Comatose #2 Activity Decreased #3			1 1 3	2	0 5	0 2	
	8364 WJ	0 5	0 5	0	1 3	2		
	Lethargic #1 Lethargic #2 Lethargic #3		1 0	1 3 2	1 4	0	0 1	
	Activity Decre		4	2	Ö	ő	Ö	
	Total Number of	Animals	5	5	5	5	5	

Table 5.1

ACUTE ORAL TOXICITY STUDY OF WR242511 IN MICE

		SUMMA	RY OF BO	DY WEIGH	ITS (Grams)		
	STUDY: 105PC	24		SEX	: MALE		
PERIOD	DOSE: (mg/k GROUP:	(g) 10 1-M	13 2-M	17 3-н	23 4-M	30 5-M	
DAY -3	MEAN S.D. N	25.9 1.12 5	26.0 1.66 5	26.1 1.14 5	25.9 1.37 5	26.0 1.43 5	
DAY 0	MEAN S.D. N	27.2 0.83 5	27.7 1.66 5	27.3 1.53 5	27.0 1.23 5	27.7 2.03 5	
DAY 7	MEAN S.D. N	28.7 0.61 5	29.9 1.31 5	28.8 2.16 5	30.3 0.51 3	0	
DAY 14	MEAN S.D. N	30.6 1.05 5	31.8 1.99 5	30.6 2.43 5	32.5 1.01 3	0	
* Pless th		Analysis of	f Variance usi	ng DUNNETT'S	Procedure		

Table 5.2

ACUTE INTRAPERITONEAL TOXICITY STUDY
OF WR242511 IN MICE

SUMMARY OF BODY WEIGHTS (Grams)	••••••
STUDY: 105IP24 SEX: MALE	
DOSE: (mg/kg) 10 13 17 23 30 PERIOD GROUP: 1-M 2-M 3-M 4-M 5-M	
DAY -3 MEAN 25.9 26.2 26.2 26.0 26.1 S.D. 1.53 1.55 1.45 1.55 1.48 N 5 5 5 5 5	
DAY 0 MEAN 27.6 27.4 28.2 27.4 27.4 5.D. 1.98 1.38 1.11 1.99 0.99 N 5 5 5 5 5	
DAY 7 MEAN 28.6 29.0 29.0 27.0 S.D. 1.79 2.03 0.23 0.00 N 5 5 5 1 0	
DAY 14 MEAN 31.0 30.8 31.7 29.6 S.D. 2.55 2.43 0.76 0.00 N 5 5 5 1 0	

^{*} P less than .05
** P less than .01

Table 5.3

ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

		SUMMARY	OF BODY	WEIGHTS	G(Grams)		
	STUDY: 105PO	26		SEX:	MALE		
PERIOD	DOSE: (mg/kg) 1100 GROUP: 1-1	1300 1 2-M	1500 3-M	1750 4-M	2000 5- <b>M</b>	800 6-M	
PRETEST	MEAN 28.3 S.D. 1.55 N		28.3 1.46 5	28.1 2.31 5	28.3 1.65 5	25.8 1.84 5	
DAY 0	MEAN 29.4 S.D. 1.24 N	2.61	29.6 1.59 5	29.1 2.37 5	29.5 1.72 5	27.7 2.65 5	
DAY 7	MEAN 29.8 S.D. 1.07 N		25.9 0.00 1	  0	26.6 0.00 1	26.6 0.00 1	
DAY 14	MEAN 30.6 S.D. 1.37 N		30.8 0.00 1		29.2 0.00 1	27.6 0.00 1	
* Pless t		Analysis of Va	riance using [	DUNNETT'S Pr	ocedure		

Table 5.4 ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

	SUM	MARY OF	BODY	WEIGHTS	(Grams)	 
STUDY:	105P06A			SEX:	MALE	
PERIOD	DOSE: (mg/kg) GROUP:	0 1-M	0 2-M	800 3-M	1000 4-M	 
DAY -2	MEAN S.D. N	28.6 1.32 5	29.0 1.33 5	28.5 1.68 5	28.3 1.61 5	
DAY 0	MEAN S.D. N	28.7 1.06 5	29.9 1.37 5	29.4 1.72 5	29.2 1.61 5	
DAY 7	MEAN S.D. N	32.4 0.88 4	32.4 1.46 4	30.2 2.90 2	31.4 2.11 4	
DAY 14	MEAN S.D. N	29.7 4.50 4	32.7 1.01 4	29.5 2.12 2	31.5 1.74 4	
than .05	Analysi	s of Varianc	e using D	OUNNETT'S Pro	cedure	

P less than .05 P less than .01

Table 5.5

ACUTE INTRAPERITONEAL TOXICITY STUDY
OF WR269410 IN MICE

								 _
			SUMMA	RY OF BOI	Y WEIGH	ITS (Grams)		-
	SI	TUDY: 105IP26	5		SEX	: MALE		-
	PERIOD	DOSE: (mg/kg) GROUP:	100 1-M	120 2-M	140 3-M	170 4-M	200 5-M	 _
	DAY -3	MEAN S.D. N	28.1 1.33 5	28.3 1.42 5	28.1 2.09 5	28.3 1.03 5	28.4 1.82 5	
	DAY 0	MEAN S.D. N	29.3 0.90 5	29.4 1.50 5	29.0 1.89 5	29.4 1.09 5	29.0 1.58 5	
	DAY 7	MEAN S.D. N	29.1 1.98 4	31.7 0.00 1	31.7 0.99 2	25.9 7.42 2	0	
	DAY 14	MEAN S.D. N	29.9 3.62 4	33.3 0.00 1	33.3 0.07 2	32.0 0.00 1	 0	
*	P less than	.05 A	nalvsis o	f Variance usi	na DUNNETT'S	Procedure		

^{*} P less than .05 ** P less than .01

Table 6.1 ACUTE ORAL TOXICITY STUDY OF WR242511 IN MICE

		SUMMARY	OF BODY	WEIGHTS	(Grams)	
 STUD	Y: 105P02			SEX:	FEMALE	
PERIOD	DOSE: (mg/kg) GROUP:	10 1-F	13 2-F	17 3-F	23 4-F	30 5-F
DAY -3	MEAN S.D. N	22.8 1.36 5	23.0 1.26 5	23.3 1.22 5	23.2 1.62 5	23.2 1.17 5
DAY 0	MEAN S.D. N	23.8 1.28 5	24.0 1.85 5	23.9 1.33 5	23.1 1.31 5	23.8 1.00 5
DAY 7	MEAN S.D. N	25.3 1.18 5	25.4 1.56 5	23.8 3.37 5	23.0 1.27 2	
DAY 14	MEAN S.D. N	26.4 1.80 5	26.9 2.01 5	27.8 2.05 5	25.0 0.71 2	0

^{*} P less than .05 ** P less than .01 -- = Data Unavailable

Table 6.2 ACUTE INTRAPERITONEAL TOXICITY STUDY OF WR242511 IN MICE

SUMMARY OF BODY WEIGHTS (Grams)	•••••
CMIDY. 105TD2/ CEY. EDMATE	
STUDY: 105IP24 SEX: FEMALE	
DOSE: (mg/kg) 10 13 17 23 30 PERIOD GROUP: 1-F 2-F 3-F 4-F 5-F	
DAY -3 MEAN 23.0 23.2 23.3 23.1 23.1 S.D. 1.35 1.12 1.39 1.06 1.94 N 5 5 5 5 5	
DAY 0 MEAN 24.3 24.4 24.8 24.4 24.2 S.D. 1.05 1.13 1.31 1.37 1.97 N 5 5 5 5 5	
DAY 7 MEAN 25.9 25.3 25.3 25.8 s.D. 2.22 0.74 1.83 0.00 N 5 5 5 1 0	
DAY 14 MEAN 26.9 27.5 27.3 26.5 S.D. 1.47 0.98 2.14 0.00 N 5 5 5 1 0	

^{*} P less than .05 ** P less than .01 -- = Data Unavailable

Table 6.3 ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

			SUMMARY C	F BODY	WEIGHTS	(Grams)		
	STUDY: 10	5P026	5		SEX: F	EMALE		
PERIOD	DOSE: (mg/kg) GROUP:	1100 1-F	1300 2-F	1500 3-F	1750 4-F	2000 5-F	800 6-F	
PRETEST	MEAN S.D. N	24.6 1.54 5	25.2 1.77 5	24.7 1.24 5	24.8 1.33 5	24.6 1.70 5	22.6 2.89 5	
DAY 0	MEAN S.D. N	24.7 1.86 5	25.1 2.01 5	24.8 0.50 5	25.4 1.13 5	24.8 2.22 5	23.6 1.74 5	
DAY 7	MEAN S.D. N	25.3 0.00 1	19.5 0.00 1	19.8 0.00 1	0	  0	  0	
DAY 14	MEAN S.D. N	26.9 0.00 1	25.0 0.00 1	26.4 0.00 1	0		0	

^{*} P less than .05
** P less than .01
-- = Data Unavailable

Table 6.4

ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

	SUM	MARY OF	BODY	WEIGHTS	(Grams)	
 STUDY:	105P06A			SEX:	FEMALE	
PERIOD	DOSE: (mg/kg) GROUP:	0 1-F	0 2-F	800 3-F	1000 4-F	 
DAY -2	MEAN S.D. N	23.4 1.24 5	23.5 1.06 5	23.2 1.33 5	23.2 1.62 5	
DAY 0	MEAN S.D. N	23.7 0.61 5	23.9 1.03 5	24.1 0.93 5	24.2 1.20 5	
DAY 7	MEAN S.D. N	26.0 1.32 5	24.4 0.81 3	26.3 1.94 3	23.6 2.80 3	
DAY 14	MEAN S.D. N	24.3 4.36 5	25.6 1.78 3	26.9 0.93 3	22.4 5.66 3	

* P less than .05 P less than .01

Table 6.5 ACUTE INTRAPERITONEAL TOXICITY STUDY OF WR269410 IN MICE

		SUMMARY	OF BODY	WEIGHTS	(Grams)	
 STUD	7: 105IP26	5		SEX:	FEMALE	
 PERIOD	DOSE: (mg/kg) GROUP:	100 1-F	120 2-F	140 3-F	170 4-F	200 5-F
DAY -3	MEAN S.D. N	24.6 1.51 5	24.8 1.16 5	25.0 1.48 5	24.9 1.66 5	24.6 1.46 5
DAY 0	MEAN S.D. N	24.9 1.56 5	24.7 1.66 5	25.5 1.57 5	25.1 2.06 5	25.0 2.06 5
DAY 7	MEAN S.D. N	25.8 1.64 5	26.0 1.92 5	26.9 1.32 3	26.9 1.19 4	27.1 0.92 2
DAY 14	MEAN S.D. N	26.3 1.50 5	26.6 1.22 5	28.2 0.65 3	27.6 1.59 4	29.2 0.35 2
P less than .05	A	nalysis of Va	riance using	DUNNETT'S Pro	cedure	

P less than .05 P less than .01

Table 7.1

ACUTE ORAL TOXICITY STUDY OF WR242511 IN MICE

		BUMMA	RY OF WE	IGHT GAI	NS (Grams)		
	STUDY: 105P02	4		SEX	: MALE		
PER100	DOSE: (mg/kg) GROUP:	10 1-M	13 2-M	17 3-н	23 4-M	30 5-M	
DAY 7	MEAN S.D. N	1.5 0.64 5	2.2 0.68 5	1.5 1.11 5	3.0* 0.10 3	0	
DAY 14	MEAN S.D. N	1.8 0.73 5	1.9 1.06 5	1.8 0.48 5	2.2 1.04 3	0	
TOTAL	GAIN MEAN S.D. N	3.3 1.04 5	4.1 1.38 5	3.3 1.26 5	5.2 1.06 3	0	

^{*} P less than .05 ** P less than .01

Table 7.2 ACUTE INTRAPERITONEAL TOXICITY STUDY OF WR242511 IN MICE

		SUMMA	RY OF WE	IGHT GAI	NS (Grams)		
ST	UDY: 105IP2	1		SEX	: MALE		
PERIOD	DOSE: (mg/kg) GROUP:	10 1-M	13 2-M	17 3-M	23 4-M	30 5-M	
DAY 7	MEAN S.D. N	0.9 0.34 5	1.6 0.65 5	0.8 1.26 5	-0.2 0.00 1	0	
DAY 14	MEAN S.D. N	2.5 1.21 5	1.8 0.64 5	2.6 0.80 5	2.6 0.00 1	0	
TOTAL GAIN	MEAN S.D. N	3.4 1.40 5	3.4 1.11 5	3.5 0.82 5	0.00		
* P less than		nalysis o	of Variance usi	ng DUNNETT'S	Procedure		

Table 7.3 ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

			SUMMARY C	F WEIGHT	GAIN	Grams)		
******	STUDY: 10	5P026			SEX:	MALE		
PERIOD	DOSE: (mg/kg) GROUP:	1100 1-M	1300 2-M	1500 З-м	1750 4-M	2000 5-M	800 6-M	
DAY 7	MEAN S.D. N	1.0 0.10 3	-2.1 5.73 2	-2.7 0.00 1		-2.2 0.00 1	0.9 0.00 1	
DAY 14	MEAN S.D. N	0.8 0.31 3	3.8 4.74 2	4.9 0.00 1		2.6 0.00 1	1.0 0.00 1	
TOTAL GAIN	MEAN S.D. N	1.8 0.25 3	1.7 0.99 2	0.00	0	0.4 0.00 1	1.9 0.00 1	

^{*} P less than .05
** P less than .01
-- = Data Unavailable

Table 7.4

ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

		SUM	MARY O	WEIGHT	GAINS	(Grams)	
****************	STUDY:	105P06A			SEX:	MALE	
	PERIOD	DOSE: (mg/kg) GROUP:	0 1-M	0 2-M	800 3-M	1000 4-H	
	DAY 7	MEAN S.D. N	4.1 1.14 4	2.9 0.51 4	1.9* 0.92 2	2.3* 0.40 4	
	DAY 14	MEAN S.D. N	-2.7 5.27 4	0.3 0.87 4	-0.7 0.78 2	0.1 0.87 4	
	TOTAL GAIN	MEAN S.D. N	1.4 4.37 4	3.2 0.53 4	1.2 0.14 2	2.4 0.53 4	

^{*} P less than .05 P less than .01

Table 7.5

ACUTE INTRAPERITONEAL TOXICITY STUDY
OF WR269410 IN MICE

	NAME OF TAXABLE PARTY OF TAXABLE PARTY.							
			SUMMA	RY OF WE	IGHT GAI	NS (Grams)		
	STU	DY: 105IP2	5		SEX	: MALE		
	PER I OD	DOSE: (mg/kg) GROUP:	100 1-H	120 2-N	140 3-N	170 4-H	200 5-M	
••••	DAY 7	MEAN S.D. N	0.1 1.30 4	0.2 0.00 1	1.0 0.14 2	-3.5 6.01 2		
	DAY 14	MEAN S.D. N	0.8 2.18 4	1.6 0.00 1	1.6 1.06 2	0.9 0.00 1		
	TOTAL GAIN	MEAN S.D. N	0.9 2.92 4	1.8 0.00 1	2.6 1.20 2	1.7 0.00 1	0	
*	P less than .0 P less than .0		nalysis o	f Variance usi	ng DUNNETT'S	Procedure		

Table 8.1 ACUTE ORAL TOXICITY STUDY OF WR242511 IN MICE

		SUMMA	RY OF WE	IGHT GAI	NB (Grams)		
••••••	STUDY: 105P02	4		SEX	FEMALE		
PERIOD	DOSE: (mg/kg) GROUP:	10 1-F	13 2-F	17 3-F	23 4-F	30 5-F	
DAY 7	MEAN S.D. N	1.6 0.83 5	1.4 1.57 5	-0.1 3.24 5	0.1 2.12 2	 0	
DAY 14	MEAN S.D. N	1.1 1.31 5	1.5 0.91 5	4.0 4.04 5	2.0 0.57 2	0	
TOTAL G	AIN MEAN S.D. N	2.6 0.62 5	2.9 2.04 5	3.9 1.12 5	2.1 1.56 2	0	

^{*} P less than .05
** P less than .01
-- = Data Unavailable

Table 8.2 ACUTE INTRAPERITONEAL TOXICITY STUDY OF WR242511 IN MICE

••••••	•••••	SUMMAR	Y OF WE	IGHT GAI	NS (Grams)		
	STUDY: 105IP2			SEX	FEMALE		
PERIOD	DOSE: (mg/kg) GROUP:	10 1-F	13 2-F	17 3-F	23 4-F	30 5-F	
DAY 7	MEAN S.D. N	1.6 1.67 5	0.9 0.50 5	0.5 0.57 5	1.6 0.00 1	0	
DAY 14	MEAN S.D. N	1.0 1.37 5	2.2 1.06 5	2.0 0.69 5	0.7 0.00 1	0	
TOTAL G	AIN MEAN S.D. N	2.6 1.49 5	3.1 1.00 5	2.5 1.08 5	2.3 0.00 1	0	

[#] P less than .05 ## P less than .01 -- = Data Unavailable

Table 8.3 ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

*******				SUMMARY	OF WEIGHT	GAINS	(Grams)		
		STUDY: 10	5P026			SEX:	FEMALE		
	PERIOD	DOSE: (mg/kg) GROUP:	1100 1-F	1300 2-F	1500 3-F	1750 4-F	2000 5-F	800 6- F	
	DAY 7	MEAN S.D.	1.2	-2.5 0.00	-5.2 0.00				
		N.	1	1	1	0	0	0	
	DAY 14	MEAN	1.6	5.5	6.6	••	••		
		S.D. N	0.00	0.00	0.00	0	0	0	
	TOTAL GAIN	MEAN	2.8	3.0	1.4		••	••	
		S.D. N	0.00	0.00	0.00	0	0	0	

^{*} P less than .05
** P less than .01
-- = Data Unavailable

Table 8.4

ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

 **********	SUM	MARY C	F WEIGHT	GAINS	(Grams)	
 STUDY:	105P06A			SEX:	FEMALE	
PERIOD	DOSE: (mg/kg) GROUP:	0 1-F	0 2-F	800 3-F	1000 4-F	
 DAY 7	MEAN S.D. N	2.3 0.80 5	0.9 0.71 3	1.9 1.19 3	0.1 3.50 3	
DAY 14	MEAN S.D. N	-1.7 3.66 5	1.2 0.99 3	0.6 1.01 3	-1.2 7.40 3	
TOTAL GAIN	MEAN S.D. N	0.6 4.12 5	2.1 1.18 3	2.5 0.21 3	-1.1 5.06 3	

^{*} P less than .05 P less than .01

Table 8.5

# ACUTE INTRAPERITONEAL TOXICITY STUDY OF WR269410 IN MICE

		SUMMA	RY OF WE	IGHT GAI	NS (Grams)		
	STUDY:	105IP26		SEX	: FEMALE		
PERIC		: (mg/kg) 100 JP: 1-F	120 2-f	140 3-F	170 4-F	200 5-F	
DAY 7	ME/ S.C N		1.4 0.93 5	0.8 1.08 3	1.4 1.49 4	-0.1 1.84 2	
DAY 1	4 MEA S.C N		0.5 0.86 5	1.3 0.70 3	0.7 0.42 4	2.1* 1.27 2	
TOTAL	GAIN MEA S.D N		1.9 0.99 5	2.1 1.42 3	2.1 1.45 4	2.0 0.57 2	

P less than .05 P less than .01

Table 9

# ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE

# Necropsy Observations

# WR242511 Tartrate (Gavage)

Dose Level (mg/base/kg)	Males	Females
10 13 17 23 30	No gross lesions	No gross lesions

# WR242511 (Intraperitoneal)

Dose Level (mg/base/kg)	Males	Females
10 13 17 23 30	No gross lesions	No gross lesions

# Table 9 (contd.)

# ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE

### Necropsy Observations

# WR269410 (Gavage; Set 1)

Dose Level (mg/kg)	Males	Females	
800	No gross lesions	No gross lesions	
1100	No gross lesions	No gross lesions	
1300	No gross lesions	No gross lesions	
1500	No gross lesions	No gross lesions	
1750	No gross lesions	No gross lesions	
2000	No gross lesions	No gross lesions	

### WR269410 (Gavage; Set 2)

Dose Level (mg/base/kg)	Males	Females
Vehicle (10 ml/kg)	Enlarged mesenteric lymph node and subcutaneous cyst for two separate animals	No gross lesions
Vehicle (20 ml/kg)	No gross lesions	No gross lesions
800 (10 ml/kg)	Subcutaneous cyst for one animal	No gross lesions
1000 (10 ml/kg)	No gross lesions	Irregular shaped, pale red- brown lesion of smooth consistency on the left kidney of one animal.

# WR269410 (Intraperitoneal)

Dose Level (mg/kg)	Males	Females
100	No gross lesions	No gross lesions
120	No gross lesions	No gross lesions
140	No gross lesions	Fusion of liver & diaphragm in one animal
170	Fusion of liver lobes in one animal	No gross lesions
200	No gross lesions	No gross lesions

Table 10

# ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE

#### Dose-Mortality Data

### WR242511 Tartrate - Gavage

	Mortality ^a	
Dose Level (mg base/kg)	<u>Males</u>	<u>Females</u>
10	0/5	0/5
13	0/5	0/5
17	0/5	0/5
23	2/5	3/5
30	5/5	5/5

*number of deaths/number of animals in group.

WR242511 Tartrate - Intraperitoneal

	Mortality ^a	
Dose Level (mg base/kg)	Males	<u>Females</u>
10	0/5	0/5
13	0/5	0/5
17	0/5	0/5
23	4/5	4/5
30	5/5	5/5

*number of deaths/number of animals in group.

#### Table 10 (contd.)

# ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE

#### Dose-Mortality Data

WR269410 - Gavage (Set 1)

	Mortality ^a	
Dose Level (mg/kg)	Males	<u>Females</u>
800	4/5	5/5
1100	2/5	4/5
1300	3/5	4/5
1500	4/5	4/5
1750	5/5	5/5
2000	4/5	5/5

*number of deaths/number of animals in group.

WR269410 - Gavage (Set 2)

	Mortality ^a	
Dose Level (mg/kg)	Males	<u>Females</u>
Vehicle (10 ml/kg)	1/5	0/5
Vehicle (20 ml/kg)	1/5	2/5
800	3/5	2/5
1000	1/5	2/5

*number of deaths/number of animals in group.

WR269410 -Intraperitoneal

	Mortality ^a	
Dose Level (mg base/kg)	Males	<u>Females</u>
100	1/5	0/5
120	4/5	0/5
140	3/5	2/5
170	4/5	1/5
200	5/5	3/5

*number of deaths/number of animals in group

# APPENDIX 1

Analytical Chemistry Methodology and Dosage Formulation Analysis

# INITIAL PURITY AND IDENTITY OF p-AMINOHEPTANOPHENONE (WR269410) STUDY NO. 105

ANALYSTS: ADAM NEGRUSZ
A. KARL LARSEN, JR.

STUDY SITE: FORENSIC TOXICOLOGY LABORATORY COLLEGE OF PHARMACY

UNIVERSITY OF ILLINOIS AT CHICAGO

CHICAGO, ILLINOIS 60612

SPONSOR: TOXICOLOGY RESEARCH LABORATORY

UNIVERSITY OF ILLINOIS AT CHICAGO

CHICAGO, ILLINOIS 60612

REPORT PREPARED: JUNE 15, 1993

APPROVED: JUNE 15, 1993

DR. EUGENE F. WOODS, Ph.D.

#### **OBJECTIVE**

The objective of this study was to confirm the initial identity and establish the purity of WR269410.

#### **EXPERIMENTAL**

The subject sample - WR269410 was supplied by the Toxicology Research Laboratory and stored at -20°C when it was not analyzed.

#### Description

A fine white powder, no obvious odor.

#### Spectrum

An ultraviolet spectrum (Figure I) recorded on a Shimadzu Spectronic 200 UV spectrometer (dual beam) was obtained from 20 ug/ml solution of WR269410 prepared in mobile phase. The sample was found with maximal absorptivity observed at 230 nm and 312 nm.

#### **PURITY**

#### **HPLC System**

Solvent Delivery System:

Perkin-Elmer Series 3B Pump

Injector:

Rheodyne 7125 with 20 ul sample loop

Analytical Column:

uBondapak C18, 300 mm x 3.9 mm (Waters)

Detector:

Kratos Spectroflow 773 UV Detector, 0.010 AUFS, 230nm and

312nm

Integrator:

3380A Hewlett-Packard Integrator

Mobile Phase:

60% of acetonitrile and 40% of 0.01 M heptanosulfonate sodium salt

in 0.1% (v/v) acetic acid (in water), flow 1.5 ml/minute

#### Procedure

Six solutions of WR269410 were prepared as follows. Twenty five mg of WR269410 sample was weighed into a 25 ml volumetric flask. The sample was dissolved in and the volume brought to mark

with mobile phase. A 20 ul aliquot of each solution was immediately chromatographed at 230 nm and next at 312 nm.

#### Results

Typical chromatograms are shown in Figure II. The initial purity study of WR269410 shows that there are no UV absorbing impurities (230 nm, 312 nm) and from this point of view the substance is 100% pure.

#### **IDENTIFICATION**

#### GC-MS System

Gas Chromatograph:

Hewlett-Packard Series II

Mass Selective Detector:

Hewlett-Packard Model 5970

Analytical Column:

30 m x 0.25 mm ID, DB-1 with a 3 micron film thickness.

GC Parameters:

injector temp. 250°C, oven temp. 70°C initial, 280°C final, 20°C/minute ramp, carrier gas - helium, flow rate 2 ml/minute,

split ratio 10:1

#### Procedure

Subject sample (WR269410) was submitted from the Toxicology Research Laboratory. The sample was dissolved in methanol to a concentration of 1 ug/ml and a 2 ul aliquot was injected on the column. The MSD scanned from 40 amu to 400 amu at a rate of 1 scan per second.

#### Results - GS-MS

The mass spectrum indicates a molecular ion m/e 205 which is in agreement with the WR269410 molecular weight. Major fragments of the sample are m/e 41, 65, 92, 120, 135, 148.

Figure III shows the mass spectrum of the initial WR269410 sample.

FIGURE I

ULTRAVIOLET SPECTRUM OF WR269410






FIGURE II

CHROMATOGRAMS OF WR269410 AT 230 NM
(A) AND 312 NM (B), CONCENTRATION 1 MG/ML



# FIGURE III MASS SPECTRUM OF INITIAL WR269410 SAMPLE



INITIAL PURITY AND IDENTITY STUDY AND SAMPLES IN 1% METHYLCELLULOSE AND 0.4% TWEEN 80 ANALYSIS OF 8-[(4-AMINO-1-METHYLBUTYL)AMINO]-5-(1-HEXYLOXY-6-METHOXY-4-METHYLQUINOLINE DL-TARTRATE (WR242511). STUDY NO. 105

ANALYSTS:

ADAM NEGRUSZ

A.KARL LARSEN, JR.

STUDY SITE:

FORENSIC TOXICOLOGY LABORATORY

**COLLEGE OF PHARMACY** 

UNIVERSITY OF ILLINOIS AT CHICAGO

CHICAGO, ILLINOIS 60612

SPONSOR:

TOXICOLOGY RESEARCH LABORATORY

UNIVERSITY OF ILLINOIS AT CHICAGO

CHICAGO, ILLINOIS 60612

REPORT PREPARED:

**JUNE 15, 1993** 

APPROVED:

**JUNE 15, 1993** 

DR. EUGENE F. WOODS, Ph.D.

#### **OBJECTIVE**

The objective of this study was to confirm the initial identity, establish the purity of WR242511 and to develop the analytical method for dosage formulation analysis.

WR242511 samples were submitted for analysis April 28,1993. Results are found on page 9.

In low concentration WR242511 is stable for 48 hours (<10% loss). In high concentration drug is stable during two weeks period of time. This will be reported with the longer term toxicological studies.

#### **EXPERIMENTAL**

The subject sample - WR242511 was supplied by the Toxicology Research Laboratory and stored at -20⁰C when it was not analyzed.

#### Description

A fine yellow powder, no obvious odor.

#### Spectrum

An ultraviolet spectrum (Figure I) recorded on a Shimadzu Spectronic 200 UV spectrometer (dual beam), was obtained from 20 ug/ml solution of WR242511 prepared in mobile phase. The sample was found with maximal absorptivity observed at 212 nm and 264 nm.

#### **ANALYTICAL METHOD**

#### Reagents

Subject sample (WR242511) was supplied by Toxicological Research Laboratory. HPLC grade methanol, acetonitrile, ammonium formate and formic acid were purchased from Fisher Scientific. HPLC grade water was supplied through a Millipore, MILLI-Q Reagent Water System which was fed with distilled water.

#### **Standards**

All WR242511 concentrations reflect free base value. A 71 mg/ml of base WR242511 stock solution was prepared by weighing 100 mg of DL-tartrate salt (mole fraction = 0.71) into 100 ml volumetric flask. The content was dissolved in and the volume brought to mark with mobile phase. Calibration standard solutions were prepared in mobile phase using 71 mg/ml of base WR242511 stock solution as follows.

Flask	Final
Volume (ml)	Concentration (ug/ml of base)
100	7.1
100	14.2
100	28.4
100	42.6
100	56.8
100	71.0
	Volume (ml) 100 100 100 100 100

Aliquots of 0.5 ml from each calibration standard solution were transferred to individually labelled crimp-top vials, sealed and stored at -20⁰C until analyzed.

#### Controls

Control A (0.639 mg/ml of base), control B (2.84 mg/ml of base) and control C (7.81 mg/ml of base) were prepared by weighing 90 mg, 400 mg and 1100 mg respectively of WR242511 DL-tartrate salt into three 100 ml volumetric flasks, dissolved in and diluted to mark with mobile phase. Aliquots of 1.5 ml of each control were transferred to individually labelled screw-capped vials, sealed and stored at -20⁰C until analyzed.

#### **Analytical Procedure**

One set of WR242511 calibration standards and three vials of each stock control solutions were removed from a -20°C freezer to warm up prior to samples analysis. Working control solutions were prepared as follows. Control A - 1 ml of stock solution was transferred to a 25 ml volumetric flask and diluted to mark with mobile phase. Control B - 1 ml of stock solution was transferred to a 25 ml volumetric flask and diluted to mark with mobile phase. Five ml were then transferred to another 25 ml volumetric flask and diluted to mark with mobile phase. Control C was prepared the same way as control B. The standard curve was run at the beginning and at the end of the day. Controls were analyzed in a random order.

#### **HPLC System**

See PURITY section, WR242511 was monitored at 230 nm.

#### Calculations

A standard curve was run at the beginning and the end of the day. Final concentration for controls and samples were determined using a composite standard curve. The composite standard curve was determined by linear least squared regression analysis of the peak areas for WR242511 as a function of concentration. WR242511 concentrations (mg/ml of base) for controls and samples were determined using the following equation:

WR242511 conc. =  $(Y-B)/M \times (d.f./1000)$ 

Y - peak area

B - Y-intercept from regression analysis of composite standard curve

M - slope from regression analysis

d.f. - dilution factor

#### **PURITY**

#### **HPLC System**

Solvent Delivery System: Perkin-Elmer Series 3B Pump

Injector: Rheodyne 7125 with 50 ul sample loop

Analytical Column: Spherisorb CN 5u, 250 mm x 4.6 mm (Alltech)

Detector: Perkin-Elmer LC-55B UV Detector, 225 nm, 264 nm

Integrator: Spectra-Physics SP4270 Integrator

Mobile Phase:

20% methanol, 50% acetonitrile, 30% 0.01 M ammonium formate (in water), Ph 3.0 (adjusted with 88% formic acid), flow 1.5

ml/minute

#### Procedure

Six solutions of WR242511 were prepared as follows. Twenty five mg of WR242511 sample was weighed into a 25 ml volumetric flask. The sample was dissolved in and the volume brought to mark with mobile phase. A 50 ul aliquot of each solution was immediately chromatographed at 225 nm and next at 264 nm.

#### Calculation of Results

Quantitations were based on the assumption of equal detector response per unit weight of all UV-absorbing components. Areas of WR242511 and other detectable components in the subject sample chromatograms were employed in the following equation to calculate the percentage of WR242511 present in the sample:

%PURITY = (area of WR242511/total area) x 100

#### Results

Typical chromatogram is shown in Figure II. The subject sample was found to contain less than 1% of one UV-absorbing impurity (225 nm). At 264 nm no visible impurities were observed. Percent purity of WR242511 was found to be 99.51%, standard deviation - 0.02%. The assay results are presented in Table I.

#### **IDENTIFICATION**

#### **GC-MS System**

Gas Chromatograph:

Hewlett-Packard Series II

Mass Selective Detector:

Hewlett-Packard Model 5970

Analytical Column:

30 m x 0.25 mm ID. DB-5 with a 3 micron film thickness.

GC Parameters:

injector temp.  $250^{0}$ C, oven temp.  $70^{0}$ C initial,  $280^{0}$ C final,  $15^{0}$ C/minute ramp, carrier gas - helium, flow rate 2 ml/minute,

split ratio 10:1

#### Procedure

Subject sample (WR242511) was submitted from the Toxicology Research Laboratory. The sample was dissolved in methanol to a concentration of 0.71 ug/ml of base and a 2 ul aliquot was injected on the column. The MSD scanned from 40 amu to 400 amu at rate of 1 scan per second.


#### Results - GC-MS

The mass spectrum indicates a molecular ion m/e 373 which is in agreement with the WR242511 molecular weight. Major fragments of WR242511 sample are m/e 84, 175, 203, 288.

Figure III shows the mass spectrum of the initial WR242511 sample.

FIGURE I

ULTRAVIOLET SPECTRUM OF WR242511



CHROMATOGRAM OF WR242511 SAMPLE (CONCENTRATION 0.71 MG/ML OF BASE, 225 NM)

FIGURE II




FIGURE III

### MASS SPECTRUM OF INITIAL WR242511 SAMPLE




TABLE I

PURITY DATA FOR WR242511 PRIOR TO INITIATING STUDY NO. 105

#### Solutions

Peak Identity	1	2	3	4	5	6
Α	4370	4354	4307	4414	3925	4509
WR242511	871097	863423	869317	869227	872867	862653
% Purity	99.501	99.498	99.507	99.495	99.552	99.480

Mean  $\pm$  S.D. - 99.505  $\pm$  0.024

#### MEMO

DATE:

April 28, 1993

TO:

Dr. Barry S. Levine

FROM:

Adam Negrusz

Forensic Toxicology Laboratory

College of Pharmacy

RE:

WR242511 samples submitted for analysis April 28, 1993.

# WR242511 Concentration (mg/ml of base)

Sample Identification	Mean (± SD)
PINK WITH BLACK DOT (3.0)	2.9738 (± 0.0061)
GREEN WITH YELLOW DOT (2.3)	2.3230 (± 0.0437)
BLUE WITH YELLOW DOT (1.7)	1.6939 (± 0.0297)
ORANGE WITH YELLOW DOT (1.3)	1.3064 (± 0.0070)
GREEN WITH BLUE DOT (1.0)	0.9893 (± 0.0133)
PINK (6.0)	4.8198 (± 0.0179)
PINK AFTER ADJUSTMENT	5.8143 (± 0.0037)
GREEN (4.6)	4.5849 (± 0.0336)
BLUE (3.4)	3.3920 (± 0.0411)
ORANGE (2.6)	2.5483 (± 0.0203)
LIGHT GREEN (2.0)	2.1742 (± 0.0096)

### APPENDIX 2

Analytical Chemistry Report from Dr. Flanagan (Univ. of Iowa)

## Analysis of p-Aminoheptanophenone (WR269410) Solutions in PEG 200 After Toxicological Testing

Douglas R. Flanagan, Ph.D. Siriporn Toongsuwan, B.S. Kirk VanDer Kamp, B.S.

July 21, 1993

Contract No. DAMD 17-92-C-2035

College of Pharmacy University of Iowa Iowa City, IA 52242 (319) 335-8824

#### Analysis of p-Aminoheptanophenone (WR269410) Solution in PEG 200 After Toxicological Testing

#### Summary

PEG 200 solutions of WR269410 were analyzed for content after receipt from the University of Illinois (Dr. Barry Levine).

#### Assay Procedure

- 1. Make fresh standard solution (about 10  $\mu$ g/mL) of PAHP in 95% ethanol.
- 2. Dilute PAHP in PEG 200 solutions that were send from UIC with 95% ethanol (dilution factor = 10,000) by diluting 1 mL of the sample to 100 mL and then diluting 1 mL of this solution to 100 mL with 95% ethanol.
- 3. Assay the concentration of the solutions by using the HP 8450 UV spectrophotometer.
- 4. Concentration of the samples were calculated as follow:

sample conc. = (std conc.*Abs_{sample})*10,000/Abs_{std}

#### Assay Results

The results from the UV assay of PAHP solutions are shown in Tables 1, 2 and 3.

Table 1: UV Assay Data of PAHP Solutions Returned from UIC on 05/21/93; Mouse Study

03/21/33, Mouse Study	
Labeled Conc.(mg/mL)	Experimental Conc.(mg/mL)
20	18.2
24	26.4
28	31.3
34	31.7
40	40.3
55	50.3
65	66.8
75	77.6
87.5	84.2

TABLE 2: UV Assay Data of PAHP Solutions Returned from UIC on 07/08/93; Rat Study

Labeled Conc.(mg/mL)	Experimental Conc.(mg/mL)
6	6.9
12	8.5
25	26.7
50	42.9
100	94.5

TABLE 3: UV Assay Data of PAHP Solutions Returned from UIC on 07/08/93; Mouse Study

Labeled Conc.(mg/mL)	Experimental Conc.(mg/mL)
80	73.2

#### APPENDIX 3

Individual Observations

										_
-				DUAL OBSER						
	STUDY: DAY 0-1	105P024 DAY 14	GROUP: DOSE:	1-M 10(mg/kg)	SEX:	MALE				
	ANIMAL #	OBSERVATIONS		• • • • • • • • • • • • • • • • • • • •	SEVERITY	LOC	TIME (	OCCUR	RED	-
	201	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacr:	ifice				DAY 1 DAY 0 DAY 0 DAY 0 DAY 1		13	
	202	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacr:	ifice				DAY 1 DAY 0 DAY 0 DAY 0 DAY 0 DAY 1 DAY 1	2	11	
	203	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1 DAY 0 DAY 0 DAY 0 DAY 0 DAY 1 DAY 1	2	11	
	204	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1 DAY 0 DAY 0 DAY 0 DAY 1		13	
	205	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY 0DAY 0DAY 0DAY 14		13	

_									
_					RVATIONS				
	STUDY: DAY 0-1	105P024 DAY 14	GROUP: DOSE:	2-M 13(mg/kg	SEX:	MALE			
	ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCUI	RRED
	211	Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri					DAY DAY DAY DAY	0 4 14	
	212	Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice				DAY	4-DAY	
	213	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY DAY DAY DAY DAY	0	13
	214	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacr:	ifice				DAY DAY DAY DAY DAY	0	13
	215	Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice				DAY DAY DAY DAY	0 0 4-DAY 12	

		INDIVII	DUAL OBSE	RVATIONS			
STUDY: DAY 0-1	105PO24 DAY 14	GROUP: DOSE:	3-M 17(mg/kg	SEX:	MALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCU	RRED
221	Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-DAY DAY 5-DAY DAY 0 DAY 0 DAY 0 DAY 4 DAY 14	3 13
222	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
223	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-DAY DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	11
224	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 1-DAY DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 5-DAY DAY 12 DAY 14	
225	Normal Normal Normal #1 Normal #2					DAY 1-DAY DAY 6-DAY DAY 13 DAY 0 DAY 0	4 11

INDIVIDUAL OBSERVATIONS										
STUDY: DAY 0-1	105P024 DAY 14	GROUP: DOSE:	3-M 17(mg/kg)	SEX:	MALE					
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED				
225 (contd.)	Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 0 DAY 5 DAY 12 DAY 14				

• •		,	INDIVI	OUAL OBSER	VATIONS				
	STUDY: DAY 0-I	105PO24 DAY 14	GROUP: DOSE:	4-M 23(mg/kg)	SEX:	MALE			
	ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIMI	OCCUP	RRED
	231	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice		,,		DAY DAY DAY DAY DAY DAY DAY DAY	0	4 11
	232	Activity Decrea Ataxia Animal Found De Normal Normal #1 Normal #2 Normal #3 Rough Coat			1		DAY DAY DAY DAY DAY DAY DAY	3 4 1 0 0 0 2-DAY	3
	233	Activity Decrea Activity Decrea Animal Found De Hunched Posture Lethargic Normal Normal #1 Normal #2 Normal #3 Rough Coat	ased ased ead		1		DAV	5-DAY 5 1 0	6
	234	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY DAY DAY DAY DAY	1-DAY 0 0 0 14	13
	235	Normal					DAY	1-DAY	11

Severity No.	<u>Description</u>
1	Slight
2	Moderate
3	Severe

INDIVIDUAL OBSERVATIONS										
STUDY: DAY 0-	105PO24 DAY 14	GROUP: DOSE:	4-M 23(mg/kg)	SEX:	MALE					
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED				
235 (contd.)	Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacr	ifice				DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14				

		INDIVI	DUAL OBSEI	RVATIONS				
STUDY: DAY 0-1	105P024 DAY 14	GROUP: DOSE:	5-M 30(mg/kg)	SEX:	MALE			
	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURRED	
	Animal Found Normal Normal #1 Normal #2 Normal #3					DAY DAY DAY DAY DAY		
242	Animal Found Normal Normal #1 Normal #2 Normal #3 Rough Coat	Dead				DAY DAY DAY DAY DAY DAY		
243	Animal Found Normal Normal #1 Normal #2 Normal #3 Rough Coat	Dead				DAY DAY DAY DAY DAY DAY		
244	Animal Found Lethargic Normal Normal #1 Normal #2 Normal #3 Rough Coat	Dead				DAY CONTROL OF CONTROL	1 3 1 0 0 0 0 2-DAY 3	
245	Comatose Animal Found Normal Normal #1 Normal #2 Normal #3	Dead				DAY DAY DAY DAY DAY DAY DAY		

INDIVIDUAL OBSERVATIONS								
STUDY: DAY 0-1	105IP24 DAY 14	GROUP: DOSE:	1-M 10(mg/kg)	SEX:	MALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCU	RRED
251	Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY DAY DAY DAY DAY DAY DAY	0	11
252	Normal Normal Normal Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice					12	
253	Normal Normal Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY DAY DAY DAY DAY DAY	0 0 12	11
254	Normal Normal Normal #2 Normal #3 Rough Coat Scheduled Sacri	fice				DAY DAY DAY DAY DAY DAY	0 0 12	11
255	Normal Normal Normal #2 Normal #3 Rough Coat Scheduled Sacri	fice				DAY DAY DAY DAY DAY DAY	0	11

		INDIVI	DUAL OBSER	RVATIONS		
STUDY: DAY 0-1	105IP24 DAY 14	GROUP: DOSE:	2-M 13(mg/kg)	SEX:	MALE	
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED
261	Normal Normal Normal Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 0-DAY 7 DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 8-DAY 10 DAY 12 DAY 14
262	Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 1-DAY 9 DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 10 DAY 10 DAY 12 DAY 14
263	Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 1-DAY 8 DAY 10-DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 9 DAY 12 DAY 14
264	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-DAY 9 DAY 11-DAY 13 DAY 0 DAY 0 DAY 0 DAY 10 DAY 10 DAY 14

	INDIVI	DUAL OBSER	VATIONS			
STUDY: 105IP24 DAY 0-DAY 14	GROUP: DOSE:	2-M 13(mg/kg)	SEX:	MALE		
ANIMAL # OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED	
265 Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Scheduled Sacr	ifice				DAY 1-DAY 4 DAY 6-DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 5 DAY 12 DAY 14	

	INDIVIDUAL OBSERVATIONS						
STUDY: DAY 0-1	105IP24 DAY 14	GROUP: DOSE:	3-M 17(mg/kg)	SEX:	MALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED	
271	Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Rough Coat Scheduled Sacr					DAY 1 DAY 3-DAY 7 DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 2 DAY 2 DAY 8-DAY 10 DAY 12 DAY 14	
272	Normal Normal Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 1 DAY 3-DAY 5 DAY 7-DAY 8 DAY 10-DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 2 DAY 2 DAY 6 DAY 9 DAY 12 DAY 12 DAY 14	
273	Normal Normal Normal Normal #1 Normal #3 Rough Coat Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 1-DAY 5 DAY 7-DAY 9 DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 0 DAY 10 DAY 10 DAY 12 DAY 14	

	INDIVI	DUAL OBSER	VATIONS	•••••	• • • • • • • • • • • • • • • • • • • •	
STUDY: 105IP24 DAY 0-DAY 14	GROUP: DOSE:	3-M 17(mg/kg)	SEX:	MALE	••••••	
ANIMAL # OBSERVA	TIONS		SEVERITY	LOC	TIME OCCUP	RED
274 Normal Normal Normal Normal Normal Normal Normal Normal Rough C Rough C Rough C Rough C Rough C Rough C	oat				DAY 1 DAY 3 DAY 5-DAY DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 2 DAY 2 DAY 4 DAY 8-DAY DAY 12 DAY 14	7
Normal Normal Normal Normal Normal Normal Normal Normal Rough C Rough C Rough C Rough C	#1 #2 #3 oat oat oat ed Sacrifice				DAY 1-DAY DAY 6-DAY DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 5 DAY 10 DAY 12 DAY 14	4 9

	4057704	INDIVII	OUAL OBSEI	RVATIONS			
DAY 0-I	DAY 14	DOSE:	4-M 23 (mg/kg)	SEX:	MALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCU	RRED
	Animal Found D Normal #1 Normal #2 Normal #3 Rough Coat					DAY 3 DAY 0 DAY 0 DAY 0 DAY 1-DAY	2
282	Animal Found D Normal Normal #1 Normal #2 Normal #3 Rough Coat	ead				DAY 3 DAY 1 DAY 0 DAY 0 DAY 0 DAY 2	
283	Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Rough Coat Scheduled Sacr	rifice				DAY 1 DAY 7 DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 0 DAY 2-DAY DAY 8-DAY DAY 12 DAY 14	6
284	Activity Decre Animal Found D Hunched Postur Normal Normal #1 Normal #2 Normal #3 Rough Coat	ased lead e		1		DAY 3-DAY DAY 4 DAY 3-DAY DAY 1 DAY 0 DAY 0 DAY 0 DAY 2-DAY	4
285	Animal Found D Hunched Postur Normal #1 Normal #2 Normal #3 Rough Coat	ead e				DAY 3 DAY 2 DAY 0 DAY 0 DAY 0 DAY 1-DAY	2

Severity No.	Description
1	Slight
2	Moderate
3	Severe

INDIVIDUAL OBSERVATIONS							
STUDY: DAY 0-	105IP24 DAY 14	GROUP: DOSE:	5-M 30(mg/kg)	SEX:	MALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCU	RRED
291	Ataxia Animal Found Normal #1 Normal #2 Normal #3 Rough Coat	Dead		1		DAY 3 DAY 4 DAY 0 DAY 0 DAY 0 DAY 1-DAY	3
292	Activity Decr Ataxia Animal Found Hunched Postu Normal #1 Normal #2 Normal #3 Rough Coat	eased Dead re		1		DAY 3-DAY DAY 5 DAY 5 DAY 5 DAY 0 DAY 0 DAY 0 DAY 1-DAY	
293	Activity Decr Animal Found Normal #1 Normal #2 Normal #3 Rough Coat	eased Dead		1		DAY 1-DAY DAY 3 DAY 0 DAY 0 DAY 0 DAY 2	2
294	Activity Decr Animal Found Normal Normal #1 Normal #2 Normal #3 Rough Coat	eased Dead		1		DAY 2 DAY 3 DAY 1 DAY 0 DAY 0 DAY 0 DAY 2	
295	Activity Decr Animal Found Normal Normal #1 Normal #2 Normal #3	eased Dead		1		DAY 2 DAY 3 DAY 1 DAY 0 DAY 0 DAY 0	

Severity No.	<u>Description</u>
1	Slight
2	Moderate
3	Severe

-				DUAL OBSERVA					
	STUDY: DAY 0-I	105P026 DAY 14	GROUP: DOSE:	1-M 1100(mg/kg)	SEX:	MALE			
	ANIMAL #	OBSERVATIONS		SE	VERITY	Loc	TIME	OCCUR	RED
		Activity Decrea Activity Decrea Activity Decrea Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat #3 Scheduled Sacri	ased #1 ased #2 ased #3				DAY DAY DAY DAY DAY DAY DAY DAY	0 0 0 4 6 13 1-DAY	3
	302	Comatose #2 Comatose #3 Animal Found De Lethargic #1	ead				DAY DAY DAY DAY	0	
	303	Activity Decrea Activity Decrea Activity Decrea Animal Found De Rough Coat #3	ased #3		1 2 2		DAY DAY DAY DAY DAY	0	
	304	Activity Decrea Activity Decrea Activity Decrea Normal Rough Coat Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacri	ased #2 ased #3		1 1 1		DAY DAY DAY DAY DAY DAY DAY DAY DAY	0 0 11 1-DAY 12-DAY 0 0	10 13
	305	Activity Decrea	ased #1 ased #2 ased #3		1 1		DAY DAY DAY	0	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

	INDIVI	OUAL OBSERV	ATIONS		
STUDY: 105P026 DAY 0-DAY 14	GROUP: DOSE:	1-M 1100(mg/kg	SEX:	MALE	
ANIMAL # OBSERVATIONS		S	EVERITY	LOC	TIME OCCURRED
305 (contd.)  Normal Normal Normal Normal Rough Coat	ifice				DAY 4 DAY 6 DAY 11 DAY 13 DAY 1-DAY 3 DAY 5 DAY 7-DAY 10 DAY 12 DAY 0 DAY 14

		INDIVII	OUAL OBSERVAT				
	105P026 DAY 14		2-M 1300(mg/kg)		IALE		
ANIMAL #	OBSERVATIONS		SEV	/ERITY	LOC	TIME OCCU	TRRED
311		ased ased #1 ased #2 ased #3 e		1 1 1		DAY 5 DAY 0 DAY 0 DAY 5 DAY 11-DAY DAY 1-DAY DAY 0 DAY 0 DAY 14	Y 13
312	Activity Decre Activity Decre Activity Decre Animal Found D Rough Coat #2 Rough Coat #3	ased #1 ased #2 ased #3 ead		1 1		DAY 0 DAY 0 DAY 0 DAY 1 DAY 0 DAY 0	
313	Comatose #2 Comatose #3 Animal Found D Lethargic #1	ead				DAY 0 DAY 0 DAY 1 DAY 0	
314	Animal Found D Lethargic #1 Lethargic #2 Lethargic #3	ead				DAY 1 DAY 0 DAY 0 DAY 0	
315	Activity Decre Normal Normal Normal Rough Coat Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacr			1		DAY 0 DAY 4 DAY 11 DAY 13 DAY 1-DAY DAY 5-DAY DAY 12 DAY 0 DAY 0 DAY 0 DAY 14	7 3 10

Severity No.	Description
1	Slight
2	Moderate
3	Severe

INDIVIDUAL OBSERVATIONS								
STUDY: DAY 0-1	105P026 DAY 14	GROUP: DOSE:	3-M 1500(mg/kg)	SEX:	MALE			
ANIMAL #	OBSERVATIONS		SI	EVERITY	LOC	TIME	OCCURRED	
	Activity Decrea Activity Decrea Activity Decrea Hunched Posture Normal Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacra	ased #1 ased #2 ased #3		1		DAY C	DAY 6 2-DAY 13	
322	Comatose #1 Comatose #2 Animal Found Do Lethargic #3	ead				DAY C DAY 1 DAY 1	)	
323	Activity Decrea Animal Found Do Lethargic #2 Lethargic #3	ased #1 ead		1		DAY C DAY C DAY C	j	
324	Comatose #2 Comatose #3 Activity Decrea	ased #1		2		DAY C DAY C DAY C DAY 1		
325	Activity Decrea Animal Found De Lethargic #1 Lethargic #2	ased #3 ead		2		DAY O	j	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

_			INDIVI	OUAL OBSERVAT	'IONS			
	STUDY: DAY 0-1	105P026 DAY 14	GROUP: DOSE:	4-M 1750(mg/kg)	SEX:	MALE		
	ANIMAL #	OBSERVATIONS		SEV	ERITY	LOC	TIME	OCCURRED
	331	Activity Decrea Activity Decrea Animal Found De Lethargic #1	ased #2 ased #3 ead		3		DAY O	
	332	Activity Decrea Animal Found De Lethargic #2 Lethargic #3	ased #1 ead		3		DAY O	
	333	Activity Decrea Activity Decrea Animal Found De Lethargic #3	ased #1 ased #2 ead		1 2		DAY C DAY 1 DAY 1	)
	334	Comatose #1 Comatose #2 Comatose #3 Animal Found De	ead				DAY C DAY C DAY C DAY 1	) )
	335	Activity Decrea Animal Found De Lethargic #2 Lethargic #3	ased #1 ead		3		DAY O	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

-			INDIVI	OUAL OBSERVA	TIONS			
• •	STUDY: DAY 0-1	105P026 DAY 14	GROUP: DOSE:	5-M 2000(mg/kg)	SEX:	MALE		
	ANIMAL #	OBSERVATIONS		SE	VERITY	LOC	TIME OCCURRE	D
		Activity Decrea Activity Decrea Animal Found De Lethargic Lethargic #2 Rough Coat Rough Coat #3			1 2		DAY 0 DAY 0 DAY 1 DAY 1 DAY 0 DAY 1 DAY 0	
	342	Comatose #1 Comatose #2 Comatose #3 Animal Found Do	ead				DAY 0 DAY 0 DAY 0 DAY 1	
	343	Activity Decrea Activity Decrea Activity Decrea Hunched Posture Normal Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacri			1 1		DAY 6 DAY 0 DAY 0 DAY 5-DAY 6 DAY 11-DAY 1 DAY 0 DAY 0 DAY 0 DAY 0 DAY 1	3
	344	Comatose Animal Found Do Lethargic #1 Lethargic #2 Lethargic #3	ead				DAY 1 DAY 1 DAY 0 DAY 0 DAY 0	
	345	Comatose #1 Comatose #2 Comatose #3 Animal Found Do	ead				DAY 0 DAY 0 DAY 0 DAY 1	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

 		INDIVII	OUAL OBSER	VATIONS				
STUDY: DAY 0-1	105PO26 DAY 14	GROUP: DOSE:	6-M 800(mg/kg	SEX:	MALE			
 ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURRE	D
401	Animal Found De Lethargic #1 Lethargic #2 Lethargic #3					DAY DAY DAY DAY	0 0	
402	Activity Decrea Activity Decrea Activity Decrea Animal Found De Lethargic Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3	ased #1 ased #2 ased #3 ead		1 1		DAY DAY DAY DAY DAY	0 0 2 1 1-DAY 2	
403	Activity Decrea Activity Decrea Activity Decrea Activity Decrea Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacri	ised #2 ised #3		1 1 1		DAY DAY DAY DAY DAY	0 0 0 3 7-DAY 8 10-DAY 1 1-DAY 2 4-DAY 6 9 0 0	3
404	Animal Found De Lethargic #1 Lethargic #2 Lethargic #3	ead				DAY DAY DAY DAY	0	
405	Activity Decrea Animal Found De Lethargic #1 Lethargic #2 Rough Coat #3	ased #3 ead		2		DAY DAY DAY DAY DAY	1 0 0	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

			DUAL OBSE	RVATIONS				
STUDY: DAY 0-1	105 <b>P</b> 06A DAY 14	GROUP: DOSE:	1-M 0(mg/kg)	SEX:	MALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCUI	RRED
631	Normal Normal Normal 1 Normal 2 Normal 3 Rough Coat Scheduled Sacr	ifice				DAY DAY DAY DAY DAY DAY DAY	1-DAY 12-DAY 0 0 0 9-DAY	1 ⁸ 13
632	Normal Normal Normal 1 Normal 2 Normal 3 Rough Coat Scheduled Sacr						1-DAY 8-DAY 0 0 0 7 14	
633	Normal Normal Normal 1 Normal 2 Normal 3 Rough Coat Rough Coat Scheduled Sacr	ifice				DAY DAY DAY DAY DAY DAY DAY	1-DAY 5-DAY 0 0 0 3-DAY 13 14	
634	Normal Normal Normal 1 Normal 2 Normal 3 Rough Coat Scheduled Sacr	ifice				DAY DAY DAY DAY DAY DAY DAY	1-DAY 8-DAY 0 0 0 5-DAY 14	
635	Decreased Action Decrea	vity vity 1 vity 2 vity 3		1 1 2		DAY DAY DAY DAY	1 0 0 0	

Severity No.	Description			
1	Slight			
2	Moderate			
3	Severe			

## ACUTE ORAL TOXICITY STUDY OF

INDIVIDUAL OBSERVATIONS									
STUDY: 105P06A DAY 0-DAY 14		GROUP: 1-M DOSE: 0(mg/kg)		SEX: MALE					
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED			
635 (contd.)	Animal Found De Hunched Posture Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3	ead e				DAY 2 DAY 1 DAY 1 DAY 0 DAY 0 DAY 0			

INDIVIDUAL OBSERVATIONS  STUDY: 105P06A GROUP: 2-M SEX: MALE DAY 0-DAY 14 DOSE: 0(mg/kg)									
			TNDTAT	DUAL OBSE	KVATIONS				
	STUDY: DAY 0-1	105PO6A DAY 14	GROUP: DOSE:	2-M 0(mg/kg)	SEX:	MALE			
	ANIMAL #	OBSERVATIONS			SEVERITY	Loc	TIME	OCCUR	RED
		Hunched Posture Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacri	e				DAY DAY DAY DAY DAY DAY DAY DAY	4 1-DAY 5-DAY 12 9-DAY 13 00 00	3
	612	Hunched Posture Hunched Posture Normal Normal Rough Coat 3 Scheduled Sacri					DAY	4 0 1-DAY 5-DAY 12 3-DAY 11 13 0 0 0	2 10 4
	613	Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacri					DAY DAY DAY DAY DAY	5 7-DAY 13 1-DAY 6 11-DAY 0 0 0 14	4
	614	Normal					DAY	1-DAY	2

INDIVIDUAL OBSERVATIONS								
STUDY: 105P06A DAY 0-DAY 14		GROUP: DOSE:	2-M 0(mg/kg)	SEX:	MALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED		
614 (contd.)	Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacr	ifice				DAY 6 DAY 12 DAY 3-DAY 5 DAY 7-DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 14		
615	Animal Found D	ead				DAY 0		

INDIVIDUAL OBSERVATIONS							
STUDY: 105PO6A DAY 0-DAY 14	GROUP: DOSE:	3-M 800(mg/kg) SEX:					
ANIMAL # OBSERVATION	S	SEVERITY	LOC TIM	IE OCCURRED			
621 Decreased Administration of the Hunched Post Normal Normal 1 Rough Coat Rough Coat Rough Coat Scheduled Schedule	ctivity 2 ture 2 3 acrifice	1	DAY DAY DAY DAY DAY DAY DAY	0			
622 Decreased Additional Decreased Additional Found Rough Coat Rough Coat Rough Coat	ctivity 1 ctivity 2 ctivity 3 d Dead 1 2 3	1 2 2	DAY DAY DAY DAY DAY DAY				
623 Decreased Ad Decreased Ad Decreased Ad Animal Found Rough Coat Rough Coat Rough Coat	ctivity 1 ctivity 2 ctivity 3	1 2 2	DAY DAY DAY DAY DAY DAY				
624 Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Scheduled S	1 2 3 acrifice		DAY DAY DAY DAY DAY DAY DAY	7 1-DAY 10 7 12-DAY 13 7 0			
625 Animal Found	d Dead		DAY	. 0			

Severity No.	Description
1	Slight
2	Moderate
3	Severe

INDIVIDUAL OBSERVATIONS											
STUDY: DAY 0-1	105P06A DAY 14	GROUP: DOSE:	4-M 1000(mg/kg	SEX:	MALE						
ANIMAL #	OBSERVATIONS		S	EVERITY	LOC	TIME OCCU	RRED				
601	Decreased Active Hunched Posture Hunched Posture Hunched Posture Normal Normal Normal Rough Coat 2 Rough Coat 3 Scheduled Sacri	vity 3		1		DAY 0 DAY 1 DAY 4-DAY DAY 0 DAY 2 DAY 6 DAY 9-DAY DAY 1 DAY 3-DAY DAY 13 DAY 0 DAY 0 DAY 0 DAY 0	5				
602	Hunched Posture Hunched Posture Hunched Posture Hunched Posture Hunched Posture Normal Rough Coat Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacri					DAY 1-DAY DAY 13 DAY 0 DAY 0 DAY 0 DAY 8 DAY 1-DAY DAY 9-DAY DAY 0 DAY 0 DAY 0 DAY 0 DAY 14	7 7 13				
603	Animal Found De					DAY 0					
604	Decreased Active Decreased Active Decreased Active Hunched Posture Hunched Posture	vity 1 vity 2 vity 3 e 1		1 1 1		DAY 3-DAY DAY 0 DAY 0 DAY 0 DAY 1-DAY DAY 0					

Severity No.	Description
1	Slight
2	Moderate
3	Severe

INDIVIDUAL OBSERVATIONS								
STUDY: DAY 0-1	105P06A DAY 14	GROUP: DOSE:	<b>4-M</b> 1000(mg/kg	SEX:	MALE			
ANIMAL #	OBSERVATIONS		S	EVERITY	LOC	TIME OCCURRED		
604 (contd.)	Hunched Posture Hunched Posture Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacr	ifice				DAY 0 DAY 0 DAY 5-DAY 6 DAY 9-DAY 12 DAY 1-DAY 4 DAY 7-DAY 8 DAY 13 DAY 0 DAY 0 DAY 0 DAY 0 DAY 14		
605	Decreased Actic Hunched Posture Hunched Posture Hunched Posture Hunched Posture Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat 2 Rough Coat 2 Rough Coat 3 Scheduled Sacr			1		DAY 0 DAY 1 DAY 3-DAY 5 DAY 0 DAY 0 DAY 0 DAY 2 DAY 8 DAY 11-DAY 13 DAY 1 DAY 3-DAY 7 DAY 9-DAY 10 DAY 0 DAY 0 DAY 0 DAY 1		

Severity No.	<u>Description</u>
1	Slight
2	Moderate
3	Severe

INDIVIDUAL OBSERVATIONS								
STUDY: DAY 0-1	105IP26 DAY 14	GROUP: DOSE:	1-M 100(mg/kg	SEX:	MALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCU	RRED	
351	Activity Decrea Activity Decrea Activity Decrea Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacri	ased #1 ased #2 ased #3				DAY 0 DAY 0 DAY 0 DAY 6 DAY 11 DAY 13 DAY 1-DAY DAY 7-DAY DAY 12 DAY 0 DAY 0 DAY 0 DAY 14	510	
352	Activity Decrea Activity Decrea Animal Found De Lethargic #1 Rough Coat Rough Coat #2 Rough Coat #3	ased #2 ased #3 ead		2		DAY 0 DAY 0 DAY 5 DAY 0 DAY 1-DAY DAY 0 DAY 0	4	
353	Activity Decrea Activity Decrea Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacri			1		DAY 0 DAY 0 DAY 6 DAY 11 DAY 13 DAY 1-DAY DAY 7-DAY DAY 12 DAY 0 DAY 0 DAY 0 DAY 0 DAY 14	5 10	
354	Activity Decrea	ased #1 ased #2		1		DAY 0 DAY 0		

Severity No.	Description				
1	Slight				
2	Moderate				
3	Severe				

INDIVIDUAL OBSERVATIONS									
STUDY: DAY 0-	105IP26 DAY 14	GROUP: DOSE:	1-M 100(mg/kg	SEX:	MALE				
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED			
654 (contd.)	Activity Decreasions Normal Normal Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacr			1		DAY 0 DAY 6 DAY 11 DAY 13 DAY 1-DAY 5 DAY 7-DAY 10 DAY 12 DAY 0 DAY 0 DAY 0 DAY 14			
355	Activity Decrea Activity Decrea Activity Decrea Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacr			1 1 1		DAY 0 DAY 0 DAY 0 DAY 4 DAY 6-DAY 7 DAY 11-DAY 13 DAY 1-DAY 3 DAY 5 DAY 8-DAY 10 DAY 0 DAY 0 DAY 14			

Severity No.	Description
1	Slight
2	Moderate
3	Severe

	INDIVIDUAL OBSERVATIONS								
	STUDY: DAY 0-	105IP26 DAY 14	GROUP: DOSE:	2-M 120(mg/kg)	SEX:	MALE			
-	ANIMAL #	OBSERVATIONS		S	EVERITY	LOC	TIME	OCCUP	RRED
	361	Activity Decrease #1 Activity Decrease Activity Decrease Normal			1 2 2		DAY DAY DAY DAY	0 0 4	3
		Normal Rough Coat Rough Coat Rough Coat #3 Scheduled Sacri	ifice				DAY DAY	1-DAY 5-DAY	3 12
	362	Activity Decrea Activity Decrea Activity Decrea Activity Decrea Animal Found De Hunched Posture Lethargic #1 Rough Coat Rough Coat #2 Rough Coat #3	ased #2 ased #3 ead		1 2 2 2		DAY DAY DAY DAY DAY	5-DAY 0 1-DAY 0	6
	363	Comatose #1 Animal Found De Lethargic #2 Lethargic #3	ead				DAY DAY DAY DAY	1 0	
	364	Activity Decrea Activity Decrea Activity Decrea Animal Found De Hunched Posture Lethargic #1 Rough Coat Rough Coat #3	ased ased #2 ased #3 ead		1 2 1		DAY DAY DAY DAY DAY DAY	3	
	365	Activity Decrea	ased		1		DAY	2-DAY	3

Severity No.	<u>Description</u>
1	Slight
2	Moderate
3	Severe

		INDIVII	OUAL OBSERVA	TIONS		
STUDY: DAY 0-	105IP26 DAY 14	GROUP: DOSE:	2-M 120(mg/kg)	SEX:	MALE	
ANIMAL #	OBSERVATIONS		SE	VERITY	LOC	TIME OCCURRED
365 (contd.)	Comatose #1 Comatose Activity Decre Animal Found D Lethargic #2 Rough Coat Rough Coat #3	ased #3 ead		2		DAY 0 DAY 5 DAY 0 DAY 5 DAY 0 DAY 1-DAY 5 DAY 0

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVII	OUAL OBSE	RVATIONS		• • • • • • • • • • • • • • • • • • • •	
STUDY: DAY 0-I	105IP26 DAY 14	GROUP: DOSE:	3-M 140(mg/kg	SEX:	MALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCU	RRED
371	Activity Decrea Comatose #1 Animal Found De Lethargic #2 Lethargic #3 Rough Coat	ased ead		1		DAY 2-DAY DAY 0 DAY 4 DAY 0 DAY 0 DAY 1-DAY	
372	Comatose #1 Lethargic #2 Lethargic #3 Normal Normal Rough Coat Rough Coat Rough Coat Scheduled Sacri	fice				DAY 0 DAY 0 DAY 0 DAY 4 DAY 7-DAY DAY 11-DA DAY 1-DAY DAY 5-DAY DAY 9-DAY	Y 13 3 6
373	Activity Decrea Activity Decrea Activity Decrea Animal Found De Hunched Posture Lethargic #1 Rough Coat Rough Coat #2 Rough Coat #3	ased ased #2 ased #3 ead		1 2 2		DAY 4 DAY 0 DAY 0 DAY 4 DAY 3 DAY 0 DAY 1-DAY DAY 0 DAY 0	4
374	Comatose #1 Comatose #2 Comatose #3 Animal Found De Rough Coat	ead				DAY 0 DAY 0 DAY 0 DAY 2 DAY 1	
375	Comatose #1 Lethargic #2 Lethargic #3					DAY 0 DAY 0 DAY 0	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVI	DUAL OBSER	VATIONS			
STUDY: DAY 0-1	105IP26 DAY 14	GROUP: DOSE:	3-M 140(mg/kg	SEX:	MALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED	
375 (contd.)	Normal Normal Rough Coat Rough Coat Scheduled Sacr	ifice				DAY 8 DAY 11-DAY 13 DAY 1-DAY 7 DAY 9-DAY 10 DAY 14	

 			OUAL OBSER					
STUDY: DAY 0-1	105IP26 DAY 14	GROUP: DOSE:	4-M 170(mg/kg	SEX:	MALE			
 ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCUI	RRED
381	Activity Decrea Comatose #1 Activity Decrea Animal Found De Lethargic #2 Rough Coat Rough Coat #3	ased #3		1		DAY DAY DAY DAY	4 0 1-DAY	
382	Comatose #1 Comatose #2 Comatose #3 Animal Found De	ead				DAY DAY DAY DAY	0	
383	Activity Decrea Activity Decrea Activity Decrea Ataxia Comatose #1 Comatose #2 Animal Found De Hunched Posture Lethargic #3 Rough Coat	ased ased		1 3 3 3		DAY DAY DAY DAY DAY DAY DAY	8-DAY 0 0	9
384	Comatose #1 Hunched Posture Lethargic #2 Lethargic #3 Normal Normal Normal Rough Coat Rough Coat Rough Coat Scheduled Sacri					DAY DAY DAY	0 4 7	6
385	Activity Decrea	ased		1		DAY	4-DAY	6

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVI	DUAL OBSERV	ATIONS		
STUDY: DAY 0-	105IP26 DAY 14	GROUP: DOSE:	4-M 170(mg/kg)	SEX:	MALE	
ANIMAL #	OBSERVATIONS		٤	EVERITY	LOC	TIME OCCURRED
385 (contd.)	Ataxia Comatose #1 Comatose #2 Animal Found Do Hunched Posture Lethargic #3 Rough Coat	ead e		1		DAY 3 DAY 0 DAY 0 DAY 6 DAY 5-DAY 6 DAY 0 DAY 1-DAY 6

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVI	DUAL OBSER	VATIONS				
STUDY: DAY 0-1	105IP26 DAY 14	GROUP: DOSE:	5-M 200(mg/kg	SEX:	MALE			
ANIMAL #	OBSERVATIONS			SEVERITY	Loc	TIME	OCCUF	RED
391	Comatose #1 Comatose #2 Comatose #3 Animal Found De	ead		,		DAY DAY DAY DAY	0	
392	Comatose #1 Comatose #2 Animal Found Do Lethargic #3	ead				DAY DAY DAY DAY	0	
393	Activity Decrea Comatose #1 Comatose #2 Animal Found De Lethargic #3 Rough Coat	ased ead		1		DAY O	2-DAY 0 0 0 4 0 1-DAY	
394	Activity Decrea Comatose #1 Comatose #2 Comatose #3 Animal Found De Hunched Posture Rough Coat			1		DAY (DAY (DAY (DAY (DAY (DAY (DAY (DAY (	2-DAY 0 0 0 0 5 3-DAY 1-DAY	4
395	Comatose #1 Comatose #2 Comatose #3 Animal Found De	ead				DAY (	0	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVI	DUAL OBSE	NATIONS .			
STUDY: DAY 0-	105PO24 DAY 14	GROUP: DOSE:	1-F 10(mg/kg)	SEX:	FEMALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCU	RRED
206	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
207	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
208	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
209	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
210	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13

		INDIVI	DUAL OBSER	RVATIONS			
STUDY: DAY 0-1	105P024 DAY 14	GROUP: DOSE:	2-F 13(mg/kg)	SEX:	FEMALE		
 ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCU	RRED
216	Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-DAY DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	11
217	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
218	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
219	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	lfice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
220	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	lfice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13

-			INDIVII	DUAL OBSE	RVATIONS				
	STUDY: DAY 0-1	105PO24 DAY 14	GROUP: DOSE:	3-F 17(mg/kg)	SEX:	FEMALE			
	ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIMI	e occui	RED
	226	Normal Normal Normal Normal #1 Normal #2 Normal #3			,		DAY DAY DAY DAY DAY DAY	1-DAY 5 9-DAY 13 0	3 11
		Rough Coat Rough Coat Rough Coat Scheduled Sacri	ifice				DAY	6-DAY 12 14	8
	227	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	fice				DAY DAY DAY DAY DAY	0	13
	228	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	fice				DAY DAY DAY DAY DAY	1-DAY 0 0 0 14	13
	229	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	fice				DAY DAY DAY DAY DAY	1-DAY 0 0 0 14	13
	230	Dehydrated Hunched Posture Normal Normal Normal Normal #1 Normal #2	2		1		DAY DAY DAY DAY DAY DAY DAY	10 10 1-DAY 11 13 0	9

Description
Slight
Moderate
Severe

		<b> </b>						
			INDIVI	DUAL OBSER	RVATIONS			
	STUDY: DAY 0-I	105P024 DAY 14	GROUP: DOSE:	3-F 17(mg/kg)	SEX:	FEMALE		
	ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED	
230	(contd.)	Normal #3 Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 0 DAY 10 DAY 12 DAY 14	

		INDIVII	DUAL OBSE	RVATIONS		
STUDY: DAY 0-1	105P024 DAY 14	GROUP: DOSE:	4-F 23(mg/kg)	SEX:	FEMALE	
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED
236	Ataxia Animal Found D Normal Normal #1 Normal #2 Normal #3			1		DAY 2 DAY 3 DAY 1 DAY 0 DAY 0 DAY 0
237	Normal Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Rough Coat Scheduled Sacr	ifice				DAY 1-DAY 2 DAY 5 DAY 10-DAY 11 DAY 13 DAY 0 DAY 0 DAY 0 DAY 0 DAY 0 DAY 3-DAY 4 DAY 6-DAY 9 DAY 12 DAY 14
238	Hunched Posture Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Rough Coat Scheduled Sacr					DAY 4-DAY 6 DAY 1-DAY 2 DAY 7 DAY 10-DAY 11 DAY 0 DAY 0 DAY 0 DAY 0 DAY 0 DAY 8-DAY 6 DAY 8-DAY 9 DAY 12-DAY 13 DAY 14
239	Animal Found Do Normal Normal #1 Normal #2 Normal #3	ead				DAY 3 DAY 1-DAY 2 DAY 0 DAY 0 DAY 0

Severity No.	Description
1	Slight
2	Moderate
3	Severe

	INDIVIDUAL OBSERVATIONS							
STUDY: DAY 0-1	105P024 DAY 14	GROUP: DOSE:	4-F 23(mg/kg)	SEX:	FEMALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED		
240	Animal Found Normal Normal #1 Normal #2 Normal #3	Dead				DAY 3 DAY 1-DAY 2 DAY 0 DAY 0 DAY 0		

INDIVIDUAL OBSERVATIONS  STUDY: 105P024 GROUP: 5-F SEX: FEMALE DAY 0-DAY 14 DOSE: 30(mg/kg)								
STUDY: DAY 0-D	105P024 AY 14	GROUP: DOSE:	5-F 30(mg/kg)	SEX:	FEMALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED		
246	Ataxia Animal Found Lethargic Normal Normal #1 Normal #2 Normal #3	Dead		1		DAY 2 DAY 2 DAY 2 DAY 1 DAY 0 DAY 0 DAY 0		
	Ataxia Animal Found Lethargic Normal Normal #1 Normal #2 Normal #3	Dead		1		DAY 2 DAY 3 DAY 2 DAY 1 DAY 0 DAY 0 DAY 0		
	Animal Found Normal Normal #1 Normal #2 Normal #3	Dead				DAY 1 DAY 1 DAY 0 DAY 0 DAY 0		
	Animal Found Normal Normal #1 Normal #2 Normal #3	Dead				DAY 3 DAY 1-DAY 2 DAY 0 DAY 0 DAY 0		
	Animal Found Normal Normal #1 Normal #2 Normal #3	Dead				DAY 2 DAY 1 DAY 0 DAY 0 DAY 0		

Severity No.	Description			
1	Slight			
2	Moderate			
3	Severe			

 			DUAL OBSE				
STUDY: DAY 0-1	105IP24 DAY 14	GROUP: DOSE:	1-F 10(mg/kg)	SEX:	FEMALE		
	OBSERVATIONS			SEVERITY			URRED
256	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	fice				DAY 1-DA DAY 0 DAY 0 DAY 0 DAY 14	Y 13
257	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	.fice				DAY 1-DA DAY 0 DAY 0 DAY 0 DAY 14	Y 13
258	Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	.fice				DAY 1-DA DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	Y 11
259	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	.fice				DAY 1-DA DAY 0 DAY 0 DAY 0 DAY 14	Y 13
260	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	fice.				DAY 1-DA DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	Y 11

			DUAL OBSEI				
STUDY: DAY 0-	105IP24 DAY 14	GROUP: DOSE:	2-F 13(mg/kg)	SEX:	FEMALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCU	RRED
266	Normal #1 Normal #2					DAY 1-DAY DAY 0 DAY 0 DAY 0	13
	Scheduled Sacr	ifice				DAY 14	
267	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-DAY DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	11
268	Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-DAY DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	11
269	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13
270	Normal Normal #1 Normal #2 Normal #3 Scheduled Sacri	ifice				DAY 1-DAY DAY 0 DAY 0 DAY 0 DAY 14	13

INDIVIDUAL OBSERVATIONS									
STUDY: DAY 0-	105IP24 DAY 14	GROUP: DOSE:	3-F 17(mg/kg)	SEX:	FEMALE				
ANIMAL #	OBSERVATIONS			SEVERITY	Loc	TIME OC	CUF	RED	
276	Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-D DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	AY	11	
277	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-D DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	AY	11	
278	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-D DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	AY	11	
279	Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Scheduled Sacri	ifice				DAY 1-D DAY 13 DAY 0 DAY 0 DAY 0 DAY 12 DAY 14	AY	11	
280	Normal Normal Normal Normal #1 Normal #2					DAY 1 DAY 6-D DAY 13 DAY 0 DAY 0	AY	11	

	INDIVIDUAL OBSERVATIONS								
STUDY: DAY 0-	105IP24 DAY 14	GROUP: DOSE:	3-F 17(mg/kg)	SEX:	FEMALE				
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCC	URRED		
280 (congd.)	Normal #3 Rough Coat Rough Coat Scheduled Sacr	ifice				DAY 0 DAY 2-DA DAY 12 DAY 14	Y 5		

				Change Street School Co. 1970 - Walter Co.						
•	INDIVIDUAL OBSERVATIONS									
	STUDY: DAY 0-1	105IP24 DAY 14	GROUP: DOSE:							
	ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCU	RED	
	286	Activity Decrea Animal Found De Normal #1 Normal #2 Normal #3 Rough Coat	ased ead		1		DAY DAY DAY DAY DAY	2 3 0		
	287	Ataxia Animal Found De Normal Normal #1 Normal #2 Normal #3 Rough Coat	ead		1		DAY	2 4 1 0 0 0 0 2-DAY	3	
	288	Activity Decrea Animal Found De Hunched Posture Normal #1 Normal #2 Normal #3 Rough Coat	ased ead e		1		DAY DAY DAY DAY DAY	1-DAY 3 2 0 0 0	2	
	289	Normal Normal Normal Normal #1 Normal #2 Normal #3 Rough Coat Rough Coat Rough Coat Scheduled Sacri	ifice				DAY DAY DAY DAY DAY DAY DAY DAY	1-DAY 9 11 13 0 0 0 7-DAY 10 12		
	290	Activity Decrea	ased ead		1			1 3		

Severity No.	Description
1	Slight
2	Moderate
3	Severe

	INDIVIDUAL OBSERVATIONS								
STUDY: DAY 0-	105IP24 DAY 14	GROUP: DOSE:	4-F 23(mg/kg)	SEX:	FEMALE				
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED			
290 (contd.)	Normal Normal #1 Normal #2 Normal #3					DAY 2 DAY 0 DAY 0 DAY 0			

 INDIVIDUAL OBSERVATIONS  STUDY: 105IP24 GROUP: 5-F SEX: FEMALE DAY 0-DAY 14 DOSE: 30(mg/kg)								
STUDY: DAY 0-1	105IP24 DAY 14	GROUP: DOSE:	5-F 30(mg/kg)	SEX:	FEMALE			
 ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURR	ED
296	Activity Decrease Animal Found Normal Normal #1 Normal #2 Normal #3 Rough Coat	eased Dead		1		DAY DAY DAY DAY DAY DAY DAY DAY	2 3 1 0	
297	Animal Found Normal #1 Normal #2 Normal #3 Rough Coat	Dead				DAY CONTROL OF CONTROL		
298	Animal Found Normal Normal #1 Normal #2 Normal #3 Rough Coat	Dead			١	DAY ODAY ODAY ODAY ODAY	L )	
299	Ataxia Animal Found I Normal Normal #1 Normal #2 Normal #3 Rough Coat	Dead				DAY 3 DAY 3 DAY 0 DAY 0 DAY 0 DAY 2		
300	Activity Decre Comatose Animal Found I Normal #1 Normal #2 Normal #3 Rough Coat	eased Dead		1		DAY DAY CODAY CO		

Description
Slight
Moderate
Severe

		INDIVI	DUAL OBSERV	TATIONS			
STUDY: DAY 0-1	105P026 DAY 14	GROUP: DOSE:	1-F 1100(mg/kg	SEX:	FEMALE		
ANIMAL #	OBSERVATIONS		S	EVERITY	LOC	TIME OCCUR	RED
	Animal Found De Lethargic #1 Lethargic #2 Lethargic #3					DAY 1 DAY 0 DAY 0 DAY 0	
307	Activity Decreated Hunched Posture Normal Normal Rough Coat Rough Coat #2 Rough Coat #3 Scheduled Sacrif			1		DAY 0 DAY 5 DAY 7 DAY 11-DAY DAY 1-DAY DAY 8-DAY DAY 0 DAY 0 DAY 14	13 6 10
308	Comatose #1 Comatose #2 Comatose #3 Animal Found De					DAY 0 DAY 0 DAY 0 DAY 1	
309	Activity Decrea Activity Decrea Activity Decrea Animal Found De Lethargic Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3	ased #1 ased #2 ased #3 ead		1 1		DAY 0 DAY 0 DAY 0 DAY 1 DAY 1 DAY 1 DAY 0 DAY 0 DAY 0 DAY 0	
310	Comatose #2 Animal Found De Lethargic #1 Lethargic #3	ead				DAY 0 DAY 1 DAY 0 DAY 0	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVII	DUAL OBSER	VATIONS		
	105PO26 DAY 14					
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED
	Comatose #2 Comatose #3 Animal Found De Lethargic #1	ead				DAY 0 DAY 0 DAY 1 DAY 0
317	Activity Decrea Activity Decrea Hunched Posture Hunched Posture Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacri	ifice		1		DAY 0 DAY 0 DAY 5-DAY 6 DAY 0 DAY 4 DAY 7 DAY 11-DAY 13 DAY 1-DAY 3 DAY 5-DAY 6 DAY 8-DAY 10 DAY 0 DAY 0 DAY 0 DAY 14
318	Activity Decrea Activity Decrea Activity Decrea Animal Found De Rough Coat #1 Rough Coat #2	ased #1 ased #2 ased #3 ead		1 2 1		DAY 0 DAY 0 DAY 0 DAY 1 DAY 0 DAY 0
319	Activity Decrea Activity Decrea Activity Decrea Animal Found De Hunched Posture Rough Coat #1 Rough Coat #2 Rough Coat #3			1 2 1		DAY 0 DAY 0 DAY 0 DAY 1 DAY 0 DAY 0 DAY 0 DAY 0 DAY 0 DAY 0
320	Animal Found De Lethargic #1 Lethargic #2 Lethargic #3	ead				DAY 1 DAY 0 DAY 0 DAY 0

Severity No.	Description
1	Slight
2	Moderate
3	Severe

 INDIVIDUAL OBSERVATIONS  STUDY: 105P026 GROUP: 3-F SEX: FEMALE DAY 0-DAY 14 DOSE: 1500(mg/kg)										
STUDY: DAY 0-1	105P026 DAY 14	GROUP: DOSE:	3-F 1500(mg/kg)	SEX:	FEMALE					
 ANIMAL #	OBSERVATIONS		SI	EVERITY	LOC	TIME	OCCURRED			
326	OBSERVATIONS  Activity Decrea Activity Decrea Animal Found De Lethargic #1 Rough Coat #2 Rough Coat #3	ased #2 ased #3 ead		2		DAY DAY DAY DAY DAY DAY	0 0 1 0 0 0			
327	Animal Found De Lethargic #1 Lethargic #2 Lethargic #3	ead				DAY DAY DAY DAY	1 0 0			
328	Comatose #1 Comatose #2 Comatose #3 Animal Found De					DAY DAY DAY DAY	0			
329	Activity Decrea Activity Decrea Animal Found De Lethargic #1 Rough Coat Rough Coat #2 Rough Coat #3	ased #2 ased #3 ead		2		DAY DAY DAY DAY DAY DAY DAY DAY	0 2 1 0			
330	Activity Decrea Activity Decrea Activity Decrea Hunched Posture Hunched Posture Normal Rough Coat Rough Coat #2 Rough Coat #3 Scheduled Sacri	ased ased #1 ased #2 e		1		DAY	6 11-DAY 13 1-DAY 10 0			

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVII	DUAL OBSERVA	TIONS				_
STUDY: DAY 0-1	105P026 DAY 14	GROUP: DOSE:						
 ANIMAL #	OBSERVATIONS		SE	VERITY	LOC	TIME	OCCURRED	
336	Activity Decrea Activity Decrea Activity Decrea Animal Found De Rough Coat #3	sed #1 sed #2 sed #3		2 3 3		DAY 0 DAY 0 DAY 0 DAY 1 DAY 0		
337	Comatose #1 Comatose #2 Comatose #3 Animal Found De	ad				DAY 0 DAY 0 DAY 0 DAY 1		
338	Comatose #1 Comatose #2 Animal Found De Lethargic #3	ad				DAY 0 DAY 0 DAY 1 DAY 0		
339	Comatose #1 Comatose #2 Comatose #3 Animal Found De	ad				DAY 0 DAY 0 DAY 0 DAY 1		
340	Activity Decrea Animal Found De Lethargic #2 Lethargic #3 Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3	sed #1		1		DAY 0 DAY 1 DAY 1 DAY 0 DAY 0 DAY 0 DAY 0 DAY 0		

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVII	DUAL OBSERVA	rions				
STUDY: DAY 0-1	105P026 DAY 14	GROUP: DOSE:	5-F 2000(mg/kg)	SEX:	FEMALE			
 ANIMAL #	OBSERVATIONS		SE	VERITY	LOC	TIME	OCCURRED	
	Comatose #2 Activity Decrea Animal Found De Lethargic #3					DAY DAY DAY DAY	0	
347	Activity Decrea Activity Decrea Activity Decrea Animal Found De Rough Coat Rough Coat #2 Rough Coat #3	ased #1 ased #2 ased #3 ead		1		DAY DAY DAY DAY DAY DAY DAY	0 0 0 2 1-DAY 2 0	
348	Comatose #2 Activity Decrea Animal Found De Lethargic #1 Rough Coat #3	ased #3 ead		2		DAY DAY DAY DAY DAY	0 0 1 0 0	
349	Comatose #2 Comatose #3 Animal Found De Lethargic #1	ead				DAY DAY DAY DAY	0	
350	Comatose #2 Animal Found De Lethargic #1	ead				DAY DAY DAY	0 0 0	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

 INDIVIDUAL OBSERVATIONS  STUDY: 105P026 GROUP: 6-F SEX: FEMALE DAY 0-DAY 14 DOSE: 800(mg/kg)							
 STUDY: DAY 0-1	105P026 DAY 14	GROUP: DOSE:	6-F 800(mg/kg)	SEX:	FEMALE		• • • • • • • • • • • • • • • • • • • •
 ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCUR	RED
	Comatose Activity Decrea Activity Decrea Activity Decrea Animal Found De Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3			2 2 2		DAY 1 DAY 0 DAY 0 DAY 0 DAY 2 DAY 1 DAY 0 DAY 0 DAY 0	
407	Activity Decrea Animal Found De Lethargic #1 Lethargic #2 Rough Coat #3	ased #3 ead		3		DAY 0 DAY 1 DAY 0 DAY 0 DAY 0	
408	Animal Found De Lethargic #1 Lethargic #2 Lethargic #3	ead				DAY 1 DAY 0 DAY 0 DAY 0	
409	Animal Found De Lethargic #1 Lethargic #2 Lethargic #3	ead				DAY 1 DAY 0 DAY 0 DAY 0	
410	Activity Decrea Activity Decrea Animal Found De Lethargic #1 Rough Coat Rough Coat #2 Rough Coat #3	ased #2 ased #3 ead		2 2		DAY 0 DAY 0 DAY 3 DAY 0 DAY 1-DAY DAY 0 DAY 0	2

Severity No.	Description
1	Slight
2	Moderate
3	Severe

			OUAL OBSE			•••••••••
STUDY: DAY 0-1	105P06A DAY 14	GROUP: DOSE:	1-F 0(mg/kg)	SEX:	FEMALE	
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED
636	Normal Normal Normal 1 Normal 2 Normal 3 Rough Coat Scheduled Sacri	ifice				DAY 1-DAY 8 DAY 11-DAY 13 DAY 0 DAY 0 DAY 0 DAY 9-DAY 10 DAY 14
637	Normal Normal Normal Normal Normal Normal Normal Normal Rough Coat Rough Scheduled Sacri	ifice				DAY 1-DAY 8 DAY 11-DAY 12 DAY 0 DAY 0 DAY 0 DAY 0 DAY 9-DAY 10 DAY 13 DAY 14
638	Normal Normal 1 Normal 2 Normal 3 Scheduled Sacri	ifice				DAY 1-DAY 13 DAY 0 DAY 0 DAY 0 DAY 14
639	Normal Normal Normal 1 Normal 2 Normal 3 Rough Coat Scheduled Sacri	ifice				DAY 1-DAY 9 DAY 11-DAY 13 DAY 0 DAY 0 DAY 0 DAY 10 DAY 14
640	Normal Normal 1 Normal 2 Normal 3 Scheduled Sacri	ifice				DAY 1-DAY 13 DAY 0 DAY 0 DAY 0 DAY 14

• • • • • • • • • • • • • • • • • • • •		INDIVI	DUAL OBSE	RVATIONS		
STUDY: DAY 0-1	105P06A DAY 14	GROUP: DOSE:	2-F 0(mg/kg)	SEX:	FEMALE	
	OBSERVATIONS				LOC	TIME OCCURRED
616		vity 1 vity 2 ead e 1 e 2		1		DAY 0
617	Decreased Active Hunched Posture Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacrif	vity 1		1		DAY 0 DAY 0 DAY 1-DAY 3 DAY 5 DAY 8-DAY 11 DAY 4 DAY 6-DAY 7 DAY 12-DAY 13 DAY 0 DAY 0 DAY 0 DAY 14
618	Decreased Active Decreased Active Decreased Active Animal Found Definition of the Hunched Posture Hunched Posture Rough Coat 1 Rough Coat 2 Rough Coat 3	vity 1 vity 2 vity 3 ead e 1 e 2 e 3		1 2 2		DAY 0 DAY 0 DAY 0 DAY 1 DAY 0
619	Hunched Posture Normal Normal	2 1				DAY 0 DAY 1-DAY 5 DAY 7-DAY 12

Severity No.	<u>Description</u>
1	Slight
2	Moderate
3	Severe

INDIVIDUAL OBSERVATIONS						
STUDY: DAY 0-	105PO6A DAY 14	GROUP: DOSE:	2-F 0(mg/kg)	SEX:	FEMALE	
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED
619 (contd.) 620	Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacri Decreased Activ Hunched Posture Normal Rough Coat 1 Rough Coat 2 Rough Coat 2 Rough Coat 3 Scheduled Sacri	vity 1		1		DAY 6 DAY 13 DAY 0 DAY 0 DAY 0 DAY 0 DAY 14  DAY 0 DAY 1 DAY 0 DAY 1-DAY 13 DAY 0 DAY 0 DAY 0 DAY 0 DAY 1

Severity No.	Description
1	Slight
2	Moderate
3	Severe

_			INDIVI	DUAL OBSERV	'ATIONS			
	STUDY: DAY 0-1	105P06A DAY 14	GROUP: DOSE:	3-F 800(mg/kg)	SEX:	FEMALE		
-	ANIMAL #	OBSERVATIONS		9	EVERITY	Loc	TIME OCCU	RRED
	626	Decreased Active Hunched Posture Normal Normal Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacri	ifice		1		DAY 0 DAY 5 DAY 1 DAY 6-DAY DAY 2-DAY DAY 8-DAY DAY 0 DAY 0 DAY 0 DAY 14	7 5 13
	627	Decreased Active Decreased Active Decreased Active Decreased Active Normal Normal Normal Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacrif	ifice		1 1 2		DAY 0 DAY 0 DAY 0 DAY 3 DAY 6 DAY 8-DAY DAY 7 DAY 7 DAY 0 DAY 0 DAY 0 DAY 14	13 5
	628	Animal Found De Labored Breath: Labored Breath: Lethargic 1 Lethargic 2 Lethargic 3 Rough Coat 2 Rough Coat 3	ad ing 2 ing 3				DAY 1 DAY 0 DAY 0 DAY 0 DAY 0 DAY 0 DAY 0 DAY 0	
	629	Hunched Posture Normal Normal Rough Coat					DAY 3-DAY DAY 1-DAY DAY 5-DAY DAY 3-DAY	4 2 13

Severity No.	Description
1	Slight
2	Moderate
3	Severe

#### ACUTE ORAL TOXICITY STUDY OF

	INDIVIDUAL OBSERVATIONS						
STUDY: DAY 0-1	105P06A DAY 14	GROUP: DOSE:	3-F 800(mg/kg)	SEX:	FEMALE		
ANIMAL #	OBSERVATIONS		S	EVERITY	Loc	TIME	OCCURRED
629 (contd.)	Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacri	ifice				DAY (DAY (DAY (DAY )	Ď
630	Decreased Active Decreased Active Decreased Active Animal Found Definition of Hunched Posture Hunched Posture Rough Coat 1 Rough Coat 2 Rough Coat 3	2 2		1 2 2		DAY O DAY O DAY O DAY O DAY O	

Description				
Slight				
Moderate				
Severe				

		INDIVI	DUAL OBSERVA	TIONS			
STUDY: DAY 0-	105PO6A DAY 14	GROUP: DOSE:	4-F 1000(mg/kg)	SEX:	FEMALE		
ANIMAL #	OBSERVATIONS		SE	VERITY	LOC	TIME OCCUR	RED
606	Blue Feet 1 Decreased Acti Decreased Acti Hunched Postur Hunched Postur Hunched Postur Hunched Postur Hunched Postur Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacr	vity 1 vity 3 e e 1 e 2 e 3					9
607	Blue Feet 1 Decreased Action Decreased Action Decreased Action Decreased Action Animal Found Do Hunched Posture Hunched Posture Hunched Posture Rough Coat 1 Rough Coat 2 Rough Coat 3	vity 1 vity 2 vity 3 ead e 1 e 2 e 3		1 2		DAY 0 DAY 0 DAY 0 DAY 0 DAY 1 DAY 0	
608	Hunched Posture Hunched Posture Hunched Posture Normal Normal Rough Coat Rough Coat Rough Coat 1 Rough Coat 2 Rough Coat 3 Scheduled Sacr	e e 2 e 3				DAY 4 DAY 0 DAY 0 DAY 2 DAY 6-DAY DAY 1 DAY 3-DAY DAY 0 DAY 0 DAY 0 DAY 14	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

INDIVIDUAL OBSERVATIONS							
STUDY: DAY 0-1	105P06A DAY 14	GROUP: DOSE:	4-F 1000(mg/kg	SEX:	FEMALE		
 ANIMAL #	OBSERVATIONS		:	SEVERITY	LOC	TIME OCCUP	RED
609 610	Animal Found Do Blue Feet 1 Blue Feet 2 Decreased Active Feet 2 Decreased Active Feet 2 Hunched Posture Hunched Posture Hunched Posture Hunched Posture Found Feet Feet Feet Feet Feet Feet Feet Fee	vity 1 vity 2 e 1 e 2 e 3		1		DAY 0 DAY 1-DAY DAY 5-DAY DAY 3-DAY DAY 13 DAY 0 DAY 0 DAY 14	4 2 12 4

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVI	DUAL OBSERVA	TIONS			
STUDY: DAY 0-	105IP26 DAY 14	GROUP: DOSE:	1-F 100(mg/kg)	SEX: 1	FEMALE		
	OBSERVATIONS					TIME OCCURR	ED
356	Activity Decre Activity Decre Lethargic #1 Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat #2 Rough Coat #3 Scheduled Sacr			1		DAY 0 DAY 0 DAY 0 DAY 4 DAY 6 DAY 11-DAY 3 DAY 5 DAY 7-DAY 1 DAY 0 DAY 0 DAY 14	
357	Activity Decre Activity Decre Activity Decre Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Scheduled Sacr			1 1 1		DAY 0 DAY 0 DAY 0 DAY 4 DAY 6-DAY 8 DAY 11-DAY 3 DAY 5 DAY 9-DAY 1 DAY 0 DAY 14	13
358	Activity Decre Activity Decre Activity Decre Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat #1 Rough Coat #3 Scheduled Sacr			1 1 1		DAY 0 DAY 0 DAY 0 DAY 4 DAY 6-DAY 7 DAY 11-DAY 3 DAY 5 DAY 8-DAY 1 DAY 0 DAY 0 DAY 14	13

Severity No.	Description
1	Slight
2	Moderate
3	Severe

	INDIVIDUAL OBSERVATIONS						
STUDY: DAY 0-1	105IP26 DAY 14	GROUP: DOSE:	1-F 100(mg/kg	SEX:	FEMALE		
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED	
359	Activity Decrea Activity Decrea Activity Decrea Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat			1 1 1		DAY 0 DAY 0 DAY 0 DAY 2-DAY 4 DAY 6 DAY 11-DAY 13 DAY 5 DAY 7-DAY 10 DAY 0 DAY 14	
360	Activity Decrea Activity Decrea Activity Decrea Normal Rough Coat Rough Coat #3 Scheduled Sacri	ased #1 ased #2 ased #3		1 1 1		DAY 0 DAY 0 DAY 0 DAY 2-DAY 13 DAY 1 DAY 0 DAY 14	

Severity No.	Description
1	Slight
2	Moderate
3	Severe

			DUAL OBSE					
	105IP26 DAY 14				FEMALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	occui	RRED
366	Comatose #1 Hunched Posture Lethargic #2 Lethargic #3 Normal Rough Coat Rough Coat #3	2				DAY DAY DAY DAY DAY	2-DAY 0 0 13 1-DAY	
	Scheduled Sacr	ifice				DAY		
367	Comatose #2 Lethargic #1 Lethargic #3 Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Scheduled Sacri	ifice				DAY DAY DAY DAY DAY DAY DAY	0 0 0 6-DAY 13 1-DAY 9-DAY 0 14	5
368	Activity Decrea Activity Decrea Lethargic #2 Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat #3 Scheduled Sacri			2 2		DAY DAY DAY DAY DAY DAY DAY DAY	0 0 0 2-DAY 6-DAY 13 15 9-DAY 0	8
369	Comatose #1 Activity Decrea Lethargic #2 Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat #3 Scheduled Sacri			2		DAY DAY DAY DAY DAY DAY	0	13

Severity No.	<b>Description</b>
1	Slight
2	Moderate
3	Severe

			and the second s	and the second second second			
INDIVIDUAL OBSERVATIONS							
STUDY: 105IP26 DAY 0-DAY 14	GROUP: DOSE:	2-F 120(mg/kg)	SEX:	FEMALE			
ANIMAL # OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED		
370 Activity Decre Activity Decre Activity Decre Activity Decre Normal Normal Rough Coat Rough Coat Rough Coat #1 Rough Coat #2 Rough Coat #3 Scheduled Sacr	ased #2 ased #3		2 1 1		DAY 0 DAY 0 DAY 0 DAY 0 DAY 2-DAY 4 DAY 6-DAY 13 DAY 1 DAY 5 DAY 0 DAY 0 DAY 0 DAY 14		

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVII	OUAL OBSERVA	TIONS				
STUDY: DAY 0-	105IP26 DAY 14	GROUP: DOSE:	3-F 140(mg/kg)	SEX:	FEMALE			
ANIMAL #	OBSERVATIONS		SE	VERITY	LOC	TIME	OCCUR	RED
376	Activity Decrea Comatose #1 Animal Found De Lethargic #2 Lethargic #3 Rough Coat	ased ead		1		DAY 2 DAY 0 DAY 4 DAY 0 DAY 0 DAY 1		
377	Comatose #1 Animal Found De Lethargic Lethargic #2 Lethargic #3 Rough Coat	ead				DAY 0 DAY 2 DAY 1 DAY 0 DAY 0 DAY 1		
378	Activity Decrea Lethargic #1 Lethargic #2 Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat #2 Rough Coat #3 Scheduled Sacri			2		DAY 0 DAY 0 DAY 2 DAY 6 DAY 1 DAY 1 DAY 5 DAY 7 DAY 0 DAY 0 DAY 1	1-DAY -DAY	13
379	Comatose #1 Comatose #2 Lethargic #3 Normal Normal Rough Coat Rough Coat Scheduled Sacri	ifice				DAY 0 DAY 0 DAY 0 DAY 4 DAY 6 DAY 1 DAY 5 DAY 1	-DAY	13
380	Comatose #1					DAY 0		

Severity No.	Description
1	Slight
2	Moderate
3	Severe

		INDIVII	OUAL OBSER	RVATIONS		
STUDY: DAY 0-	105IP26 DAY 14	GROUP: DOSE:	3-F 140(mg/kg	SEX:	FEMALE	
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME OCCURRED
380 (contd.)	Lethargic #2 Lethargic #3 Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat #2 Rough Coat #3 Scheduled Sacri	ifice				DAY 0 DAY 0 DAY 3-DAY 4 DAY 6 DAY 8-DAY 13 DAY 1-DAY 2 DAY 5 DAY 7 DAY 0 DAY 0 DAY 14

----

								10000000
		INDIVII	DUAL OBSE	RVATIONS				
STUDY: DAY 0-I	105IP26 DAY 14	GROUP: DOSE:	4-F 170(mg/kg	SEX:	FEMALE			
ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCURR	ED
386	Comatose #1 Comatose #2 Comatose #3 Animal Found D Lethargic Rough Coat					DAY ODAY ODAY ODAY ODAY ODAY ODAY ODAY		
387	Comatose #1 Comatose #2 Lethargic #3 Normal Normal Normal Rough Coat Rough Coat Rough Coat Rough Coat Rough Coat Scheduled Sacr	ifice				DAY 5 DAY 8 DAY 1	) L )	
388	Comatose #1 Comatose #2 Lethargic #3 Rough Coat Rough Coat #3 Scheduled Sacr	ifice				DAY C	)  -DAY 1:	3
389	Comatose #1 Comatose #2 Lethargic #3 Normal Normal Rough Coat #3 Scheduled Sacr	ifice				DAY I	DAY 7 11-DAY 1 1-DAY 3 5-DAY 1	

 		INDIVI	OUAL OBSER	VATIONS				
STUDY: DAY 0-1	105IP26 DAY 14	GROUP: DOSE:	4-F 170(mg/kg		FEMALE			
 ANIMAL #	OBSERVATIONS			SEVERITY	LOC	TIME	OCCUR	RED
390	Comatose #1 Comatose #2 Activity Decre Normal Normal Rough Coat			1		DAY DAY DAY DAY DAY DAY DAY	0 0 4 6-DAY 13 1-DAY 5 8-DAY	3

Severity No.	Description
1	Slight
2	Moderate
3	Severe

INDIVIDU	JAL OBSERVATIONS		•••••
GROUP: 5 DOSE: 2	S-F SEX:	FEMALE	
rions	SEVERITY	LOC I	TIME OCCURRED
#1 #2 #3 Posture Posture  pat pat pat pat pat pat pat pat pat pa			DAY 0 DAY 0 DAY 0 DAY 1-DAY 3 DAY 4 DAY 7 DAY 13 DAY 1-DAY 3 DAY 5-DAY 6 DAY 8-DAY 12
e #1 Found Dead		D	DAY O DAY O
#1 Posture Posture ic #2 ic #3  pat pat pad Sacrifice			DAY 0 DAY 1-DAY 2 DAY 6 DAY 0 DAY 0 DAY 4 DAY 11-DAY 13 DAY 1-DAY 3 DAY 5-DAY 10 DAY 14
e #1 e #2 e #3 Found Dead Posture oat			DAY 0 DAY 0 DAY 0 DAY 2 DAY 1 DAY 1
#1 Found Dead		D	DAY O DAY O
	GROUP: 5 DOSE: 2 FIONS  #1 #2 #3 Posture Posture  #1 Posture Posture  #2 #3 Posture Posture  #2 #3 Posture Posture  #2 #3 Posture #2 #3 Posture #3 Posture #4 Posture	#1 Posture Posture  #1 Posture  #1 Posture  #1 Posture  #1 Posture  #2 #2 #3  Posture  #2 #3  Posture  #1 Posture  #2 #3  Posture  #2 #3  Posture  #3  Posture  #4  Posture  #4  Posture  #5  #6  #6  #7  Posture  #6  #7  Posture  #7  Posture  #8  #8  Posture  #8  #8  Posture  #8  #8  Posture  #8  #8  Posture  Posture  #8  Posture  Posture  Posture  #8  Posture  Posture  #8  Posture  Postu	GROUP: 5-F DOSE: 200 (mg/kg)  FIONS SEVERITY LOC TO SEVERITY L

#### APPENDIX 4

Individual Body Weights and Body Weight Gains

	IN	DIVIDU	AL BO	DY WE	GHTS (Gra	ms)
STUDY: 105P024	GR	OUP: 1 SE: 1	-M 0 (mg/		SEX:	MALE
	DO	SE: 1	0 (mg/	ka)		
	ANIMAL #	DAY -3	DAY O	DAY 7	DAY 14	
	201	26.0	27.4	28.8	29.4	
	202	24.6	26.2	28.6	30.8	
	203	26.7	27.8	28.4	30.4	
	204	27.2	28.2	29.7	32.2	
	205	24.9	26.6	28.1	30.0	
	-45		20.0		5010	
	MEAN	25.9	27.2	28.7	30.6	
	S.D.	1.12	0.83	0.61	1.05	
	N.	5	0.55	0.51	5	
	П.	J	ata Unava	ماطمان	,	
		: U	ata Unava	illante		

	1	NDIVID	UAL BO	DY WE	<b>IGHTS</b> (Gra	ms)
STUDY: 105P024	Ç	ROUP:	2-M	lr~\	SEX:	MALE
	ANIMAL A		13 (mg/	DAY 7	DAY 14	
	211	28.4	30.3	31.8	34.1	
	212	24.0	25.7	28.6	30.7	
	213	26.8	27.7	30.7	32.9	
	214	25.8	27.7	29.6	32.3	
	215	25.2	27.2	29.0	29.0	
	MEAN	26.0	27.7	29.9	31.8	
	S.D.	1.66	1.66	1.31	1.99	
	N	5	5	5	5	
		:	Data Unav	ailable		

		IN	DIVIDU	AL BO	DY WE	IGHTS (Gra	ems)		
STUDY:	105P024	GR	OUP: 3 SE: 1	-M 7 (mg/	ka)	SEX:	MALE		
 		ANIMAL #	DAY -3	DAY 0	DAY 7	DAY 14			
 								,	
		221	27.0	28.6	30.4	32.2			
		222	24.6	25.5	25.2	26.7			
		223	27.3	28.7	30.3	32.9			
		224	26.4	27.8	29.7	31.1			
		225	25.3	25.8	28.5	30.1			
		MEAN	26.1	27.3	28.8	30.6			
		S.D.	1.14	1.53	2.16	2.43			
		N	5	5	5	5			
		~	: D	ata Únava	ilable	,			

 		IN	DIVIDUZ	L B	ODY WE	IGHTS (G	rams)	
STUDY:	105PO24	GR	OUP: 4- SE: 23 DAY -3	-M	/ka)	SEX	K: MALE	
		ANIMAL #	DAY -3	DAY 0	DAY 7	DAY 14		
 						m		
		231	27.1	27.4	30.4	31.4		
		232	23.7	25.1	С	C		
		233	26.9	28.2	C	C		
		234	26.3	27.8	30.7	33.4		
		235	25.7	26.6	29.7	32.6		
		MEAN	25.9	27.0	30.3	32.5		
		S.D.	1.37	1.23	0.51	1.01		
		N	5	5	3	3		
			Unavailabl	e	c: Animal	Found Dead		

		IN	DIVIDUA	L BO	DDY WE	IGHTS (Gra	oms)
STUDY:	105P024	GRO	OUP: 5- SE: 30 DAY -3	-M	/ka)	SEX:	MALE
 		ANIMAL #	DAY -3	DAY 0	DAY 7	DAY 14	
		241	28.0	30.3	C	C	
		242	24.2	25.1	C	C	
		243	26.5	28.9	C	С	
		244	25.2	26.5	c	C	
		245	26.2	27.8	c	c	
		MEAN	26.0	27.7			
		S.D.	1.43	2.03			
		N	5	5	0	0	
			Unavailabl	e (	: Animal	Found Dead	

	IN	DIVIDU	AL BO	DY WE	GHTS (Gra	ams)	
STUDY: 105IP24	GR DO ANIMAL #	OUP: 1 SE: 1 DAY -3	-M 0 (mg/: DAY 0	kg) DAY 7		MALE	
	251 252 253 254 255 MEAN S.D. N	26.7 24.2 24.7 28.0 25.9 25.9 1.53 5	27.9 25.5 25.9 30.3 28.6 27.6 1.98 5	28.8 27.0 26.7 31.1 29.2 28.6 1.79 5	30.6 30.7 27.5 34.6 31.8 31.0 2.55		

		IN	DIVIDU	AL BO	DY WE	GHTS (Gra	ms)
 STUDY:	105IP24	GR DO ANIMAL #	OUP: 2 SE: 1 DAY -3	-M 3 (mg/) DAY 0	kg) DAY 7	SEX:	MALE
 		2/4	AF 7	27.	20 /	~4.4	
		261	25.7	27.6	29.4	31.1	
		262	24.0	25.1	25.7	26.6	
		263	26.9	28.0	29.8	31.6	
		264	26.4	27.4	29.0	31.7	
		265	28.2	28.8	31.2	32.9	
		203	20.2	20.0	31.2	32.7	
		MEAN	26-2	27.4	29_0	30.8	
		S.D.	1.55	1.38	2.03	2.43	
		N	5	5	5	5	
		.,	D	ata Unava	ilable		

IN	DIVIDU	AL BO	DY WE	GHTS (Gra	ms)
GR	OUP: 3	-M	le \	SEX:	MALE
	DAY -3	/ (mg/)	NAY 7	DAY 14	
271	25.2	27.5	29.1	31.1	
272	24.7	27.2	28.9	30.8	
273	26.8	28.4	29.1	32.7	
275	26.1	27.8	29.3	31.6	
MEAN	26.2	28.2	29.0	31.7	
S.D.	1.45	1.11	0.23	0.76	
N	5	5	5	5	
	: Da	ata Unava	ilable		
	GR DO ANIMAL # 271 272 273 274 275 MEAN S.D.	GROUP: 3: DOSE: 1  ANIMAL # DAY -3  271	GROUP: 3-M DOSE: 17 (mg/ ANIMAL # DAY -3 DAY 0	GROUP: 3-M DOSE: 17 (mg/kg) ANIMAL # DAY -3 DAY 0 DAY 7  271	271 25.2 27.5 29.1 31.1 272 24.7 27.2 28.9 30.8 27.5 26.8 28.4 29.1 32.7 27.4 28.4 30.0 28.7 32.1 27.5 26.1 27.8 29.3 31.6 MEAN 26.2 28.2 29.0 31.7 S.D. 1.45 1.11 0.23 0.76 N 5 5 5 5

	IN	DIVIDUA	L BC	DY WE	IGHTS (Gr	ams)
STUDY: 105IP24	GRO	OUP: 4- SE: 23	-M	kg)	SEX	MALE
	ANIMAL #	DAY -3	DAY 0	DAY 7	DAY 14	
	204	47.4	00.0			
	281	27.8	29.9	c	C	
	282	23.7	24.8	C	C	
	283	25.7	27.2	27.0	29.6	
	284	27.0	28.8	C	С	
	285	25.9	26.5	С	С	
	MEAN	26.0	27.4	27.0	29.6	
	S.D.	1.55	1.99			
	N	5	5	1	1	
	: Data	Unavailabl	e c	: Animal	Found Dead	

	IN	DIVIDU	IAL BO	DY WE	<b>IGHTS</b> (Gra	ams)	
STUDY: 105IP24	GR DO ANIMAL#	OUP: 5 SE: 3 DAY -3	-M 0 (mg/)	kg) DAY 7	SEX:	MALE	
	291	28.0	28.7	C	C		
	292	25.5	27.2	С	С		
	293	24.0	26.0	C	C		
	294	26.2	27.2	c	c		
	295	26.7	27.8	c			
	273	20.7	21.0	C	C		
	MEAN	26.1	27.4				
	S.D.	1.48	0.99				
	N	5	5	0	0		
		Unavailat	ole c:	Animal	Found Dead		

		INDIVIE	UAL BOI	Y WE	IGHTS (Grad	ns)	
STUDY:	105P026	GROUP: DOSE:	1-M 1100 (mg	ı/kg)	SEX:	MALE	
	AN	IMAL # PRETEST	DAY 0	DAY 7	DAY 14		
	3.	01 28.2	29.7	30.7	31.8		
		02 29.0	29.7	C	C		
		03 30.3	30.9	c	c		
		04 27.8	29.1	30.0	30.9		
		05 26.1	27.5	28.6	29.1		
		MEAN 28.3	29.4	29.8	30.6		
		S.D. 1.55	1.24	1.07	1.37		
		N 5	5	3	3		
		: Data Unavail	able c:	Animal	Found Dead		

		IN	DIVIDUA	L B	ODY WE	<b>IGHTS</b> (Gr	ams)	
STUDY:	105P026	GR	OUP: 2- SE: 13	M	mg/kg)	SEX	: MALE	
		NIMAL #	PRETEST	DAY 0	DAY 7	DAY 14		
		744	20.7	70 /	2/ 7	74 /		
		311 312	29.3 25.3	30.4	24.3	31.4		
		313	28.0	29.5	<u> </u>	C		
		314	31.3	32.5				
		315	27.7	28.6	30.6	31.0		
		317	21.1	20.0	30.0	31.0		
		MEAN	28.3	29.3	27.5	31.2		
		S.D.	2.20	2.61	4.45	0.28		
		N	5	5	2	2		
		: Data	Unavailable	e (	c: Animal	Found Dead		

 						IGHTS (Gr	ams)	
 STUDY:	105PO26	GR DO	OUP: 3- SE: 1! PRETEST	-M 500(	mg/kg)	SEX	: MALE	
 		ANIMAL #	PRETEST	DAY 0	DAY /	DAY 14		
		321	27.6	28.6	25.9	30.8		
		322	26.7	28.0	C	C		
		323	27.8	29.2	C	C		
		324	28.9	30.0	C	c		
		325	30.5	32.1	c	c		
		MEAN	28.3	29.6	25.9	30.8		
		S.D.	1.46	1.59				
		N	5	5	1	1		
			Unavailabl	e	c: Animal	Found Dead		

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY: 105P026	GR	OUP: 4	-M	ng/kg)	SEX:	MALE					
	ANIMAL #	SE: 1 PRETEST	DAY 0	DAY 7	DAY 14						
	331	29.3	30.3	C	С						
	332	25.0	25.2	C	C						
	333	27.0	28.8	c	C						
	334	31.1	31.4	c	C						
	335	28.1	29.7	c	c						
	337	20.1		•							
	MEAN	28.1	29.1								
	S.D.	2.31	2.37								
	N	5	5	0	0						
	: Data	Unavailab	ole d	: Animal	Found Dead						

	INDI	VIDUAL	BODY WE	IGHTS (Gran	ns)
STUDY: 105P026	GROU DOSE	P: 5-M		SEX:	MALE
	DOSE	: 2000	(mg/kg)		
	NIMAL # PR	ETEST DAY	(mg/kg)	DAY 14	
	7/4	70 5 74	•		
	341	30.5 31.		С	
	342	26.5 28.	.0 с	С	
	343	26.5 28. 27.1 28.		29.2	
	344	29.4 31.		c	
	345	27.9 28.			
	343	21.7 20.	.1 с	С	
	MEAN	28.3 29.	.5 26.6	29.2	
		28.3 29. 1.65 1.7	72		
		1.03	2		
	N	5	5 1	1	
	: Data Un	available	c: Animal	Found Dead	

#### ACUTE ORAL TOXICITY STUDY OF

INDIVIDUAL BODY WEIGHTS (Grams)  STUDY: 105P026 GROUP: 6-M SEX: MALE DOSE: 800 (mg/kg) ANIMAL # PRETEST DAY 0 DAY 7 DAY 14											
STUDY:	105P026	GR	QUP:	6-M	~ /le~\	SEX	MALE				
		ANIMAL #	PRETEST	DAY 0	DAY 7	DAY 14					
		401	22.7	24.6	C	C					
		402	26.5	31.1	C	C					
		403	22.7 26.5 25.7	25.7	26.6	27.6					
		404	26.3	27.9	C	C					
		405	27.6	29.4	c	C					
		MEAN	25.8	27.7	26.6	27.6					
		S.D.	1.84	2.65	••	••					
		N	5	5	1	1					
		: Data	Unavail	able	c: Animal	Found Dead					

		INDIVI	DUAL B	ODY WE	IGHTS (Gra	ms)
STUDY:	105P06A	GROUP: DOSE: MAL # DAY	1-M 0 (mg/ DAY 0	kg) DAY 7	SEX:	MALE
	63	1 28.1	28.8	32.6	32.2	
	63	2 28.2	29.1	31.7	32.8	
	63	3 26.8	27.3	31.8	30.8	
	63			33.6	23.1	
	63			С	C	
		MEAN 28.6	28.7	32.4	29.7	
		S.D. 1.32	1.06	0.88	4.50	
		N 5	5	4	4	
	•	-: Data Unavai	lable	c: Animal	Found Dead	

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY: 105PO6A	GR	OUP: 2 SE: 0	-M	۳)	SEX:	MALE					
	ANIMAL #	DAY -2	(mg/k	DAY 7	DAY 14						
	611	27.4	28.9	32.0	31.6						
	612	30.0	31.1	34.5	34.0						
	613	28.3	29.1	31.3	32.3						
	614	28.6	28.8	31.6	32.7						
	615	30.7	31.7	С	c						
	MEAN	29.0	29.9	32.4	32.7						
	S.D.	1.33	1.37	1.46	1.01						
	N	5	5	4	4						
	: Data	Unavailab	ole c	Animal	Found Dead						

INDIVIDUAL BODY WEIGHTS (Grams)										
STUDY:	105PO6A	GROUP DOSE:	: 3-M 800(	mg/kg	a)		MALE			
	AN	IMAL # DAY	-2 DAY	U DA	AY 7 DA	Y 14				
	6	21 28	.4 29.	.7 32	2.2 3	1.0				
		22 30 23 27	.5 31.	4	C	C				
		23 27	.5 28.		6	-				
		24 26	.3 26.		8.1 2	28.0				
	0	25 29	.7 30.	.4	C	C				
		MEAN 28				29.5				
		S.D. 1.	68 1.7	2 2.	.90 2	2.12				
		N	5 5	,	2	2				
		: Data Unav	ailable	c: Ani	imal Four	nd Dead				

	IN	DIVIDU	AL B	ODY WE	IGHTS (Gr	ams)	 
STUDY: 105PO6A	GR DO: ANIMAL #	OUP: 4 SE: 1 DAY -2	-M 000 (1 DAY 0	mg/kg) DAY 7	SEX:	MALE	
	601 602 603 604 605 MEAN S.D. N	27.5 26.1 29.0 30.4 28.3 1.61 5 Unavailab	28.2 27.1 29.3 31.3 29.9 29.2 1.61 5	30.7 28.8 c 33.6 32.5 31.4 2.11 4 c: Animal	30.6 29.9 c 33.9 31.5 1.74 4 Found Dead		

		IN	DIVIDU	IAL B	ODY WE	IGHTS (Gr	rams)	
STUDY:	105IP26		GROUP: 1-M DOSE: 100(m				: MALE	
		ANIMAL #	DAY -3	DAY 0	DAY 7	DAY 14		
		351	27.8	28.7	28.0	30.1		
		352	29.8	30.4	C	C		
		353	28.7	29.8	31.8	33.3		
		354	26.2	29.3	29.3	31.2		
			27.8		27.3			
		355	21.0	28.1	21.3	24.8		
		MEAN	28.1	29.3	29.1	29.9		
		S.D.	1.33	0.90	1.98	3.62		
		N.	55	5.50	1.90	4.02		
			11	1-		Cound Sand		
		: Data	Unavailab	ole	c: Animal	Found Dead		

	I	NDIVIDU	AL BO	DY WE	IGHTS (Gr	ams)	 
STUDY: 105IP26	G] D( ANIMAL #	ROUP: 2 DSE: 1 DAY -3	-M 20 (mg	/kg) DAY 7	SEX:	MALE	
	361 362 363 364 365 MEAN S.D. N	30.2 26.4 27.6 28.7 28.8 28.3 1.42 5 a Unavailab	31.5 27.8 28.1 30.0 29.5 29.4 1.50 5	31.7 c c c c 31.7  1	33.3 c c c c 33.3		

INDIVIDUAL BODY WEIGHTS (Grams)										
STUDY:	105IP26	GRO DOS	UP: 3- E: 14	M O (mg/	ka)	SEX:	MALE	_		
		ANIMAL #	DAY -3	DAY 0	DAY 7	DAY 14				
								-		
		371	28.7	29.1	31.0	33.3				
		372	29.4	29.9	31.0	33.3				
		373	29.4 27.2	28.3	C	C				
		374	24.9	26.4	C	C				
		375	30.2	31.5	32.4	33.2				
		MEAN	28.1	29.0	31.7	33.3				
		S.D.	2.09	1.89	0.99	0.07				
		N	5	5	2	2				
		: Data U	navailable	e c:	Animal	Found Dead				

	INDIVIDUAL BODY WEIGHTS (Grams)								
STUDY: 105IP26	G] D(	ROUP: 4 DSE: 1 DAY -3	-M 70 (ma	/ka)	SEX:	MALE			
	ANIMAL #	DAY -3	DAY O	DAY 7	DAY 14				
	381	27.6	28.2	c					
	382	28.6	29.7	c	c				
	383	26.9	29.7 28.3	20.6	c				
	384	28.8	30.3	31.1	32.0				
	385	29.5	30.5	C	c				
	MEAN	28.3	29.4	25.9	32.0				
	S.D.	1.03	1.09	7.42					
	N	5	5	2	1				
	: Dat	a Unavailab	le c:	Animal	Found Dead				

			IN	DIVIDU	AL BO	DY WE	GHTS (Gra	ms)
•••••	STUDY:	105IP26	GR DO ANIMAL #	OUP: 5 SE: 2 DAY -3	-M 00 (mg	/kg)	SEX:	MALE
			VUILUE M	ב- ואם	יאם		DAT 14	
			391	28.8	29.4	C	C	
			392	26.2	27.0	С	С	
			393	28.3	29.1	c	С	
			394	27.4	28.3	c	C	
			395	31.1	31.3	c	c	
			373	31.1	31.3	-	C	
			MEAN	28.4	29.0		••	
			S.D.	1.82	1.58			
			N	5	5	0	0	
				Unavailab	ole c:	Animal F	ound Dead	

	INDIVI	DUAL W	EIGHT (	GAIN (Gran	ns)
STUDY: 105P024	GROUP: DOSE:	1-M 10(mg/)	kg)		MALE
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN	
	201	1.4	0.6	2.0	
	202	2.4	2.2	4.6	
	203	0.6	2.0	2.6	
			2.5		
	204	1.5		4.0	
	205	1.5	1.9	3.4	
	MEAN	1.5	1.8	3.3	
	S.D.	0.64	0.73	1.04	
	N	5	5	5	
	Data Unavail	abla be	Schodulad	Sacrifice	
	Data Unavait	able b:	scheduted	Sacrifice	

	INDIV	IDUAL W	EIGHT	GAIN (Gran	ns)
STUDY: 105P024	GROUP: DOSE:	2-M 13(mg/	kg)		MALE
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN	
	211 212	1.5 2.9 3.0	2.3	3.8 5.0 5.2	
	213 214	3.0 1.9	2.2	5.2 4.6	
	215	1.8	0.0	1.8	
	MEAN	2.2	1.9	4.1	
	S.D. N	0.68 5	1.06 5	1.38	
	: Data Unavai	lable b	Schedule	d Sacrifice	

#### ACUTE ORAL TOXICITY STUDY OF

	INDIVI	DUAL W	EIGHT	GAIN (Gran	ns)	 	
STUDY: 105P024	GROUP: DOSE:	3-M 17(mg/kg)			MALE		
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN		 	
	221 222	1.8	1.8 1.5	3.6 1.2			
	223 224 225	1.6 1.9 2.7	2.6 1.4 1.6	4.2 3.3 4.3			
	MEAN S.D.	1.5 1.11	1.8 0.48	3.3 1.26			
	·: Data Unavail	able b	: Schedule	ed Sacrifice			

	INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)	 
STUDY: 105P024	GROUP: DOSE:	4-M 23 (mg	/kg)		MALE	
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN		
	231	3.0	1.0	4.0		
	232	С	С			
	233	C	С			
	234	2.9	2.7	5.6		
	235	3.1	2.9	6.0		
	MEAN	3.0	2.2	5.2		
	S.D.	0.10	1.04	1.06		
	N	3	3	3		
: Data Unavaila	able b:	Schedul ed	Sacrifice	c: Animal	Found Dead	

INDIVIDUAL WEIGHT GAIN (Grams)									
STUDY: 105P024	GROUP: 5-N DOSE: 30	GROUP: 5-M DOSE: 30(mg/kg)			MALE				
	ANIMAL # D	DAY 7	DAY 14	TOTAL GAIN					
	241	С	С						
	242	C	С						
	242 243	С	C						
	244	C	C						
	245	С	С						
	MEAN			• •					
	S.D.								
	N	0	0	0					
	: Data Unavailable	c:	Animal	Found Dead					

	INDIVIDUAL	WEIGHT (	GAIN (Gram	ns)
STUDY: 105IP24	GROUP: 1-M DOSE: 10 (mg	g/kg)		MALE
	ANIMAL # DAY	7 DAY 14	TOTAL GAIN	
	251 0.9	1.8	2.7	
	252 1.5 253 0.8	3.7	5.2	
	254 0.8 255 0.6	3.5	4.3	
	MEAN 0.9		3.4	
	S.D. 0.34 N 5		1.40	
:	Data Unavailable	b: Scheduled	Sacrifice	

	INDIVIDUA	L WEIGHT	GAIN (Gram	ns)
STUDY: 105IP24	GROUP: 2-M DOSE: 13(	ROUP: 2-M DSE: 13(mg/kg)		MALE
		AY 7 DAY 14	TOTAL GAIN	
	261	1.8 1.7	3.5	
		0.6 0.9	1.5	
		1.8 1.8	3.6	
		1.6 2.7	4.3	
		2.4 1.7	4.1	
	MEAN 1	1.6 1.8	3.4	
	S.D. 0.	.65 0.64	1.11	
	N	5 5	5	
:	Data Unavailable	b: Scheduled	d Sacrifice	

	INDIVI	DUAL WI	EIGHT G	AIN (Gram	ns)
STUDY: 105IP24	GROUP: DOSE:	3-M 17(mg/)	kg)	SEX:	MALE
	ANIMAL #	DAY 7	DAY 14	GAIN	
	271	1.6	2.0	3.6	
	272	1.7	1.9	3.6 3.6	
	273	0.7	3.6	4.3	
	274	-1.3	3.4	4.3	
	275	1.5	2.3	3.8	
	MEAN	0.8	2.6	3.5	
	S.D.	1.26	0.80	0.82	
	N	5	5	5	
:	Data Unavail	able b:	Scheduled	Sacrifice	

			INDIV	IDUAL	WEIGHT	GAIN (Grad	ms)	
STUDY:	105IP24	G	ROUP:	4-M 23 (mg	(kg)	SEX:	MALE	
			ANIMAL #			TOTAL GAIN		
			281	С	С			
			282	-0.2	С			
			283	-0.2	2.6	2.4		
			284	С	С			
			285	С	С			
			MEAN	-0.2	2.6	2.4		
			S.D.					
			N	1	1	1		
	:	Data Unavailabl	e b:	Scheduled	Sacrifice	c: Animal	Found Dead	

	INDIVIDUZ	AL WI	EIGHT	GAIN (Gran	ns)
STUDY: 105IP24	GROUP: 5-1 DOSE: 30	M (mg/k	cg)	SEX:	MALE
	ANIMAL #	DAY 7	DAY 14	GAIN	
	291	С	С		
	292	C	С		
	293	C	C		
	294	C	С		
	295	С	С		
	MEAN				
	S.D.				
	N	0	0	0	
:	Data Unavailable	c:	Animal	Found Dead	

			I	NDIV	IDUAI	W	EIGHT	GAIN (Gra	ams)
STUD	Y: 1	05P026	GR DO	OUP: SE:	1-M 1100	( m	g/kg)	SEX:	MALE
			Al	IMAL #	DAY	7	DAY 14	TOTAL GAIN	
				301	1.	.0	1.1	2.1	
				302		C	C		
			3	303		C	С		
			3	304	0.	9	0.9	1.8	
			3	305	1.		0.5	1.6	
				MEAN	1.	.0	0.8	1.8	
				S.D.	0.	0	0.31	0.25	
				N	3	3	3	3	
			: Data	Unavai	lable	C	: Animal	Found Dead	

			INDIV	IDUAL	WEIGHT	GAIN (Gra	ams)
S	STUDY:	105P026	GROUP: DOSE:	2-M 1300(	mg/kg)		MALE
			ANIMAL #	DAY 7	7 DAY 14	TOTAL GAIN	
			311	-6.1	7.1	1.0	
			312	C	С		
			313	C	C		
			314	С	C		
			315	2.0	0.4	2.4	
			MEAN	-2.1	3.8	1.7	
			S.D.	5.73	4.74	0.99	
			N	2	2	2	
			-: Data Unavai	lable	c: Animal	Found Dead	

	INDIV	DUAL	WEIGHT	GAIN (Gra	ms)
STUDY: 105P026	GROUP: DOSE:	3-M 1500(	mg/kg)	SEX:	MALE
	DODE.	1000/	9/ 1.9/	TOTAL	
	ANIMAL #	DAY 7	DAY 14	GAIN	
					****************
	321	-2.7	4.9	2.2	
	322	C	С		
	323	C	С		
	324	C	С		
	325	С	С		
	MEAN	-2.7	4.9	2.2	
	S.D.				
	N	1	1	1	
• •	: Data Unavail	able	c: Animal	Found Dead	

 			INDIV	DUAL	WI	EIGHT	GAI	N (Gran	ns)			
 STUDY:	105P026	G. D	ROUP:	4-M 1750	(mç	g/kg)	τ	SEX:	MALE	• • • • • • • • • • • • • • • • • • • •	 	
 			ANIMAL #	DAY	7	DAY 14		SAIN			 	
			331			C						
			332			C						
			333		:	C						
			334		:	C						
			335			С						
			MEAN									
			S.D.									
			N	0		0		0				
		: Dat	a Unavail	lable	c:	Animal	Found	Dead				

		INDI	VIDUAL	WI	EIGHT	GAIN (Gra	nms)	
 STUDY:	105P026	GROUP:	5-M 2000	(mc	g/kg)	SEX:	MALE	
		ANIMAL			DAY 14	TOTAL GAIN		
		341 342 343		С	С			
		342		С	C			
		343	-2.	2	2.6	0.4		
		344		С	C			
		345		С	С			
		MEAN	-2.	2	2.6	0.4		
		S.D.	-	-				
		N	1		1	1		
		: Data Unava	ilable	c:	Animal	Found Dead		

			]	INDIV	IDUAL	WEIGHT	GAIN (Gra	ims)			
SI	rudy:	105P026	GI DO	ROUP:	6-M 800(m	a/ka)	SEX:	MALE			
						31 - 31	TOTAL				
				ANIMAL #	DAY	7 DAY 14					
										,	
				401	С	С					
				402	С	С					
				403	0.9	1.0	1.9				
				404	C	C					
				405	С	С	• •				
				MEAN	0.9	1.0	1.9				
				S.D.							
				N	1	1	1				
		: Da	ata Unavailable	b:	Scheduled	Sacrifice	c: Animal	Found Dead	I		

	INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)
STUDY: 105P06	A GROUP: DOSE:	1-M 0(mg/	kg)	SEX:	MALE
	ANIMAL #	DAY 7	DAY 14	GAIN	
	/74	7.0		7 /	
	631 632	3.8 2.6	-D.4 1.1	3.4 3.7 3.5	
	633 634	4.5 5.3	-1.0 -10.5	3.5 -5.2	
	635	c	c		
	MEAN	4.1	-2.7	1.4	
	S.D.	1.14	5.27	4.37	
	**	Scheduled		•	Found Dead

	INDIVIDU	AL WEIGHT	GAIN (Grams)	
STUDY: 105P06A	GROUP: 2- DOSE: 0(	M mg/kg)	SEX: MALE	
	ANIMAL #	DAY 7 DAY 14	TOTAL GAIN	
	611	3.1 -0.4	2 7	
	612	3.4 -0.5	2.7 2.9 3.2	
	613 614	2.2 1.0 2.8 1.1	3.9	
	615	СС	••	
	MEAN S.D.	2.9 0.3 0.51 0.87	3.2 0.53	
	N	4 4	4	
: Dat	a Unavailable b: Sched	Huled Sacrifice	c: Animal Found Dead	

				INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)		
 STUDY:	105PC	6A		GROUP: DOSE:	3-M 800(m	g/kg)		MALE	 	
 				ANIMAL #	DAY 7	7 DAY 14	TOTAL GAIN		 	
				621	2.5	-1.2	1.3			
				622	С	С				
				623	С	C				
				624	1.2	-0.1	1.1			
				625	С	С				
				MEAN	1.9	-0.7	1.2			
				S.D.	0.92	0.78	0.14			
				J.D.	2	2.70	2			
	-	-: Data	Unavailab	ole b:	Schedul ed	Sacrifice	-	Found Dead		

 			INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)		 
STUDY:	105P06A	7	GROUP: DOSE:	4-M 1000(	mg/kg)		MALE		
 			ANIMAL #	DAY 7	7 DAY 14	TOTAL GAIN			 
			601	2.5	-0.1	2.4			
			602	1.7	1.1	2.8			
			603 604	2.3 2.6	0.3	2.6			
			605		-1.0	1.6			
			MEAN S.D.	2.3 0.40	0.1 0.87	0.53			
	:	Data Unavaila	ble b:	Scheduled	4 Sacrifice	4 c: Animal	Found Dead	<b>d</b>	

	INDIVII	DUAL W	EIGHT	GAIN (Gran	ns)	 
STUDY: 105IP26	GROUP: 1 DOSE: 1	1-M 100(mg	/kg)		MALE	
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN		 
	351	-0.7	2.1	1.4		
	352 353	2.0	1.5	3.5		
	354 355	0.0	1.9	1.9		
	MEAN	0.1	0.8	0.9		
: Data Unavai	S.D. N	1.30 4 heduled Sa	2.18	2.92 4	Found Dead	
: Data Unavai	rance p: sc	neduced 58	crifice	C: Animal	round bead	

		INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)	
 STUDY: 105I	P26	GROUP: DOSE:	2-M 120 (m	g/kg)		MALE	
 		ANIMAL #	DAY 7	DAY 14	TOTAL GAIN		 
		361	0.2	1.6	1.8		
		362	C	C			
		363	С	С			
		364	C	c			
		365	c	c			
		MEAN	0.2	1.6	1.8		
		S.D.					
		N	1	1	1		
	: Data Unavaila	ble b:	Scheduled	Sacrifice	c: Animal	Found Dead	

	INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)
STUDY: 1051P2	6 GROUP: DOSE:	3-M 140(m	g/kg)		MALE
	ANIMAL :	# DAY	7 DAY 14	TOTAL GAIN	
	371	C	С		
	372	1.1	2.3	3.4	
	373	С	С		
	374	C	С		
	375	0.9	0.8	1.7	
	MEAN		1.6	2.6	
	S.D.	0.14	1.06	1.20	
	N	2	2	2	
	: Data Unavailable b:	Scheduled	Sacrifice	c: Animal	Found Dead

••••••	INDIV	GAIN (Gra	ms)		
STUDY: 105IP26	GROUP: DOSE:	4-M 170 (m	g/kg)	SEX:	MALE
	ANIMAL #	DAY 7	DAY 14	GAIN	
	381	c	С	• •	
	382	C	C	• •	
	383	-7.7	С		
	384	0.8	0.9	1.7	
	385	С	С		
	MEAN	-3.5	0.9	1.7	
	S.D.	6.01			
	N	2	1	1	
: Data	Unavailable b:	Scheduled	Sacrifice	c: Animal	Found Dead

 			INDIV	[DUA]	. W	EIGHT	GAIN (Gr	ams)	
 STUDY:	105IP26	G	ROUP: OSE:	5-M 200	(mg	/kg)		: MALE	
			ANIMAL #	DA	Y 7	DAY 14	TOTAL GAIN		 
			391		C	C			
			392		C	C			
			393		C	C			
			394		C	C			
			395		C	C			
			MEAN						
			S.D.						
			N		0	0	0		
		: Dat	ta Unavai	lable	C	: Animal	Found Dead		

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY: 1		DOSE:	1-F 10(mg/	kg)		FEMALE					
	ANIMAL	# DAY -3	DAY 0	DAY 7	DAY 14						
	206	22.7	23.9	25.7	26.1						
	207	23.5	23.3	25.5	25.4						
	208	20.9	22.3	24.6	24.7						
	209	22.2	23.6	23.9	26.5						
	210	24.5	25.8	27.0	29.4						
	MEAI	22.8	23.8	25.3	26.4						
	S.D.	1.36	1.28	1.18	1.80						
	N	5	5	5	5						
			Data Ilnav	ailabla							

INDIVIDUAL BODY WEIGHTS (Grams)										
STUDY: 105P024	GRO DO: ANIMAL #	OUP: 2 SE: 1 DAY -3	-F 3 (mg/	kg) DAY 7	SEX DAY 14	: FEMALE				
	216 217 218 219 220 MEAN S.D. N	24.5 21.3 23.9 23.1 22.4 23.0 1.26 5	26.3 21.2 24.7 23.7 24.0 24.0 1.85 5	26.5 24.3 27.2 25.7 23.4 25.4 1.56 5	29.0 26.7 28.5 26.5 23.9 26.9 2.01					

 INDIVIDUAL BODY WEIGHTS (Grams)											
 STUDY:	105P024	GR DO ANIMAL #	OUP: 3: SE: 1: DAY -3	-F 7 (mg/) DAY 0	cg)		FEMALE				
		226 227 228 229 230	23.2 25.1 22.6 21.9 23.8	24.2 25.9 22.5 22.9 24.0	26.2 26.6 23.6 24.5 18.2	28.9 29.5 25.0 26.2 29.3					
		MEAN S.D. N	23.3 1.22 5	23.9 1.33 5	23.8 3.37 5	27.8 2.05 5					
			: Da	ata Unava	ilable						

Walter Street Control of the Control								_
 						IGHTS (Gr	°ams)	
STUDY:	105PO24	GR	OUP: 4- SE: 23	F	/ka)	SEX	: FEMALE	
		ANIMAL #	DAY -3	DAY 0	DAY 7	SEX DAY 14		
		236	22.4	22.3	C	C		
		237	21.1	22.3	23.9	25.5		
		238	24.2	23.5	22.1	24.5		
		239	25.3	25.3	С	С		
		240	23.2	22.3	c	c		
		MEAN	23.2	23.1	23.0	25.0		
		S.D.	1.62	1.31	1.27	0.71		
		N	5	5	2	2		
			Unavailabl	e .	c: Animal	Found Dead		

		IN	DIVIDU	AL B	DDY WE	IGHTS (Gra	ams)	
 STUDY:	105P024	GR	OUP: 5	-F	/1= e= \	SEX:	FEMALE	
		ANIMAL #	SE: 30	DAY 0	DAY 7	DAY 14		
		246	25.0	25.3	c	C		
		247	22.9	23.9	C	C		
		248	22.3	22.5	C	C		
		249	23.5	23.6	С	C		
		250	22.1	23.8	С	С		
		MEAN	23.2	23.8		••		
		S.D.	1.17	1.00	• •			
		N	5	5	0	0		
		: Data	Unavailabl	e	c: Animal	Found Dead		

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY: 105IP24	GR	OUP: 1 SE: 1	-F 0 (mg/	ka)	SEX:	FEMALE					
	ANIHAL #	DAY -3	DAY 0	DAY 7	DAY 14						
	256	22.9	23.2	24.9	26.1						
	257 258	24.9	25.5	26.7 28.9	25.9						
	259	23.5	25.0	26.3	27.6						
	260	21.2	23.2	22.9	25.8						
	MEAN S.D.	23.0 1.35	24.3 1.05	25.9 2.22	26.9 1.47						
	N	5 : D	5 ata Unava	5 ilable	5						

			IN	DIVIDUZ	AL BOI	Y WEI	GHTS (Gram	s)
Sī	rudy:	105IP24	GR DO: ANIMAL #	OUP: 2 SE: 13 DAY -3	F 3 (mg/k DAY 0	g) DAY 7		FEMALE
			266 267 268 269 270 MEAN S.D. N	24.3 21.8 22.4 23.1 24.3 23.2 1.12 5	25.7 23.7 23.9 23.2 25.5 24.4 1.13 5	26.2 24.5 25.0 24.9 26.0 25.3 0.74 5	28.3 28.3 27.6 25.9 27.6 27.5 0.98	

		IN	DIVIDU	AL BO	DY WE	<b>[GHT8</b> (Gra	oms)	
 STUDY:	105IP24	GR	OUP: 3 SE: 1	-F	ka)	SEX:	FEMALE	
		ANIMAL #	DAY -3	7 (mg/)	DAY 7	DAY 14		
		276	22.6	24.4	24.3	25.2		
		277	25.3	26.7	28.0	30.4		
		278	23.9	24.8	25.5	27.3		
		279	21.6	25.2	25.7	28.3		
		280	23.3	23.1	23.1	25.5		
		MEAN	23.3	24.8	25.3	27.3		
		S.D.	1.39	1.31	1.83	2.14		
		N N	5	5	5	5		
			: 0	ata Unava	ilable	,		

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY:	105IP24	GR	OUP: 4 SE: 2	-F 3 (mg/	/k~\	SEX:	FEMALE				
 		ANIMAL #	DAY -3	DAY 0	DAY 7	DAY 14					
		20/	22.2	27.0	_	_					
		286 287	22.2 24.6	23.8	C	C					
		288	23.5	25.2	C	C					
		289	23.3	24.2	25.8	26.5					
		290	22.0	22.5	c	c					
		MEAN	23.1	24.4	25.8	26.5					
		S.D.	1.06	1.37							
		N	5	5		. 1					
		: Data	Unavailab	le d	:: Animal	Found Dead					

INDIVIDUAL BODY WEIGHTS (Grams)										
STUDY: 105IP24	GROU DOSE NIMAL # DA	P: 5-F : 30 (m	g/kg) 0 DAY 7		FEMALE					
		**********	•••••		•••••••					
	296 2	5.4 26.	1 c	С						
		4.2 26.	3 с	С						
		3.2 23.		C						
		0.3 21.		C						
	300 2	22.3 22.	8 с	С						
	MEAN 2	3.1 24.								
	S.D. 1	.94 1.9	7							
	N	5 5	0	0						
	: Data Una	vailable	c: Animal	Found Dead						

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY: 105P026	(	ROUP:	1-F	/	SEX:	FEMALE					
	ANIMAL :	PRETEST	1100 (T	ng/kg) DAY 7	DAY 14						
	306	26.2	26.5	C	С						
	307	25.1	24.1	25.3	26.9						
	308	23.6	23.7	С	С						
	309	25.7	26.7	c	C						
	310	22.5	22.4	c	c						
	MEAN	24.6	24.7	25.3	26.9						
	S.D.	1.54	1.86								
	N	5	5	1	1						
	: Da	ata Unavaila	able o	:: Animal	Found Dead						

		INDIVII	DUAL BO	DDY WE	IGHTS (Gra	ms)	
STUDY:	105P026	GROUP: DOSE: # PRETEST	2-F 1300(1 DAY 0	ng/kg) DAY 7	SEX:	FEMALE	
	316 317 318 319 320	23.9 23.2 26.0 27.7 25.3	24.3 22.0 26.0 27.2 25.9	19.5 c c c	25.0 c c		
	MEA S.D N :		25.1 2.01 5 lable	19.5  1 c: Animal	25.0  1 Found Dead		

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY: 105P026	G D ANIMAL #	ROUP: OSE: PRETEST	3-F 1500 (n	ng/kg)	SEX:	FEMALE					
	• • • • • • • • • • • • • • • • • • • •										
	326	24.5	24.9	c	c						
	327	23.4	24.5	C	C						
	328	23.6	24.2	C	C						
	329	26.1	25.5	C	C						
	330	25.8	25.0	19.8	26.4						
	MEAN	24.7	24.8	19.8	26.4						
	S.D.	1.24	0.50								
	N	5	5	1	1						
	: Dat	ta Unavail	able d	: Animal	Found Dead						

INDIVIDUAL BODY WEIGHTS (Grams)										
STUDY: 105P026	GR DO ANIMAL #	OUP: SE: PRETEST	4-F 1750(: DAY 0	mg/kg)	SEX:	FEMALE				
	336	24.9	25.2	С	C					
	337	24.1	24.4	C	C					
	338	23.0	24.3	c	C					
	339	25.5	26.7	c	c					
	340	26.5	26.5		-					
	340	20.5	20.5	С	С					
	MEAN	24.8	25.4							
	S.D.	1.33	1.13		• •					
	N	5	5	0	0					
	: Data	Unavaila	able	c: Animal	Found Dead					

INDIVIDUAL BODY WEIGHTS (Grams)  STUDY: 105P026											
ANIMAL # PRETEST DAY 0 DAY 7 DAY 14  346	INDIVIDUAL BODY WEIGHTS (Grams)										
346		GROUP: 5- DOSE: 20	F 000 (mg/kg)	SEX: F	EMALE						
347 26.5 27.5 c c c 348 25.4 25.8 c c 349 22.1 23.2 c c 350 23.8 21.9 c c  MEAN 24.6 24.8 S.D. 1.70 2.22 N 5 5 0 0		rkeiest									
348 25.4 25.8 c c c 349 22.1 23.2 c c c c 2350 23.8 21.9 c c c c c c c c c c c c c c c c c c c											
349 22.1 23.2 c c c 350 23.8 21.9 c c c c 24.8 3.D. 1.70 2.22 N 5 5 0 0											
350 23.8 21.9 c c  MEAN 24.6 24.8  S.D. 1.70 2.22  N 5 5 0 0	<u>ع</u>	48 25.4	25.8 C								
MEAN 24.6 24.8 S.D. 1.70 2.22 N 5 5 0 0											
S.D. 1.70 2.22 N 5 5 0 0	3:	50 23.8	21.9 c	С							
N 5 5 0 0				••							
		s.D. 1.70	2.22								
: Data Unavailable		N 5	5 0	0							
	•	: Data Unavailable	e c: Animal	Found Dead							

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY: 105P026	GR	OUP:	6-F	/le~\	SEX:	FEMALE					
	ANIMAL #	PRETEST	6-F 800 (mg bay 0	DAY 7	DAY 14						
	406	18.6	21.8	C	C						
	407	24.4	24.7	C	C						
	408	23.4	23.6	C	C						
	409	20.8	21.9	C	C						
	410	25.8	25.8	C	c						
	MEAN	22.6	23.6								
	S.D.	2.89	1.74								
	N	5	5	0	0						
	: Data	Unavaila	ble c	: Animal	Found Dead						

INDIVIDUAL BODY WEIGHTS (Grams)											
STUDY:	105P06A	GRO	UP: 1- E: 0(	F ma/ka	`	SEX:	FEMALE				
		ANIMAL #	DAY -2	DAY 0	DAY 7	DAY 14					
		636	23.3	23.6	26.6	25.2					
		637	25.3	24.7	27.9	28.6					
		638	22.4	23.1	24.6	25.1					
		639	22.2	23.4	25.8	25.5					
		640	23.7	23.5	25.0	16.9					
		040	20.1		23.0						
		MEAN	23.4	23.7	26.0	24.3					
		S.D.	1.24	0.61	1.32	4.36					
		N.	5	5	5	5					
			: Da	ta Únavai	lable	-					

		IN	DIVIDU	JAL BO	DY WE	IGHTS (Gra	ms)
 STUDY:	105P06A	GR	OUP: 2	P-F (mg/k	~\	SEX:	FEMALE
		ANIMAL #	DAY -2	DAY 0	DAY 7	DAY 14	
 		• • • • • • • • • • • • • • • • • • • •					••••••••••••
		616	24.2	25.3	С	C	
		617	21.8	22.5	23.5	23.6	
		618	23.2	23.9	C	C	
		619	23.6	23.6	25.1	27.0	
		620	24.5	24.4	24.5	26.2	
		MEAN	23.5	23.9	24.4	25.6	
		S.D.	1.06	1.03	0.81	1.78	
		N Data	5 Unavailab	ble c	· Animal	3 Found Dead	
		. Data	OTTO TO TOO	0,0	. Millimat	TOUR DEED	

				IGHTS (Gram	s)
STUDY: 105P06A	GROUI DOSE	3-F 800(	mg/kg) 0 DAY 7	SEX:	FEMALE
	ANIMAL # DA	Y -2 DAY	0 DAY 7	DAY 14	
	(2)	7 ( )/	5 3/ 0	27.2	
	627 20	3.6 24. 4.3 25.	1 28.0	27.2 27.7	
		1.3 22. 2.4 23.		25.9	
		4.4 24.		c	
		3.2 24.		26.9	
	S.D. 1	.33 0.9	3 1.94	0.93	
	: Data Una	vailable	c: Animal	Found Dead	

	IN	DIVIDU	JAL BO	DY WEI	GHTS (Gr	ams)
STUDY: 105PO6A	GF DC ANIMAL #	OUP: 4 OSE: 1 DAY -2	-F 000 (m	ng/kg) DAY 7	SEX:	FEMALE
	606 607 608 609 610 MEAN S.D.	24.0 25.4 22.4 23.3 21.1 23.2 1.62	24.3 25.9 23.4 24.7 22.8 24.2 1.20	20.4 25.4 c 25.1 23.6 2.80	25.8 c 25.6 c 15.9 22.4 5.66	
	: Data	Unavailab	ole c	: Animal F	ound Dead	

INDIVIDUAL BODY WEIGHTS (Grams)									
STUDY:	105IP26	GRO DOS ANIMAL #	OUP: 1 SE: 1 DAY -3	-F 00 (mg,	/kg) DAY 7		FEMALE		
		356 357 358 359 360 MEAN S.D.	23.8 24.9 26.2 25.8 22.5 24.6 1.51 5	25.0 25.5 26.2 25.5 22.2 24.9 1.56 5 ata Unava	25.9 26.1 26.7 27.4 23.1 25.8 1.64 5	26.4 27.1 27.1 27.3 23.7 26.3 1.50			

INDIVIDUAL BODY WEIGHTS (Grams)									
STUDY: 105IP2	DOSE	P: 2-F 120 (mg y -3 DAY 0	g/kg) DAY 7 DA	SEX:	FEMALE				
	367 2 368 2 369 2 370 2	5.5 24.5 3.6 24.2 6.3 27.2 3.7 22.6 4.9 24.9 4.8 24.7 .16 1.66 5 5	24.0 21 28.5 2 24.2 27.0 2 26.0 2 1.92 1	7.5 5.3 7.9 5.3 6.8 6.6					

									_
INDIVIDUAL BODY WEIGHTS (Grams)									
	STUDY:	105IP26	GRO DOS ANIMAL #	UP: 3- E: 14	F 0 (mg/	kg)		: FEMALE	
••••			376 377 378 379 380 MEAN	24.9 23.3 24.0 25.9 27.0	25.1 23.9 24.2 26.5 27.6	25.5 28.1 27.2	c c 27.6 28.9 28.2 28.2		
			S.D. N : Data (	1.48 5 Unavailable	1.57 5 c:	1.32 3 Animal	0.65 3 Found Dead		

INDIVIDUAL BODY WEIGHTS (Grams)									
STUDY: 105IP26	GR	OUP: 4 SE: 1	-F	1/ka)	SEX:	FEMALE			
	ANIMAL #	DAY -3	DAY 0	g/kg) DAY 7	DAY 14				
	386	23.6	23.4	С	C				
	387	24.5	24.5	25.4	25.7				
	388	25.3	24.9	26.8	27.2				
	389	23.4	23.9	27.1	28.0				
	390	27.5	28.6	28.3	29.5				
	MEAN	24.9	25.1	26.9	27.6				
	S.D.	1.66	2.06	1.19	1.59				
	N	5	5	4	4				
	: Data	Unavailab	le c	: Animal	Found Dead				

	IN	DIVIDU	AL BO	DY WE	IGHTS (Gra	ams)
STUDY: 105IP26	GR DO ANIMAL #	OUP: 5 SE: 2 DAY -3	-F 00 (mg DAY 0	/kg) DAY 7	SEX: DAY 14	FEMALE
	396 397 398 399 400 MEAN S.D.	26.2 22.8 25.9 24.3 23.6 24.6 1.46 5	27.8 22.8 26.5 23.9 24.1 25.0 2.06 5	26.4 c 27.7 c c	29.4 c 28.9 c c 29.2 0.35 2 Found Dead	

INDIVIDUAL WEIGHT GAIN (Grams)									
STUDY: 105P024	GROU DOSE	P:	1-F 10(mg	/kg)	SEX:	FEMALE			
	ANIMA	AL #	DAY 7	DAY 14	GAIN				
	206 207		1.8	0.4 -0.1	2.2				
	208 209		2.3	0.1	2.4				
	210		1.2	2.6	3.6				
		EAN	1.6	1.1	2.6				
	S	.D.	0.83	1.31	0.62				
	: Data Una	availa	able	b: Schedule	d Sacrifice				

			And the control of the latest control to			
	INDIVI	DUAL V	VEIGHT	GAIN (Gran	ns)	
STUDY: 105P024	GROUP: DOSE:	2-F 13 (mg/	/kg)		FEMALE	
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN		
	216	0.2	2.5	2.7		
	217	3.1	2.4	5.5		
	218	2.5	1.3	3.8		
	219	0.2 3.1 2.5 2.0	0.8	2.7 5.5 3.8 2.8		
		2.0		2.0		
	220	-0.6	0.5	-0.1		
	MEAN	1.4	1.5	2.9		
	S.D.	1.57	0.91	2.04		
	N	5	5	5		
	: Data Unavail	able t	: Schedul	ed Sacrifice		

	INDIVIDUAL WEIG	GHT GAIN (Grams)
STUDY: 105P024	GROUP: 3-F DOSE: 17(mg/kg)	SEX: FEMALE
	,	TOTAL Y 14 GAIN
	226 2.0 2.	2.7 4.7 2.9 3.6 1.4 2.5
	227 0.7 2.	2.9 3.6
		1.4 2.5
		1.7 3.3
	230 -5.8 11.	1.1 5.3
		4.0 3.9
	S.D. 3.24 4.0	.04 1.12
	N 5 5	5 5
	: Data Unavailable b: Sche	cheduled Sacrifice

 		INDI	VIDUAL	WEIGHT	GAIN (Gra	ms)	
 STUDY:	105P024	GROUP DOSE:	: 4-F 23 (mg	1/ka)	SEX:	FEMALE	
		DODE.	23 / 1119	1/159/	TOTAL		
		ANIMAL	# DAY	7 DAY 14	GAIN		 
		236	С	С	~ ~		
		237	1.6	1.6	3.2		
		238	-1.4	2.4	1.0		
		239	C				
		240	C				
		MEA		2.0	2.1		
		S.D	. 2.12	0.57	1.56		
		N	2	2	2		
	: Data	a Unavailable b	: Scheduled	Sacrifice	c: Animal	Found Dead	

	INDIVID	UAL WE	IGHT	GAIN (Gram	s)
STUDY: 105P024	GROUP: 50 DOSE: 30	-F 0(mg/k	(a)	SEX:	FEMALE
	ANIMAL #		DAY 14	TOTAL GAIN	
	246	С	С		
	247	С	С		
	248	С	С		
	249	С	С		
	250	С	C		
	MEAN				
	S.D.				
	N	0	0	0	
:	Data Unavailabl	le c:	Animal F	ound Dead	

	INDIVI	DUAL	WEIGHT	GAIN (Gran	ns)
STUDY: 105IP24	GROUP: DOSE:	1-F 10(mg	/kg)		FEMALE
	ANIMAL #	DAY 7	7 DAY 14	TOTAL GAIN	
	256	1.7	1.2	2.9	
	257 258 259	1.2 4.3 1.3	-0.8 0.3 1.3	0.4 4.6 2.6	
	260	-0.3	2.9	2.6	
	MEAN S.D.	1.67 1.67	1.0 1.37	2.6 1.49	
	N : Data Unavail	able	b: Schedule	d Sacrifice	

	INDIV	DUAL W	EIGHT	GAIN (Gran	ns)
STUDY: 105IP24	GROUP: DOSE:	2-F 13(mg/	kg)	SEX:	FEMALE
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN	
	266 267	0.5	2.1 3.8	2.6	
	268	1.1	2.6	4.6 3.7	
	269	1.7	1.0	2.7	
	270	0.5	1.6	2.1	
	MEAN	0.9	2.2	3.1	
	S.D.	0.50	1.06	1.00	
	N : Data Unavail	able b	: Scheduled	Sacrifice	

			Street Market Street William Toward			
 		INDIV	IDUAL W	EIGHT	GAIN (Gran	ns)
 STUDY:	105IP24	GROUP: DOSE:	3-F 17(mg/	ka)	SEX:	FEMALE
		ANIMAL #		DAY 14	TOTAL GAIN	
		276 277	-0.1 1.3	0.9 2.4	0.8 3.7 2.5	
		278 279	0.7	1.8	2.5 3.1	
		280	0.0	2.4	2.4	
		MEAN	0.5	2.0	2.5	
		S.D. N	0.57 5	0.69	1.08	
		: Data Unavai	lable b	: Schedule	d Sacrifice	

	INDIV	IDUAL W	FIGHT	GAIN (Gran	ns)
					,
STUDY: 105IP24 G	ROUP:	4-F 23 (mg/	(kg)	SEX:	FEMALE
		, ,,	2,	TOTAL	
	ANIMAL #	DAY 7	DAY 14	GAIN	
	286	6	6		
	287		-		
		C	С		
	288	C	С		
	289	1.6	0.7	2.3	
	290	C	С	* *	
	MEAN	1.6	0.7	2.3	
	S.D.			• •	
	N	1	1	1	
: Data Unavailabl		Scheduled S	acrifice	c: Animal	Found Dead

	INDIVIDU	AL WE	EIGHT	GAIN (Gram	s)
STUDY: 105IP24	GROUP: 5- DOSE: 30	F (mg/k	cd)	SEX:	FEMALE
	ANIMAL #	DAY 7	DAY 14	GAIN	
***************************************					
	296	С	С		
	297	C	C		
	298	С	С		
	299	С	c		
	300	C	С		
	MEAN				
	S.D.				
	N	0	0	0	
:	Data Unavailable	c:	Animal I	Found Dead	

	INDIV	IDUAL W	EIGHT	GAIN (Gra	ms)
STUDY: 105PO	GROUP: DOSE:	1-F 1100(m	a/ka)	SEX:	FEMALE
	ANIMAL #		DAY 14	TOTAL GAIN	
	306	C	C		
	307	1.2	1.6	2.8	
	308	C	C		
	309	С	C		
	310	C	C		
	MEAN	1.2	1.6	2.8	
	S.D.				
	N	1	1	1	
	: Data Unavai	lable c	: Animal	Found Dead	

		INDIV	DUAL	WEIGH	T GAIN (	Grams)	 
STUDY:	105P026	GROUP: DOSE:	2-F 1300	mg/kg	)	X: FEMALE	
		ANIMAL #	DAY		TOTAL		 
		316	c	c			
		317	-2.5	5.5	3.0		
		318	C	С			
		319	c	С			
		320	C	С			
		MEAN	-2.5	5.5	3.0		
		S.D.					
		N	1	1	1		
		Data Unavail	lable	c: Anima	l Found Dead		

	INDIVI	DUAL W	EIGHT	GAIN (Grad	ns)
STUDY: 105P026	GROUP: DOSE:	3-F 1500(m	g/kg)		FEMALE
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN	
	326		С		
	327	C	C		
	328	c	c		
	329		c		
	330	-5.2	6.6	1.4	
	MEAN	-5.2	6.6	1.4	
	S.D.				
	N	1	1	1	
	: Data Unavail	able c	: Animal I	Found Dead	

	INDIVIDU	AL WE	IGHT	GAIN (Gran	ns)
STUDY: 105P026	GROUP: 4- DOSE: 17	F 50(mg	/kg)		FEMALE
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN	
	336	С	С		
	337	C	C		
	338	C	C		
	339	C	C		
	340	С	С		
	MEAN				
	S.D.				
	N	0	0	0	
••	: Data Unavailable	e c:	Animal F	ound Dead	

 		INDIV	IDUAL	WEIGH	T GAIN	(Grams	)
STUDY:	105P026	GROUP: DOSE:	5-F		S	EX:	FEMALE
		DOSE:	2000	(mg/kg	()		
					TOTA	L	
		ANIMAL #	DAY	7 DAY 1	4 GAI	N	
 							•••••
		346	С				
		347	C				
		348	С				
		349	С				
		350	С				
		MEAN					
		S.D.					
		N	0	0	0		
		: Data Unavai	lable	c: Anima	al Found De	ad	

		INDI	VIDUAL	WEIGH'	r GAIN (Gr	ams)	
 STUDY:	105P026	GROUP DOSE:	: 6-F 800 (r	na/ka)	SEX	FEMALE	•••••
		ANIMAL			TOTAL GAIN		
		406	c	c			
		407	c	С			
		408	c	С			
		409	c	С			
		410	c	С			
		MEAN					
		S.D.					
		N	0	0	0		
		: Data Unava	ailable	c: Animal	Found Dead		

	INDIVI	DUAL W	EIGHT	GAIN (Gram	is)
STUDY: 105P06A	GROUP: DOSE:	1-F 0(mg/kg	a) 	SEX:	FEMALE
	ANIMAL #	DAY 7	DAY 14	GAIN	
	636	3.0	-1.4	1.6	
	637	3.2	0.7	1.6 3.9	
	638	3.0 3.2 1.5	0.5	2.0	
	639	2.4	-0.3	2.0	
	640	1.5	-8.1	-6.6	
	MEAN	2.3	-1.7	0.6	
	S.D.	0.80	3.66	4.12	
	N	5	5	5	
	: Data Unavail	able b:	Schedule	ed Sacrifice	

				INDIV	IDUAL	WEIGHT	GAIN (Gra	ns)	
	STUDY:	105P06	A	GROUP: 2-F DOSE: 0(mg/kg)		kg)		FEMALE	
/				ANIMAL #			TOTAL GAIN		 
				616	1.0	С			
				617	1.0	0.1	1.1		
				618	С	С			
				619	1.5	1.9	3.4		
				620	0.1	1.7	1.8		
				MEAN	0.9	1.2	2.1		
				S.D.	0.71	0.99	1.18		
				N	3	3	3		
		;	Data Unavaila	ble b:	Scheduled	Sacrifice	c: Animal	Found Dead	

#### ACUTE ORAL TOXICITY STUDY OF

 			INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)	
 STUDY:	105P06	A	GROUP: DOSE:	3-F 800(m	g/kg)		FEMALE	
 			ANIMAL #			TOTAL GAIN		 
			626 627	2.3	0.4	2.7		
			628 629 630	0.6 c	1.7	2.3		
			MEAN S.D.	1.9	0.6	2.5 0.21		
		: Data Unavaila	N	3	3 Sacrifice	3	Found Dead	

# ACUTE ORAL TOXICITY STUDY OF WR269410 IN MICE

			INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)	
STUDY:	105P06	A	GROUP: DOSE:	4-F 1000(	mg/kg)		FEMALE	
			ANIMAL #	DAY 7	7 DAY 14	TOTAL GAIN		
			606 607	-3.9 c	5.4 c	1.5		
			608	2.0	0.2	2.2		
			610	2.3	-9.2	-6.9		
			MEAN	0.1	-1.2	-1.1		
			S.D. N	3.50	7.40 3	5.06 3		
	:	Data Unavailab	ole b:	Scheduled	Sacrifice	c: Animal	Found Dead	

	INDIV	DUAL	WEIGHT	GAIN (Gran	ns)
STUDY: 105IP26	GROUP: DOSE:	1-F 100 (m	g/kg)		FEMALE
	ANIMAL #	DAY 7	7 DAY 14	TOTAL GAIN	
	356	0.9	0.5	1.4	
	357	0.6	1.0	1.6	
	358	0.5	0.4	0.9	
	359	1.9	-0.1	1.8	
	360	0.9	0.6	1.5	
	MEAN	1.0	0.5	1.4	
	S.D.	0.55	0.40	0.34	
	N	5	5	5	
•-:	Data Unavail	able	b: Schedule	d Sacrifice	

	INDIVI	DUAL V	WEIGHT G	AIN (Gran	ns)
STUDY: 105IP26	GROUP: DOSE:	2-F 120 (mg	g/kg)		FEMALE
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN	
•	744	2.0	4.0	7.0	
	366 367	2.0 -0.2	1.0	3.0 1.1	
	368 369	1.3	-0.6 1.1	0.7 2.7	
	370	2.1	-0.2	1.9	
	MEAN	1.4	0.5	1.9	
	S.D. N	0.93 5	0.86 5	0.99	
	: Data Unavail	able b	o: Scheduled	Sacrifice	

	INDIV	IDUAL	WEIGHT	GAIN (Gra	ms)		
STUDY: 105IP26	GROUP: DOSE:	3-F 140(m	g/kg)		FEMALE	•	
	ANIMAL #	DAY 7	DAY 14	TOTAL GAIN			
	376	С	С				
	377	C	C				
	378	1.3	2.1	3.4			
	379	1.6	0.8	2.4			
	380	-0.4	1.0	0.6			
	MEAN	0.8	1.3	2.1			
	S.D.	1.08	0.70	1.42			
	N	3	3	3			
: Data Unavail	able b:	Scheduled	Sacrifice	c: Animal	Found Dead		

		INDIV	IDUAL V	VEIGHT	GAIN (Gra	ms)	
STUDY:	105IP26	GROUP: DOSE:	4-F 170 (mg	g/kg)	SEX:	FEMALE	
		ANIMAL #	DAY 7	DAY 14	GAIN		
							-
		386	С	С			
		387	0.9	0.3	1.2		
		388	1.9	0.4	2.3		
		389	3.2	0.9	4.1		
		390	-0.3	1.2	0.9		
		MEAN	1.4	0.7	2.1		
		S.D.	1.49	0.42	1.45		
		N	4	4	4		
	: Data Unavaila	able b: S	Scheduled S	Sacrifice	c: Animal	Found Dead	

	INDIV	IDUAL 1	WEIGHT	GAIN (Gra	ms)	
STUDY: 105IP26	GROUP: DOSE:	5-F 200 (m		SEX:	FEMALE	
	DOSE:	200 (m	g/kg)			
				TOTAL		
	ANIMAL #	DAY 7	DAY 14	GAIN		
					• • • • • • • • • • • • • • • • • • • •	
	201		-			
	396	-1.4	3.0	1.6		
	397	C	C			
	398	1.2	1.2	2.4		
	399	C	C	••		
	400	C	C			
	MEAN	-0.1	2.1	2.0		
	S.D.	1.84	1.27	0.57		
	N	2	2	2		
: Data Unava	ailable b:	Scheduled	Sacrifice	c: Animal	Found Dead	

APPENDIX 5

LD50 Data

#### LD50 Data

WR242511 Tartrate (Gavage - Males)

### PROGRAM NAME: LD50 VERSION 1, EFFECTIVE DATE 6/25/91

STUDY	NUMBER	TEST ARTICLE	SPECIES	SEX
105PC	024	1720614	MICE	MALE
	AVERAGE # A	NIMALS/SEX/GROUP	1	5
,	TOTAL ANIMA	ALS USED		15
,	TOTAL ANIMA	ALS USED 6.7%-93.3%	ó	5
			CALC	ULATIONS
	Y-INTERCEPT		-16.5	1719
	SLOPE		15.8	0134
	16% CONCENT	TRATION	19.8	8137
	50% CONCENT	TRATION	23.0	0023
	84% CONCENT	TRATION	26.6	0835
	Γ-VALUE		4.3	
(	CORRELATION	N COEFFICIENT	.9	938315

#### DATA SUMMARY

LEVEL	DOSE	LOG DOSE	# DEAD	% DEAD	<b>PROBIT</b>
1	17.00	1.23	0	0.0	3.04
2	23.00	1.36	2	40.0	4.75
3	30.00	1.48	5	100.0	6.96

THE LD50 FOR MALES IS 23 mg base/kg
THE 95% CONFIDENCE LIMITS 15.47 TO 34.19 mg base/kg

#### LD50 Data

WR242511 Tartrate (Gavage - Females)

# PROGRAM NAME: LD50 VERSION 1, EFFECTIVE DATE 6/25/91

STUDY 105PC	NUMBER 024	TEST ARTICLE 1720614	SPECIES MICE	SEX FEMALES
1	AVERAGE # A	NIMALS/SEX/GROUP	5 15 5	
			CALC	CULATIONS
,	Y-INTERCEPT		-16.46	818
S	SLOPE		15.88	871
1	6% CONCENT	RATION	19.41	876
5	0% CONCENT	TRATION	22.44	705
8	4% CONCENT	TRATION	25.94	759
I	-VALUE		4.3	
	CORRELATION	N COEFFICIENT	.99	93269

### DATA SUMMARY

LEVEL	DOSE L	OG DOSE	# DEAD	% DEAD	<b>PROBIT</b>
1	17.00	1.23	0	0.0	3.04
2	23.00	1.36	3	60.0	5.25
3	30.00	1.48	5	100.0	6.96

THE LD50 FOR FEMALES IS 22.45 mg base/kg
THE 95% CONFIDENCE LIMITS 15.14 TO 33.29 mg base/kg

#### LD50 Data

WR242511 Tartrate (Intraperitoneal - Males)

### PROGRAM NAME: LD50 VERSION 1, EFFECTIVE DATE 6/25/91

STUDY NUMBER	TEST ARTICLE	SPECIES	SEX
105IP24	1720614	MICE	MALE
AVERAGE #	ANIMALS/SEX/GRO	UP 5	
TOTAL ANIN	MALS USED	15	
TOTAL ANIN	MALS USED 6.7%-93.	3% 5	

#### **CALCULATIONS**

Y-INTERCEPT	-16.41074
SLOPE	15.99084
16% CONCENTRATION	18.89741
50% CONCENTRATION	21.82419
84% CONCENTRATION	25.20426
T-VALUE	4.3
CORRELATION COEFFICIENT	.9789533

#### **DATA SUMMARY**

LEVEL	DOSE	LOG DOSE	# DEAD	% DEAD	<b>PROBIT</b>
1	17.00	1.23	0	0.0	3.04
2	23.00	1.36	4	80.0	5.84
3	30.00	1.48	5	100.0	6.96

THE LD50 FOR MALES IS 21.82 mg base/kg
THE 95% CONFIDENCE LIMITS 14.75 TO 32.29 mg base/kg

#### LD50 Data

### WR242511 Tartrate (Intraperitoneal - Females)

### PROGRAM NAME: LD50 VERSION 1, EFFECTIVE DATE 6/25/91

STUDY N 105IP24	UMBER	TEST ARTICLE 1720614	SPECI MICE	ES	SEX FEMALES
10011 21		.,2001.	11102		I DIVILLEDO
AV	'ERAGE # A	ANIMALS/SEX/G	ROUP	5	
TO	TAL ANIM	ALS USED		15	
TO	TAL ANIM	ALS USED 6.7-9	3.3%	5	
			CALC	ULATIONS	
Y-1	NTERCEPT	•	-16.410	074	
SL	OPE		15.990	84	
169	% CONCEN	TRATION	18.897	41	
509	% CONCEN	TRATION	21.824	19	
	% CONCEN	TRATION	25.204	26	
	VALUE		4.3		
CC	RRELATIO	N COEFFICIENT	.978	9533	

#### DATA SUMMARY

LEVEL	DOSE	LOG DOSE	# DEAD	% DEAD	<b>PROBIT</b>
1	17.00	1.23	0	0.0	3.04
2	23.00	1.36	4	80.0	5.84
3	30.00	1.48	5	100.0	6.96

THE LD50 FOR FEMALES IS 21.82 mg base/kg
THE 95% CONFIDENCE LIMITS 14.75 TO 32.29 mg base/kg

#### LD50 Data

WR269410 (Intraperitoneal - Males)

PROGRAM NAME: LD50 VERSION 1, EFFECTIVE DATE 6/25/91

STUDY NUMBER	TEST ARTICLE	SPECIES	SEX
105IP26	1620614	MICE	MALE
AVERAGE # ANIN	AAT C/CEY/GDOUD	5	
TOTAL ANIMALS		25	
IOIAL ANIMALS	USED 6.7%-93.3%	20	
		CALCULATIONS	
		CHECCEMINONS	
Y-INTERCEPT		-10.46356	
SLOPE		7.471125	
16% CONCENTRA	TION	86.2835	
50% CONCENTRA	TION	117.4293	
84% CONCENTRA	TION	159.8177	
T-VALUE		2.78	
CORRELATION C	OEFFICIENT	.8743011	

#### **DATA SUMMARY**

LEVEL	DOSE	LOG DOSE	# DEAD	% DEAD	<b>PROBIT</b>
1	100.00	2.00	1	20.0	4.16
2	120.00	2.08	4	80.0	5.84
3	140.00	2.15	3	60.0	5.25
4	170.00	2.23	4	80.0	5.84
5	200.00	2.30	5	100.0	6.96

THE LD50 FOR MALES IS 117.43 mg/kg
THE 95% CONFIDENCE LIMITS 89.56 TO 153.97 mg/kg

#### LD50 Data

#### WR269410 (Intraperitoneal - Females)

## PROGRAM NAME: LD50 VERSION 1, EFFECTIVE DATE 6/25/91

STUDY NUMBER 105IM	TEST ARTICLE 1620614	SPECIES MICE	SEX MALE
1031101	1020014	MICE	WALE
AVERAGE # ANIMA	LS/SEX/GROUP	5	
TOTAL ANIMALS U	SED	25	
TOTAL ANIMALS U	SED 6.7%-93.3%	20	
	CALC	ULATIONS	
	0.120	O E I I I I I I I I I I I I I I I I I I	
Y-INTERCEPT	-10.46	356	
SLOPE	7.47	1125	
16% CONCENTRATION	ON 86.28	35	
50% CONCENTRATION	ON 117.42	93	
84% CONCENTRATION	ON 159.81	77	
T-VALUE	2.78		
CORRELATION COE	FFICIENT .87	43011	

#### **DATA SUMMARY**

LEVEL	DOSE	LOG DOSE	# DEAD	% DEAD	<b>PROBIT</b>
1	100.00	2.00	1	20.0	4.16
2	120.00	2.08	4	80.0	5.84
3	140.00	2.15	3	60.0	5.25
4	170.00	2.23	4	80.0	5.84
5	200.00	2.30	5	100.0	6.96

THE LD50 FOR MALES IS 117.43 mg/kg
THE 95% CONFIDENCE LIMITS 89.56 TO 153.97 mg/kg

# APPENDIX 6

Protocol and Amendments

Task Order No.: UIC-7A UIC/TRL Study No.: 105

# ACUTE ORAL AND INTRAPERITONEAL TOXICITY STUDY OF WR242511 AND WR269410 IN MICE

### 1.0 PURPOSE OF THE STUDY:

The purpose of this study is to assess the toxicity of the test articles in CD₁ mice following either a single oral or intraperitoneal dose.

### 2.0 SPONSOR:

- 2.1 Name:
- U.S. Army Medical Research
- and Development Command
- 2.2 Address:

Fort Detrick

Frederick, MD 21702-5009

2.3 Representative:

George Schieferstein, Ph.D.

### 3.0 TESTING FACILITY:

3.1 Name:

Toxicology Research Laboratory (TRL)

3.2 Address:

University of Illinois at Chicago (UIC)

Department of Pharmacology

P.O. Box 6998

Chicago, Illinois 60680

3.3 Study Director:

Barry S. Levine, D.Sc., D.A.B.T.

#### 4.0 DATES:

- 4.1 Study Initiation (see Section; 12.0):
- 4.2 Proposed Initiation of Dosing:

April 29, 1993

May 6, 1993

WR269410

WR242511

4.3 Proposed Necropsy Date:

May 13, 1993

May 20, 1993

4.4 Proposed Study Completion

(Final Report):

July 1, 1993

REVISED PAGE
STUDY NO: 105 INITIAL: BAL

DATE: ILY 143

Task Order No.: UIC-7A UIC/TRL Study No.: 105

### 5.0 TEST ARTICLES

5A.1 Name or Code No:

WR242511 Tartrate

Bottle number will be identified in the raw

data.

5A.2 TRL Chemical No:

1720614

5A.3 Physical Description:

Orange powder

5A.4 Stability and Handling of Test Article:

5A.4.1 <u>Storage Conditions to Maintain Stability:</u>

5A.4.1.1 <u>Temperature</u>:

-20 to -15°C.

5A.4.1.2 Humidity:

Ambient conditions at

-20 to -15°C in a

freezer.

5A.4.1.3 Light:

Protect from light.

5A.4.1.4 Special Requirements: None.

5A.4.2 <u>Special Handling Procedures:</u> Standard precautions including gloves, labcoat and eye protection.

5A.4.3 Log of Test Article: The amount, date, identity of person(s) removing aliquots and the purpose for which each aliquot of the test article was removed from the batch will be documented. At termination of the study, all unused test article will be returned to the Sponsor.

5B.1 Name or Code No:

WR269410 (p-Aminoheptanophenone; PAHP)

Bottle number will be identified in the raw

data.

5B.2 TRL Chemical No:

1620614

5B.3 Physical Description:

Solution in polyethylne glycol 200 in a

concentration of 100 mg/ml.

5B.4 Stability and Handling of Test Article:

5B.4.1 Storage Conditions to Maintain Stability:

5B.4.1.1 Temperature:

0 to 4°C.

5B.4.1.2 Humidity:

Ambient conditions at 0

to 4°C in the

refrigerator.

5B.4.1.3 Light:

Protect from light.

STUDY NO: 103 INITIAL:

DATE: 1/27/43

Task Order No.: UIC-7A UIC/TRL Study No.: 105

## 5B.4.1.4 <u>Special Requirements:</u> None.

- 5B.4.2 <u>Special Handling Procedures:</u> Standard precautions including gloves, labcoat and eye protection.
- 5B.4.3 Log of Test Article: The amount, date, identity of person(s) removing aliquots and the purpose for which each aliquot of the test article was removed from the batch will be documented. At termination of the study, all unused test article will be returned to the Sponsor.

#### 6.0 PERSONNEL:

Study Director
Toxicologist
Analytical Chemist
Clinical Veterinarian
Veterinarian Support
Tox. Lab Supervisor
Lead Technician
Chemistry Specialist
Quality Assurance

Barry S. Levine, D.Sc., D.A.B.T.
E. Marianna Furedi-Machacek, D.V.M.
Adam Negrusz, Ph.D.
James Artwohl, D.V.M., M.S., D.A.C.L.A.M.
To be documented in the raw data
Soudabeh Soura, B.S.
Nancy Dinger, B.S.
Thomas Tolhurst, B.S.
Ronald C. Schoenbeck

## 7.0 TEST SYSTEM:

7.1 Species:

Mouse

7.2 Strain:

CD₁ (Virus Antibody Free)

7.3 Sex(s) and Number:

100 Males and 100 females for LD50 test. Up to 40/sex for the range-finding test.

7.4 Age of Animals:

6 - 7 weeks old at dosing initiation.

- 7.5 Weight of Animals: Approximately 27 32 g (males) and  $\approx$  22 26 g (females) at dosing initiation.
- 7.6 <u>Source of Animals:</u> Charles River Breeding Laboratories. The specific breeding facility will be documented in the raw data.
- 7.7 <u>Justification for Selection of Test System:</u> The mouse is a standard and accepted rodent species for toxicology studies, and is specified by the Sponsor.
- 7.8 Procedure for Unique Identification of Test System: Upon arrival, each animal will be given a study-unique quarantine/pretest number. During the test animal selection process, each test animal will be assigned a test animal number unique to it within the population making up the study. This number will appear as an ear tag and will

STUDY NO: 105 INITIAL: WL
DATE: 12163

PRTL105

Task Order No.: UIC-7A UIC/TRL Study No.: 105

also appear on a cage card visible on the front of each cage. The cage card will additionally contain the study number, test article identification, treatment group number and dose level. Cage cards will be color-coded as a function of treatment group. Raw data records and specimens will also be identified by the unique test animal number.

- 7.9 Housing: The animals will be housed in an AAALAC-accredited facility. Animals will be singly housed in polycarbonate cages with Anderson-bed-o-cob bedding (Heinold, Kankakee, Illinois) in a temperature (65-78°F) and humidity (30-70%) controlled room with a 14 hour light/10 hour dark cycle. The cage size, 390 cm area and 12.5 cm height, is adequate to house mice at the upper weight range as described in the Guide for the Care and Use of Laboratory Animals, DHHS (NIH) No. 86.23. All animals will be routinely transferred to clean cages with fresh bedding once weekly.
- 7.10 Quarantine Procedure: Animals for the LD50 study will be quarantined for an approximate one week period. The range-finding test will start before the end of the quarantine period. During quarantine, the animals will be observed daily for signs of illness, and all unusual observations will be reported to the Study Director, Toxicologist or Clinical Veterinarian. Animals will be examined during quarantine and approved for use by the Clinical Veterinarian prior to being placed on test. Any sickly animals will be eliminated prior to the test animal selection process. If a selected animal appears sickly prior to initiation of treatment, it will be replaced by a healthy animal prior to initiation of treatment under the direction of the Study Director or Toxicologist. Quarantine release will be documented on the Clinical Veterinarian Log by the veterinarian prior to study initiation.
- 7.11 Food: Purina Certified Rodent Chow No. 5002 (Ralston Purina Company, St. Louis, MO) will be provided ad libitum from arrival until termination except for an approximate 3-6 hour fast prior to gavage treatment. Food will be returned 1-2 hours post treatment.
- 7.12 <u>Water:</u> Tap water from an automatic watering system in which the room distribution lines are flushed daily will be provided ad *libitum* from arrival until termination. The water is untreated with additional chlorine or HCl.
- 7.13 There are no known contaminants in the feed or water which are expected to influence the study. A copy of the feed certification will be kept with the study records. The results of bimonthly comprehensive chemical analyses of Chicago water are documented in files maintained by Quality Assurance.

STUDY NO: 101 INITIAL: DATE: 1 12 143

Task Order No.: UIC-7A UIC/TRL Study No.: 105

## 8.0 EXPERIMENTAL DESIGN:

### 8.1 LD50 Test:


Test Article	Dose Level (mg base/kg) ^a	Route of Administration	Number of <u>Males</u>	Number of <u>Females</u>
WR269410 WR269410 WR269410 WR269410 WR269410	TBD TBD TBD TBD TBD	Oral Oral Oral Oral Oral	5 5 5 5	5 5 5 5
WR269410 WR269410 WR269410 WR269410 WR269410	TBD TBD TBD TBD TBD	Intraperitoneal Intraperitoneal Intraperitoneal Intraperitoneal Intraperitoneal	5 5 5 5	5 5 5 5
WR242511 WR242511 WR242511 WR242511 WR242511	TBD TBD TBD TBD TBD	Oral Oral Oral Oral Oral	5 5 5 5 5	5 5 5 5 5
WR242511 WR242511 WR242511 WR242511 WR242511	TBD TBD TBD TBD TBD	Intraperitoneal Intraperitoneal Intraperitoneal Intraperitoneal Intraperitoneal	5 5 5 5	5 5 5 5

^aTBD = To be determined (WR242511 doses will be expressed as mg base per kg).

Additional dose levels will be included as necessary to more accurately define the LD50. The number of animals in each group is necessary for statistical analyses.

Doses will be selected from range-finding study data in which 5 groups of 2 animals/sex/dose will be routinely used (Section 8.6).

8.2 Procedure to Control Bias during the Assignment of Animals to Treatment Groups: The animals will be randomly selected, within sex, using a table of random numbers or a computer-generated randomization program. The specific procedure will be documented in the raw data.



Task Order No.: UIC-7A UIC/TRL Study No.: 105

8.3 Frequency and Route of Administration of Test Article: Five groups of five animals/sex will receive a single dose of the appropriate test article by intraperitoneal injection or gavage as shown in Section 8.1. Dosing volumes will be constant on the basis of body weight and will be routinely 1 or 5 ml/kg (ip), and 5 or 10 ml/kg (oral). The specific dosing volume (ml/kg) will be constant throughout each phase of the study and will be documented in the raw data. Mice which are dosed by gavage will be fasted approximately 3 - 6 hours prior to dosing. Food will be returned approximately 1 - 2 hours after dosing.

- 8.4 <u>Justification of Route(s):</u> The oral and intraperitoneal routes are convenient and accepted procedures for administering a specific amount of a test article to each animal, and are required by the Sponsor.
- 8.5 <u>Test Article Vehicle:</u> WR242511 1% Methylcellulose/0.4% Tween 80 WR269410 Polyethylene glycol (PEG) 200, supplied by the University of Iowa
- Range-Finding Test: For WR242511, an initial range-finding dose of 25 mg base/kg will be administered orally and intraperitoneally to separate groups of 2 animals/sex. This dose is approximately the oral LD50 determined in a previously conducted acute toxicity study in mice (UIC/TRL Study No. 061). For WR269410, an initial range-finding dose of 800 mg/kg will be used for each route (2 animals/sex). This is the approximate intramuscular LD50 for this drug in mice as indicated by the Sponsor.

Additional range-finding dose levels, routinely either twice or one-half the previous dose level, will be subsequently administered to groups of 2 animals/sex/appropriate route based on the previous results. Five range-finding doses/sex will be routinely administered for each drug by the appropriate route. The range-finding animals will be observed once daily for at least 5 days, and will be discarded when it is apparent they will survive.

- 8.7 Test Article Dosage Form Preparation and Analyses: The stability and homogeneity of the test article/carrier mixtures will be determined prior to study start. Dosage formulations will be prepared by suspending the appropriate quantity of test article in the vehicle using a mortar and pestle. They will be analyzed for test article concentration prior to use, and only samples within 10% of their intended concentration will be used. A stock solution of WR269410 in PEG 200 (100 mg/ml) will be prepared and supplied by the University of Iowa. Appropriate quantities of the stock solution will be further diluted in PEG 200 for each dose level. The final dosage formulations used in the LD50 test will be returned to the University of Iowa for test article concentration assay.
- 8.8 Type and Frequency of Observations, Tests, Analyses and Measurements:
  - 8.8.1 <u>Body Weight:</u> Body weights of all animals will be recorded at test animal selection in Week -1, and on Days 0 (prior to dosing), 7 and 14.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

8.8.2 Clinical Signs: All test animals will be observed for clinical signs at least three times after treatment on the day of dosing, and daily thereafter until termination. All pharmacologic and/or toxicologic effects will be recorded on an individual test animal basis. The animals will also be observed daily in the afternoon for moribundity/mortality during the 2 week holding period.

- 8.8.3 Postmortem Observations: All test animals which die during the 14-day observation period will be grossly necropsied as soon as possible. Those test animals that survive to Day 14 will be sacrificed by carbon dioxide asphyxiation and grossly necropsied on that day. The necropsy procedure will be a thorough and systematic examination and dissection of the animal viscera and carcass. A veterinary pathologist will be routinely available to verify gross lesions. All tissues and organs will be discarded following termination of the gross necropsy procedure.
- 8.8.4 <u>Data Analyses:</u> The incidence of all pharmacologic and/or toxicologic effects will be tabulated for each dose level by sex. For body weights, means and standard deviations will be calculated for each dose level by sex and time point. Probit analysis of dose-mortality data as described by Finney (1977) will be used to calculate the LD50 and its 95% confidence interval for each sex, and the slope of each dose-mortality curve.

### 9.0 RECORDS TO BE MAINTAINED:

All data generated during the conduct of the study, except those that are generated as direct computer input, will be recorded directly, promptly, and accurately in ink in bound books with prenumbered pages or on worksheets that will be bound during or at the conclusion of the nonclinical laboratory study. All appropriate computer and machine output will be bound during or at the conclusion of the study. All data entries will be dated on the day of entry and signed or initialed by the person entering the data.

Any changes in entries for whatever reason (e.g., to correct an error or transposition) will be made so as not to obscure the original entry, will indicate the reason for such change, and will be dated and signed or identified at the time of data input. In computer driven collection systems, the operator responsible for direct data input will be identified at the time of data input. Any changes in computer entries for whatever reason (e.g., to correct an error or transposition) will be made in such a manner so as not to obscure the original entry, if possible, will indicate the reason for such change, and will be dated and the responsible individual will be identified.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

All recorded data will be reviewed, signed, and dated by a knowledgeable person, other than the person making the entry, to assure adherence to procedures and to verify observations.

Upon completion of the study and submission of the final report, all raw data, documentation, specimens, test article reserves and other materials necessary to reconstruct the study will be stored in the TRL Archives maintained by Quality Assurance, unless otherwise specified by the Sponsor.

All changes or revisions, and reasons therefore, to this protocol once it is approved will be documented, signed by the Study Director and Sponsor, dated and maintained with the protocol.

### 10.0 REGULATORY REQUIREMENTS:

This study will be performed in compliance with the UIC/TRL Quality Assurance Program designed to conform with FDA Good Laboratory Practice Regulations and EPA Good Laboratory Practice Standards. The protocol for this study was approved by the UIC Animal care committee.

Will this study be submitted to a regulatory agency? Yes

If so, to which agency(ies)? U.S. Food and Drug Administration

Dose the Sponsor request that remaining test articles be returned? Yes

Does the Sponsor request that samples of the test article/carrier

mixture(s) be sent? No

# 11.0 REFERENCES

Finney, D.J., 1977. Probit Analysis, 3rd Edition. Cambridge University Press, Cambridge, England.

Task Order No.: UIC-7A UIC/TRL Study No.: 105

12.0 PROTOCOL APPROVAL:

STUDY DIRECTOR:

Barry S. Leving, D.Sc., D.A.B.T.

12/3/41 Date

QUALITY ASSURANCE:

Ronald Schoenbeck

12/7/92

SPONSOR APPROVAL:

George Schieferstein, Ph.D.

Date

Contracting Officer's Representative (COR)

COMMENTS FROM THE COR:

#### PROTOCOL AMENDMENT

Study No.: 105

Title: Acute Oral and Intraperitoneal Toxicity Study of WR242511 and

WR269410 in Mice

1. Page 1 Section 4.0

Complete the study dates as follows:

4.2 Proposed Initiation of Dosing: April 29, 1993 May 6, 1993

WR269410 WR242511

4.3 Proposed Necropsy Date: May 20, 1993 May 13, 1993

4.4 Proposed Study Completion (Final Report): July 1, 1993

The dates were not specified in the Protocol. Reason:

2. Page 2 Section 5A.2

Change TRL Cemical No. "0930614" to "1720614"

A different composition of the test article was supplied by the Reason:

Sponsor (tartarate instead of disulfate which was previously tested

and was assigned number 0930614).

3. Page 2 Section 5B.3

> Change "White powder" to "Solution in polyethylene glycol 200 in a concentration of 100 mg/ml"

Because of difficulties with test article solubility, it was Reason:

supplied by the Sponsor as a solution.

4. Page 2 Secion 5B.4.1.1 and 5B.4.1.2

Add 0 - 4°C for solution in the refrigerator.

PEG 200 solutions of WR269410 do not need to be frozen.

5. Page 3 Section 6.0

A. Change the Analytical Chemist to Adam Negrusz, Ph.D."

B. Change "Veterinary Support" to "Veterinarian Support"

Mistakes in protocol. Reason:

#### PROTOCOL AMENDMENT

Study No.: 105

Title: Acute Oral and Intraperitoneal Toxicity Study of WR242511 and

WR269410 in Mice

6. Page 3 Section 7.3

Change the number of mice used for the range-finding test from "Up to 20/sex" to "Up to 40/sex".

Reason: Mistake in protocol.

- 7. Page 4 Section 7.9
  - A. Change animal room humidity range from "(40-70%)" to "(30-70%)" in the second sentence.
  - B. Change "DHEW" to "DHHS" in the third sentence.

Reason: Mistakes in protocol.

8. Page 4 Section 7.11

Add to the end of the last sentence "except for an approximate 3-6 hour fast prior to gavage treatment. Food will be returned 1-2 hours post treatment."

Reason: Inadvertently omitted from the protocol.

9. Page 4 Section 7.12

Change "HCL" to "HC1" at the end of last sentence.

Reason: Mistake in protocol.

10. Page 5 Section 8.1

Add the following sentence to the beginning of the first paragraph:

"Additional dose levels will be included as necessary to more accurately define the LD50."

Reason: To allow for additional dose levels as necessary.

11. Page 6 Section 8.5

A. Change the test article vehicle for WR242511 from "0.5% Na* Carboxymethylcellulose/0.3% Tween 80" to "1% Methylcellulose/0.4% Tween 80."

Reason: Better suspendability was achieved with this vehicle.

#### PROTOCOL AMENDMENT

Study No.: 105

Title:

Acute Oral and Intraperitoneal Toxicity Study of WR242511 and

WR269410 in Mice

B. Change the test article vehicle for WR269410 from "0.5% Na* Carboxymethylcellulose/0.3% Tween 80" to "Polyethylene glycol (PEG) 200, supplied by the University of Iowa."

Reason:

WR269410 in suspension could not be passed through a needle.

12. Page 6 Section 8.6

> Add "base" to the first sentence to read as follows: For WR242511, an initial range-finding dose of 25 mg base/kg will be administered..."

Reason:

Inadvertently not included in the protocol.

13. Page 6 Section 8.7

Add the following sentences at the end of the paragraph:

"A stock solution of WR269410 in PEG 200 (100 mg/ml) will be prepared and supplied by the University of Iowa. Appropriate quantities of the stock solution will be further diluted in PEG 200 for each dose level. The final dosage formulations used in the LD50 test will be returned to the University of Iowa for test article concentration assay."

Reason:

Difficulties were encountered in preparation of dosage formulation suspensions.

APPROVALS:

STUDY DIRECTOR:

D.Sc., D.A.B.T.

SPONSOR APPROVAL:

George Schieferstein, Ph.D.

Contracting Officer's

Representative (COR)

Page 3

ENCL.)

APPENDIX 7

Study Deviations

## Study Deviations*

Deviation Type	Specific Deviation	Effect on Study
Protocol	The method of Miller and Tainter (1944) was used to calculate LD50s because it is an accepted means to analyze dose-mortality curves and it is able to perform linear regression with one only data point between 0% and 100% mortality.	None.
Protocol	WR242511 tartrate is incorrectly described in the protocol as an orange powder. The tartrate salt of WR242511 is a yellow powder.	None.
Protocol	The humidity in the animal room was out of range on two occasions ( $\pm 1\%$ out of range).	None; deviation was minimal.
Protocol	The WR269410 (intraperitoneal) dosage formulation for the mid dose (140 mg/kg) treatment group exceeded the target concentration by 11.8%.	None; deviation was minimal.

*The detailed "Deviation Reports" are contained in the raw data which are archive at the University of Illinois at Chicago, Department of Pharmacology, Chicago, Illinois.

The above deviations did not affect the integrity of the study.

Barry S. Levine, D.Sc., D.A.B.T.

Date